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CHAPTER I

INTRODUCTION

The

renin-angiotensin-aldosterone

system

is

involved

in

the

regulation of blood volume and pressure (Fujii and Vatner, 1985; Joy
and Lowe, 1970), and the maintenance of sodium balance (Parfrey et al.,
1981; Davis and Freeman, 1976).

Renin is the rate limiting enzyme in

the formation of the vasopressor substance angiotensin II (ANG II).
ANG II is

the active component of this system and is involved in

several physiological functions
effect.

in addition to its vasoconstriction

The primary source of renin in the blood is the specialized

juxtaglomerular cells located in the afferent arterioles of the kidney.
The

synthesis,

storage

and

secretion

of

renin

occurs

in

these

juxtaglomerular cells (Taugner et al., 1984).
Renin secretion is regulated in part, by a renal baroreceptor that
senses changes in renal perfusion pressure (Blaine et al., 1971).

The

release of renin from the kidney is also modulated by the amount of
sodium that is reabsorbed across the specialized macula densa cells in
the distal tubule (Fray, 1978; Itoh and Carretero, 1985).
the

renal

nerves

and

circulating

catecholamines

secretion by stimulating renal beta-receptors.
inhibit renin release (Bunag et al., 1967).
1

In addition,

increase

renin

ANG II and vasopressin

Studies by De Vito et al.

2

(1971) provided evidence for the presence of a renin-releasing factor
in the plasma of hypovolemic dogs.
replicated by Polomski et al

However, these results could not be

(1974),

and no

further

studies were

reported.
serotonergic

Brain

Administration

of

neurons

quipazine

produced

renin

(5-HT)

releasers,

serotonin

the

chloroamphetamine) or fenfluramine,
and

stimulate

secretion.
PCA

(p-

or the serotonin agonists MK-212

dose-dependent

increases

in

plasma

renin

activity (PRA; Lorens and Van de Kar, 1987; Van de Kar et al., 1985b;
1981).

The effect of fenfluramine could be prevented by pretreatment

with the 5-HT uptake inhibitors indalpine and fluoxetine or the 5-HT
synthesis inhibitor PCPA (p-chlorophenylalanine; Van de Kar et al.,
1985b).

Injections

of the

5-HT neurotoxin 5, 7-dihydroxytryptamine

(5,7-DHT) into the dorsal raphe nucleus prevented the effect of PCA on
renin secretion suggesting that brain 5-HT neurons in the dorsal raphe
nucleus mediate the effect of PCA (Van de Kar et al., 1982).

The

dorsal raphe nucleus sends projections to the arcuate, anterolateral
and the suprachiasmatic nuclei of the hypothalamus
Lorens, 1979; Azmitia and Segal, 1978).

(Van de Kar and

Posterolateral deafferentation

or mechanical ablation of the hypothalamus prevented the PCA- induced
increase in PRA (Karteszi et al., 1982), suggesting that the dorsal
raphe

nucleus

may

send

projections

to

the

hypothalamus

that

are

involved in the regulation of renin secretion.
The role of the sympathetic nervous system in mediating the PCAinduced increase in PRA has also been investigated.
stimulation

of

renin

secretion

was

not

mediated

The serotonergic
by

either

the

3

sympathetic nervous system or adrenal catecholamines (Van de Kar and
Richardson-Morton, 1986).

Transection of the spinal cord proximal to

the exit of the renal nerves did not prevent the effect of PCA on renin
These studies suggest that the sympathetic nervous system

secretion .

.is not involved in mediating the serotonergic stimulation of renin
secretion.
Taken together, these results indicate that a serotonergic pathway
originating in the dorsal raphe nucleus with nerve terminals in the
hypothalamus
terminals

regulate

has

not

renin secretion.

been

identified.

The
It

exact location of the
is

possible

that

the

paraventricular nucleus (PVN) may play a role in mediating the 5-HTinduced increase

in renin secretion since studies by Gotoh et al.

(1987) have demonstrated that electrolytic lesions of the PVN prevent
the PCA-induced increase in PRA.
(1986) and Gotoh et al.

Studies by Richardson Morton et al.

(1987) have also indicated that the PVN is

involved in the stress-induced increase in PRA.

Since the sympathetic

nervous system was not shown to play a role in the PCA-induced increase
in PRA, there should be another way for the brain to communicate with
the kidneys.
hormonal factor

One possibility is that the hypothalamus releases a
into the blood that circulates

to the kidneys and

increase renin secretion.
In order to test this hypothesis,

a group of donor rats were

treated with PCA or saline.

Their plasma was collected and injected in

a group of recipient rats.

The PRA values in the recipient rats were

increased after injection of the PCA-plasma, but injection of plasma
from rats that were treated with saline did not alter PRA (Van de Kar

4
~

al.,

1982a).

These

data

suggested that

PCA may

stimulate

the

release of a factor (renin-releasing factor; RRF) into the circulation
that

produces

Pretreatment

an
of

increase
the

chlorophenylalanine
administration of

in

rats

(PCPA)
the

renin

with
did

secretion

the
not

5-HT
alter

in

conscious

synthesis
the

rats.

inhibitor

response

of

PRA

pto

Depleting 5-HT stores with PCPA

PCA-plasma.

prevented any release of 5-HT by residual PCA molecules present in the
plasma fractions.
The

present

studies were

designed

to

investigate RRF in vitro

using a kidney slice renin release bioassay.

Studies were designed to

determine the molecular weight of RRF and to characterize the nature of
this substance is a peptide.

Plasma from rats that received either

injections of serotonin agonists or rats that were stressed were tested
to determine if these stimuli could increase the plasma concentration
of RRF.

Other experiments were developed to study the distribution of

RRF in the rat brain and attempt to identify where RRF cell bodies are
located.
with

a

In addition, hypothalamic explants were superfused in vitro
high

potassium

solution

to

test

if

depolarization

of

the

hypothalamus could stimulate the release of RRF.
Many neuroendocrine systems have a feedback system that regulates
the

synthesis

and

pituitary gland.

release

of

a

hormone

from

the

hypothalamus

or

Once the factor reaches the target organ, the target

increases the secretion of its hormone which acts as a message to the
brain

to

halt

the

production

of

the

hormone.

To

test

for

the

possibility of a feedback loop in the regulation of the release of the
RRF from the hypothalamus, the concentration of RRF in the hypothalami

5

of nephrectomized rats was compared with the RRF concentration in shamoperated rats.
negative

The results of this experiment suggest that there is a

feedback

loop

from

regulates the release of RRF.

the

kidney

to

the

hypothalamus

that

CHAPTER II

LITERATURE REVIEW

A.

overview

1.

Renin-angiotensin enzyme cascade
The regulation of blood pressure in the body relies to a large

extent on the
(RAAS).
The

integrity of the renin-angiotensin-aldosterone system

Renin is the rate limiting enzyme in the formation of ANG II.

enzyme

is

synthesized,

stored and

released

from the

granular

juxtaglomerular cells located in the afferent arterioles of the kidney
(Taugner et al., 1986; Cantin et al., 1977).
The juxtaglomerular cells, afferent and efferent arterioles and
distal

tubule

are

apparatus (JGA) .

referred

to collectively as

the

juxtaglomerular

The JG cells are in close proximity to the macula

densa, a specialized portion of the distal tubule that is sensitive to
changes in sodium reabsorption across the tubular epithelium.
When released from the kidney, renin circulates in the blood and
cleaves the leucine-leucine bond (a leucine-valine bond in humans) in
the

renin substrate,

angiotensin I (ANG I).
amino

acids

from

ANG

angiotensinogen,

to

liberate

the

decapeptide,

Angiotensin converting enzyme (ACE) cleaves two
I

to

form

the

octapeptide

angiotensin

II.

Degradation of ANG II by the action of aminopeptidase A leads to the
6

7

formation of angiotensin III, while the action of other angiotensinases
leads to inactive peptide fragments.

asp-arg-val-tyr-ile-his-pro-phe-his-leu-leu-ile-his-ser-R
Angiotensinogen

l

Renin

asp-arg-val-tyr-ile-his-pro-phe-his-leu
angiotensin I

l

+

leu-ile-his-ser-R

angiotensin converting enzyme

asp-arg-val-tyr-ile-his-pro-phe
angiotensin II

+

his-leu

~ aminopeptidase

arg-val-tyr-ile-his-pro-phe
angiotensin III

l

angiotensinases

inactive fragments
Figure 1. Diagrammatic representation of the renin-angiotensin system
enzyme cascade.

2.

Role of the angiotensins
The angiotensins (ANG I, ANG II and ANG III) exert a number of

pharmacological actions, all of which are involved in maintaining blood
pressure and plasma volume.

ANG II is the most active peptide of the

renin-angiotensin enzyme cascade and produces profound increases in
blood pressure (Fujii and Vatner, 1985; Fagard et al., 1985; Ross and
White,

1966).

vascular
(Fujii

smooth

ANG

II

muscle

and Vatner,

is

a

potent vasoconstrictor

directly

1985;

by

and contracts

stimulating vascular

Coruzzi et al.,

1983).

receptors

In addition to
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increasing systemic blood pressure, ANG II acts directly on the heart
to

increase

myocardial

contractility

(Koch-Weser,

1965).

ANG

I

enhances the release of catecholamines from the adrenal medulla and
sympathetic nerve terminals (Peach et al., 1971; Ross and White, 1966).
In addition, ANG II also prevents the reuptake of norepinephrine by the
sympathetic nerves (Khairallah, 1972), thus prolonging the effect of
norepinephrine at the synapse.

ANG I is equally effective as ANG II in

stimulating the release of adrenal catecholamines but is less potent in
producing vasoconstriction (Peach et al., 1971).
Another
stimulation

principal
of

mechanism

aldosterone

of

synthesis

action
and

for

ANG

secretion

II

from

is
the

the
zona

glomerulosa of the adrenal cortex (Aguilera et al., 1980; Davis and
Freeman, 1976).
reabsorption

Aldosterone produces an increase in sodium and water

from

the

distal

tubule

(Biron

increasing extracellular fluid and volume.

et

al.,

1961)

thus

The heptapeptide, ANG III

has been reported to be equally effective in inducing steroid synthesis
in the adrenal cortex (Braley et al., 1983; Blair-West et al., 1980).
Circulating levels of ANG II are able to influence the release of
pituitary hormones.

Systemic ANG II facilitates the neuronal firing of

neurohypophysial neurons of the paraventricular and supraoptic nuclei
(Ferguson and Renaud, 1986).

It has been demonstrated that the release

of vasopressin and ACTH (adrenocorticotropin hormone) are stimulated by
increased plasma levels of ANG II (Keller-Wood et al., 1986; Spinedi
and Negro-Vilar, 1983; Ramsay et al., 1978).
secretion is also stimulated by ANG II.

LH (luteinizing hormone)

However, this effect does not

appear to be mediated by circulating intravenous ANG II but rather by
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intracerebral injections of ANG II

(Steele~

al., 1983).

The subfornical organ (SFO), median eminence and area postrema are
These brain regions are not

circumventricular organs of the brain.

located within the blood-brain barrier and therefore may be responsive
to circulating factors.

Immunoreactive staining for ANG II has been

demonstrated in the SFO and area postrema (Gehlert et al., 1986; Lind
~al.,

1985).

Destruction of the subfornical organ (SFO) prevents the

increased neuronal firing of neurohypophysial neurons
Renaud, 1986).
firing

rate

(Ferguson and

This finding suggests that ANG II may influence the
and

neurohypophysial

possibly

neurons

by

the

release

influencing

of

substances

SFO neuronal

from

firing.

The

pressor response to ANG II and the ANG II-induced drinking response
were also attenuated by lesions in the SFO (Lind et al., 1983).

Joy

and Lowe (1970) and Fink et l!l., (1987) demonstrated that ablation of
the

area

postrema

prevents

the

Therefore it appears that ANG II,
circumventricular

organs,

can

ANG

II-induced

pressor

response.

by stimulating receptors

further

influence

the

in the

regulation of

plasma volume through central nervous system pathways.

B.

Historical Overview
Studies in the late 1800's, Tigersteadt and Bergmann (as reviewed

by Brod, 1986) demonstrated that kidney extracts, when injected into
bilaterally nephrectomized rabbits, produced a prolonged increase in
blood pressure.

This pressor material was found primarily in the renal

cortex of the kidney whereas other tissue extracts did not produce an
increase in blood pressure.

This substance was called renin.

Later,
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in 1934, Goldblatt et al produced an increase in blood pressure by
placing a clamp around, and occluding the renal arteries.

The degree

of hypertension appeared to be dependent on the tightness of the clamp
around the renal artery.

They concluded that the kidney may play a

.role in the

development

of hypertension.

pressure was

independent of

the

This

increase

in blood

sympathetic nervous system or the

adrenal medulla (Goldblatt et al., 1934).

Tying off the renal veins

prevented the hypertension from developing (Goldblatt et al., 1937).
This indicated that the kidney releases a substance that is responsible
for the development of hypertension.
The attention then turned to renin as a causative substance for
hypertension.

When renin was purified, it increased blood pressure in

intact animals but had no vasopressor activity when it was infused into
the isolated dog tail (Friedman et al., 1938).

However, when blood was

used to perfuse the dog tail preparation, the vasoconstrictor effect of
the kidney extracts returned.

This finding led to the theory that

renin was not the vasoactive substance but it was the interaction of
renin and renin-activator that led to the formation of the vasoactive
product.

The substrate

(renin-activator) is present in the alpha-2

globulin fraction of plasma.
Two
States

independent groups,

and Braun-Menendez

effect of renin.

Page

(1940)

and Helmer
in Argentina,

(1940)

in the United

studied the pressor

They found that plasma (renin-activator) and renin

when incubated together formed a heat stable and potent vasoconstrictor
substance that produced an immediate and dose-dependent increase in
blood pressure.

Renin, when administered, had a latent period before
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the vasopressor effect could be observed.

It became evident that renin

was the enzymatic catalyst in the formation of this peptide.

Page and

Helmer named this peptide angiotonin and Braun-Menendez referred to it
as hypertensin.

It was not until 1958 that the nomenclature was

standardized when the two groups compromised and called the substance
angiotensin.

The

renin-activator

became

known

as

angiotensinogen

(renin-substrate; proangiotensin).
Studies were begun to isolate and purify angiotensin.
upon

purification

it

was

discovered

that

dialyzing

However,

the

solution

containing angiotensin with sodium chloride instead of water, produced
a pressor material in a different molecular weight range.

This led to

the discovery that there were two forms of angiotensin.

The second

peptide could be formed from angiotensin I by plasma supplemented with
sodium chloride.

However, if renin was incubated with plasma in the

absence of chloride only angiotensin I was formed.
perfused kidneys, Skeggs et al.
potent vasoconstrictor that ANG I.

Using isolated

(1954) showed that ANG II was a more
Therefore rapid conversion of ANG I

to ANG II results in the pressor activity.

These results suggested

that an additional enzyme was required for the conversion of ANG I to
ANG II.

This newly found enzyme was named angiotensin converting

enzyme (ACE).

ACE circulated in the plasma and required the presence

of chloride ions for its activity (Skeggs et al., 1956).

A later study

by Ng and Vane (1967) showed that as blood circulated through the lungs
there

was

a

stronger

vasoconstriction

circulated through other vascular beds.

produced

than

blood

that

They therefore concluded that

the highest concentration of this enzyme occurred in the lung.

12
The association of renin with the glomeruli was identified by Cook
and Pickering (1959).

They succeeded in separating the glomeruli from

the rest of the kidney tissue by first injecting iron oxide into the
glomerulus.

The cortex was dissected and put through a sieve.

A

magnet was then used to separate the glomerular fragments from the
tubules.

Bioassay indicated that the vascular pole of the glomerulus

contained more renin activity than the tubules.

Similar results were

reported by Bing and Wiberg (1958) who showed that destruction of the
renal cortex reduces the renin content of the kidney.

These data

support earlier findings of Goormaghtigh (1939) who demonstrated that
renin was localized in the arterioles of the juxtaglomerular apparatus.
These were some of the first studies that reported the localization of
renin at the glomerular area of the renal cortex.
These studies have indicated that there are two enzymatic steps
needed

to

form

ANG

II

from

angiotensinogen.

Since

renin

and

angiotensin have been implicated in the pathogenesis of hypertension,
many studies have focussed on the inhibition of this enzyme cascade as
a possible treatment of hypertension.

The development of substrate

analogues (Plattner et al., 1986), converting enzyme inhibitors (Mento
and Wilkes,

1987),

renin antibodies

antagonists

(Wilkes,

1984)

are

(Dzau et al.,

pharmacological

1980) and ANG II
approaches

to

the

possible treatment of hypertension.

C.

Angiotensinogen
Angiotensinogen is the substrate for renin and thus the precursor

for ANG I, and ultimately ANG II.

There is renin-substrate specificity
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that allows the interaction of renin only with homologous substrate.
For example, human renin will only react with human angiotensinogen;
non-primate angiotensinogen will preferentially react with homologous
substrate.

It has been proposed that the specificity of the enzyme-

substrate interaction may be due to the variation in the amino acid
sequence between the human and non-primate forms

(Tewksbury et al. ,

1981; Bouhnik et al., 1981).
Angiotensinogen is a glycoprotein that is primarily localized in
the

liver

although

angiotensinogen.

other

organs

have

been

found

to

contain

Recent studies using immunocytochemistry (Richoux et

al., 1983) and Northern Blot analysis with complementary mRNA sequences
for

angiotensinogen

(Ingelfinger et al.,

1986)

liver contains and synthesizes angiotensinogen.

identified

that

the

Clauser et al., (1983)

demonstrated that angiotensinogen is released from liver slices and its
productions can be prevented by treatment with cycloheximide, a protein
synthesis

inhibitor.

Incubation of liver slices

in the absence of

oxygen also prevents the secretion of angiotensinogen indicating that
the release is an active process.
Angiotensinogen circulates in the plasma in two forms which are
referred

to

Tewksbury,

as Aol

and Ao2

1983).

The

(Hilgenfeldt and Schott,
dissimilarity

in

l987a;

molecular

1987b;

weight

is

attributable to the difference in the number of carbohydrate residues
present on Aol and Ao2.

Hilgenfelt and Schott (1987) demonstrated that

the two forms of angiotensinogen do not differ in their affinity for
endogenous renin.
There

are

a

variety

of

factors

that

can modulate

the

plasma
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concentration of angiotensinogen.

The levels of renin substrate can be

decreased by diseases that affect liver function,
(Schroeder et al., 1970; Ayers, 1967).

such as cirrhosis

Adrenalectomy (Carretero and

Gross, 1967; Nasjletti and Masson, 1969; Reid, 1977) and hypophysectomy
(Goodwin

et

al.,

1970)

also

reduce

the

circulating

levels

of

The decrease in angiotensinogen levels produced by

angiotensinogen.

adrenalectomy can be prevented by administration glucocorticoids (Reid,
1977; Nasjletti and Masson, 1969).
that

mineralocorticoids

and

Nasjletti and Masson, (1969) found

sodium

replacement

From these

effect of adrenalectomy.

reports

also

inhibited

it appears

that

the
the

pituitary adrenal-axis is necessary for maintaining plasma substrate
levels.

In addition to

the pituitary-adrenal

thyroid

axis

a

may

angiotensinogen.

play

role

in

axis,

regulating

the pituitary-

the

synthesis

of

Rats that have been thyroidectomized have a decreased

plasma angiotensinogen concentration;

this

decrease

is

reversed by

thyroid hormone replacement therapy (Bouhnik et al., 1981; Dzau and
Herrmann, 1982).

Rats that were made hyperthyroid by administration of

1-thyroxine also had elevated levels of renin substrate
Herrmann, 1982).

(Dzau and

Increased levels of angiotensinogen are also achieved

by administration of ethinyl estradiol (Glauser et al., 1983; Krakoff
and Eisenfeld,

1977).

However,

this

treatment

does not

angiotensinogen levels in hypophysectomized animals.

increase

Dexamethasone, a

glucocorticoid, also increases the production of angiotensinogen by the
liver.
The

release

of

angiotensinogen may be

control by the renin-angiotensin system.

subject

to a

feedback

The final product of the
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pathway,

ANG

II

has

been

shown

angiotensinogen (Herrmann et al.,

to

1980;

stimulate
Reid,

the

1977).

release

of

Captopril,

a

converting enzyme inhibitor, reduces circulating levels of ANG II, and
also produces a decrease in the circulating levels of angiotensinogen
(Radziwill et al., 1986; Hermann and Dzau, 1983).

D.

Renin

1.

Renin synthesis
Renin

is

a

proteolytic

enzyme

approximately 36, 000 to 40, 000.

with

a

molecular

weight

of

Renin is primarily localized in and

secreted from the granulated cells of the afferent arterioles (Lacasse
et al., 1985; Taugner et al., 1982a; Taugner et al., 1979).
immunoreactivity has

also

been

demonstrated

in

the

Renin-like

cells

of

the

efferent arteriole (Taugner et al., 1981) and along extended lengths of
the afferent arteriole and interlobular artery (Taugner et al., 1979;
Taugner et al.,

1981).

Renin-like

immunoreactivity has also been

described in tissues other than the kidney.
renin include blood vessels (Re et al., 1982),

Extrarenal sources of
pituitary (Deschepper

et al., 1986; Naruse et al., 1985), adrenal gland (Baba et al., 1982),
testes (Deschepper et al., 1986) and heart (Dzau and Re, 1987).

These

studies were performed by using either immunocytochemical techniques or
in situ hybridization using renin messenger RNA.

These extrarenal

renin sources are not identified in all species, only kidney renin is
universally present in all species.

Perhaps the richest source of

renin is the submaxillary gland of the mouse (Menzie et al., 1978;
Cohen~ al., 1972).

Purification and isolation studies for renin have
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been performed using submaxillary renin.

It is important to keep in

mind that renal and submaxillary renin are not identical in structure;
renal renin is glycosylated whereas submaxillary gland renin does not
contain carbohydrate moieties (Kawamura et al., 1986).

Studies have

indicated that renal renin may be the major source of the circulating
enzyme.

Van de Kar and Richardson Morton (1986) have reported that

after bilateral nephrectomy the plasma levels of renin are below the
sensitivity limit of the radioimmunoassay (less than 10 pg) suggesting
that renal renin is the major source of renin in the plasma.
Renin is synthesized from messenger RNA as a preprozymogen that is
processed at the endoplasmic reticulum and converted to prorenin.
proenzyme

(prorenin)

This

is further processed in the rough endoplasmic

reticulum and is packaged in a crystalline form in the golgi apparatus
which then forms protogranules.

The protogranules mature into dense

secretory granules (Taugner et al., 1987; Lacasse et al., 1985) which
secrete renin from the epithelial cells.
that only the dense granules contain renin.

It has long been believed
Recently, the presence of

immunoreactive renin vacuoles in the cytoplasm of these granule cells
may suggest an alternative pathway for the packaging and release of
renin (Lacasse et al., 1985; Taugner et sij.., 1984).
There has been some debate as

to whether

the

dense

contain and release active or inactive (prorenin) renin.

granules

The presence

of prorenin has been identified in both plasma and kidney (Sealey et

fil., 1983; Morris and Johnston, 1976) and has been immunologically
identified as inactive renin (Bouhnik et al., 1985).

Kawamura et al.

(1986) showed that isoelectric focusing of stored renin resulted in
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several peaks

of differing

renin activity present
isolated
However,

glomeruli
there

isoelectric points with the majority of

in one peak.

also

was

a

exhibited

redistribution

Renin that was secreted from
different
of

isoelectric

points.

renin activity between the

different isoelectric points, and there were two peaks that contained a
considerable
therefore

amount

of

concluded

renin

that

activity.

there

may

be

Kawamura
some

et

al.

processing

of

(1986)
renin

Cathepsin B is an intracellular enzyme

occurring in the cytoplasm.

that has been cited to convert inactive to active renin (Takahashi et
al., 1982).

In other studies, Taugner et al.

(1983) have found that

mature secretory granule cells exhibit both renin-like and cathepsin Blike immunoreactivity.

It is suggested that cathepsin B is involved in

the activation of prorenin to active renin which probably occurs in the
dense granules.
Studies using antisera raised against different determinants of
the

renin

prosegment

indicated

have

that

prorenin

is

found

predominantly in the protogranules of the epithelioid cells while there
is very little staining in the mature granules (Taugner et al., 1987).
Therefore it was concluded that this prosegment was cleaved off in the
golgi

complex.

In

contrast,

increases from the protogranules
al. ,

198 7;

activation

Lacasse
of

et al. ,

renin

from

labelling

for

immunoreactive

to the mature granules

1985) .
prorenin

It is
occurs

renin

(Taugner et

therefore suggested that
in

the

protogranules.

Altogether, these results indicate that there may be stores of inactive
renin that are further processed to active renin and released into the
circulation.
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2.

Renin release
Renin

is

mechanisms.

released

from

the

kidney

primarily

by

exocytotic

The granules have been observed to fuse with the plasma

membrane of the juxtaglomerular cell and release their contents into
the extracellular space
Nobiling,

(Taugner et al.,

Other groups have

1984).

1986; Taugner,

Buhr le and

reported invaginations of the

plasma membrane into the interior of the epithelioid cell that come in
close contact with the dense granules (Ryan et al., 1982; Peter, 1976).
These

invaginations

appears
suggests

of

the

plasma membrane

contain material

that

to be similar to that present in the dense granules which
that

these

granules

empty

their

contents

into

these

invaginations.
It has been hypothesized that renin is released from the JG cells
into the lymphatics and not directly into the blood.

Lever and Peart

(1962) first demonstrated renin activity in renal lymph.

The highest

renin activity was present in the renal venous plasma which correlated
with

increased

levels

in the

injection of renin into

lymph

(Horky et al.,

the plasma produced an

1971).

increase

Since
in blood

pressure without altering the renin concentration in the lymphatics,
Horky et al. (1971) hypothesized that renin was first secreted into the
lymph and then diffused into the circulation.

The relationship between

renin in the plasma and renal lymph was illustrated by O'Morchoe et al.
(1981).

In response to injection of furosemide, renin concentration

rose in the renal artery, renal vein and lymph.

The increase in renin

concentration was more immediate and marked in the renal lymph whereas
a few minutes were required to reach peak renin levels in the plasma.
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Therefore, renin may be released into the lymph where it then diffuses
into the blood.

3.

Metabolism of renin
Renin circulates in the plasma with a half-life of approximately

7.0 minutes (Kim et al., 1987).

Other half-life values for renin have

been reported to be between 3. 0 and 15. 0 minutes (Fiselier et al. ,
1984; Assaykeen et al.,
follows

1968).

The clearance of renin from plasma

a two component system with a rapid component (t1;2 -

7. 0

minutes) and a slow component with a t1;2 of about 65 minutes (Kim et
al., 1987).
Plasma renin values are dependent on the relative rates of renin
release and the clearance from the plasma.

A major portion of renin is

inactivated by the liver (Heacox et al., 1967), however the kidney is
also involved in eliminating renin from the plasma (Kim et al., 1987;
Peters-Haefeli et al., 1971).

Partial hepatectomy produced a decrease

in the clearance of renin and increased the half-life of the slow phase
(from 65 minutes to 94 minutes) while nephrectomy prolonged the halflife of the rapid phase (6 minutes to 10. 5 minutes).

The increased

half-life suggests that both the kidney and the liver are involved in
the catabolism of renin.

Intravenous infusion of radiolabelled renin

accumulated preferentially in the liver and kidney.

Fifteen minutes

after

products,

injection

of

renin,

radioactive

degradation

with

molecular weights lower than that for renin, were present in both the
liver and kidney (Kim et al., 1987).

Although the liver accumulated

about 60% of the radiolabelled renin, the kidney accumulated only 11%.
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These studies suggest that both the liver and kidney are responsible
for the clearance of circulating renin with the liver being the more
predominant.
A pure antibody against renin is not widely available for use in a
direct radioimmunoassay (RIA) for renin.

Renin is measured in the

plasma primarily by RIA of generated ANG I.

To prevent conversion of

ANG I to ANG II, ACE inhibitors are added to the samples.

Plasma renin

activity (PRA) is the measure of the ability of plasma to generate ANG
I, which depends on the amount of renin and renin substrate present in
the plasma sample.

Unless there is saturation of the enzyme with the

substrate, variations in substrate levels may influence the amount of
ANG I produced.

Plasma renin concentration (PRC) is a measure of the

ability of renin to generate ANG I in the presence of a saturating
concentration of renin substrate.

The normal plasma concentration of

angiotensinogen is less than the Km required for renin to generate ANG
I at maximum velocity.
samples

are

In order to measure renin concentration, the

saturated with

proceeds at Vmax·

renin

substrate

so

that

the

reaction

Therefore any variation in substrate levels will not

influence PRC values.

PRC is a better indication of the amount of

renin circulating in the plasma.

E.

Regulation of renin secretion

1.

Role of plasma electrolytes
la.

Macula densa
The macula densa region of the

distal

tubule

is composed of

columnar cells that are in contact with the afferent arteriole.

The
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basement membrane of the macula densa cells appears to fuse with the
membranes of the afferent arteriole that surround the granular cells
(Barajas and Powers, 1984).

In addition, the macula densa cells have

short extensions of cytoplasm that extend into the mesangial cell area
of the JGA and the granule cells of the arterioles {Sottiurai and
Malvin, 1982).

These anatomical findings suggest that there may be a

functional relationship between the cells of the macula densa and the
renin

containing

cells

of

the

afferent

arteriole.

It

has

been

hypothesized that the macula densa is the sensor for changes in ionic
concentrations of the tubular fluid that signals the granular cells to
alter renin release.

lb.

Sodium
Sodium has been shown to play a role in hypertension and the

regulation of blood pressure (Parfrey et al., 1981;
1987; McCaa, 1982; Takata et al., 1986).
appears

to

concentration.

be

inversely

regulated

Dawson and Oparil,

In addition, renin secretion
by

distal

tubular

sodium

In the study by Parfrey et al. (1981) it was observed

that as patients were changed from a high to a low sodium diet their
PRA values increased.

In hypertensive patients, reduction of sodium

led to lowered blood pressure.

However, reduction in sodium levels did

not alter blood pressure in normotensive patients.
hypertensive patients
sodium.

there

It appears that in

is a greater sensitivity to changes in

Rats that are supplemented with NaCl in their drinking water

also have decreased PRA values and increased blood pressure (Pyykonen

.tl. al., 1986).

It is conceivable that increased sodium may decrease
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renin

by

stimulating

the

renal

baroreceptor

as

a

result

of

increased blood pressure and extracellular fluid (ECF) volume.
this hypothesis, Anderson et al.

the

To test

(1975) infused dextran solutions of

different osmolarities or a Ringer's salt solution into sodium depleted
dogs.
salt

PRA was decreased only in the group that received the Ringer's
solution

extracellular

which
fluid

The

values.

restored
with

plasma

the

volume

the

sodium

dextran
and

levels.

solutions

mean

Replacement

did not

arterial

pressure

of

reduce

PRA

were

not

significantly different between the dextran-infused and saline-infused
groups.

This

proportional
performed

in

to

suggests
plasma

that

sodium

renin

secretion

concentration.

salt-depleted humans

subjects received saline infusions,

(Tuck

et

be

inversely

A similar

study was

al.,

may

1975).

When

the

PRA decreased, but there were no

alterations in PRA after dextran infusion.

The increase in ECF volume

was similar in both the saline-infused and dextran-infused groups.

If

the renal baroreceptor contributed to the suppression of renin release,
then all of the groups would be expected to have a similar decrease in
PRA

after

proposed

restoration
mechanism

independent

of

of

plasma

volume.

sodium-induced

These

suppression

data
of

support

renin

the

release

of changes in plasma volume.

One of the first

studies

that actually measured the amount of

sodium at the macula dens a area was performed by Churchill et al. ,
(1978).

The changes in sodium concentration in the distal tubule were

correlated with alterations in renin secretion.

Micropuncture sampling

of the distal tubular fluid showed that the tubular sodium load was
proportional

to

dietary

sodium.

In

sodium-deprived

rats,

renin
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secretion was increased when compared with the control group maintained
on a standard diet.

Renin secretion was decreased in the animals that

were fed a high sodium diet.

This study suggested that there was an

inverse correlation between plasma renin activity and the sodium load
in the distal tubule.

le.

High ceiling diuretics, sodium and renin secretion
The effect of sodium on renin secretion was also tested using the

high

ceiling

diuretic

ethacrynic

acid

chlorothiazide (Cooke et al., 1970).

and

a

thiazide

diuretic,

Ethacrynic acid prevents sodium

and chloride reabsorption by inhibiting the active sodium-chloride cotransporter in the ascending loop of Henle.

The thiazides inhibit

sodium reabsorption in the distal tubule downstream from the macula
It was

densa.

observed that

renin secretion was

increased after

administration of ethacrynic acid and persisted when the volume was
restored.
secretion

Chlorothiazide
during

volume

failed

to

restoration.

produce
The

an

increase

effects

of

in renin
these

two

diuretics implies that the effect of chlorothiazide on renin release is
mediated by changes in plasma volume.

The effect of ethacrynic acid

appears to be mediated by the macula densa.

The results of this study

suggest that changes in sodium sensed by the macula densa cells in the
early part of the distal tubule serve as a regulator of renin release.
The finding with ethacrynic acid seems to contradict the results of
other

studies

indicating

that

sodium

ions

decrease

renin release

(Parfrey et al., 1981; Fray, 1978; Churchill et al., 1978;
1975; Anderson et al., 1975; Bunag et al., 1966a).

Tuck~

.al.,

However, another
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study which

used

furosemide,

a

diuretic

with

actions

similar

to

ethacrynic acid, to investigate the effect of salt and water loss on
PRA (Vander and Carlson, 1969) supported the findings by Cooke et al.
(1970).

Small doses of furosemide produced a natriuresis and diuresis

that was prevented by replacing the volume loss.

Larger doses of

furosemide produced significant increases in PRA in dogs that were not
reversed by replenishing the salt and water losses.

These results

provided evidence that the loop diuretics may inhibit sodium transport
at the macula densa cells, resulting in elevated PRA.
One proposed hypothesis by Meyer et al. (1968) was that furosemide
might affect renin release by inhibiting sodium transport into the
macula densa cells.

This would account for

the

inability of the

increased sodium load to the macula densa after furosemide to decrease
renin release.

Meyer et al. (1968) noticed that furosemide produced a

large

in renin release

increase

in volume-replete

rabbits.

They

concluded that since the loss of volume did not increase renin there
may be a change in the delivery of sodium to the cells of the macula
densa.

This theory was tested in 1982 by Sottiurai and Malvin.

They

correlated intracellular sodium concentration in the macula densa cells
with changes
intake.

in PRA that occurred as a result of altering sodium

In sodium-depleted states, there was the expected rise in PRA

but without any changes in the intracellular content of sodium in the
macula densa cells.

Infusion of saline reduced PRA but did not alter

the intracellular concentration of sodium.

The authors concluded that

intracellular sodium in the macula densa cells is not affected by
changes

in dietary

sodium and

furthermore,

that

this

is

not

the
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mechanism by which the macula densa regulates renin secretion from the
afferent arteriole.
Itoh and Carretero (1985) have observed that the macula densa is
necessary for the regulation of renin release from isolated afferent
arteriole preparations.
preparations

had

a

They noted that in vitro afferent arteriole

higher

rate

of

renin

than

afferent

When these arterioles are

arterioles with an intact macula densa.
incubated with furosemide,

release

in doses that correspond to those used in

vivo studies, only the arterioles with the macula densa were stimulated
to increase renin release.

This implies a role for the macula densa in

the furosemide-induced increase in renin release that is independent of
the baroreceptor effect.

Since this was an in vitro study, it appears

that furosemide may directly affect the macula densa.
Upon histological analysis of the macula densa cells Sottiurai and
Malvin (1982) noted that the intercellular spaces between the cells
were dilated after perfusion.
Kaissling and Kitz

(1982).

This

finding was

In addition,

also

observed by

they noted that when rats

received either mannitol infusion (osmotic diuretic) or furosemide, the
intercellular spaces between the macula densa cells were narrower than
those of control animals.

From a functional perspective, the closing

of these spaces might prevent sodium from gaining access to the JG
cells

and

therefore

secretion.
dilated.
artifacts

sodium

would

not

be

able

to

inhibit

renin

In hypervolemic conditions the intercellular spaces were
Kaissling and Kitz (1982) did not attribute these findings as
of

the

tissue

processing

since

the

spacing between the

epithelial cells of the tubules were not altered under the different
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test conditions.

Whether the treatment effects on the macula densa

cell spaces reflect a true occurrence in vivo remains to be determined.
However, these findings are interesting and may suggest a mechanism of
action for the macula densa in transducing the signal from the ionic
concentration of the tubular lumen to the renin secreting cells.

ld.

Potassium
In addition to sodium, another cation, potassium, is thought to

regulate renin secretion.

The first study on potassium-regulated renin

release was done by Vander

(1970).

In normal dogs,

infusion of

potassium chloride into the renal artery produced a decrease in PRA
without altering renal plasma flow or blood pressure.

Infusion of

potassium increased the urinary excretion of both sodium and potassium
from the perfused kidney.

The decrease in PRA could have been due to a

decrease in either sodium or potassium reabsorption that would have
resulted in an increase of sodium delivery to the distal tubule/macula
densa.
not

The possibility that potassium exerts its effect on the JGA was

ruled

out.

Shade

et

al.

(1972)

demonstrated

that

potassium

produces a decrease in renin secretion that is dependent on an intact
renal system and glomerular filtration rate.

In the non-filtering

kidney, potassium was without effect on renin secretion (Shade et al.,
1972).

Kirchner

and

Mueller

(1982)

tested

the

potassium-induced

inhibition of renin secretion using salts other than chloride.

PRA was

measured after infusion of potassium chloride, bicarbonate, nitrate and
acetate in sodium deficient rats.

After each infusion,

decreased about 50% from the control values.

PRA levels

Arterial pressure, plasma
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volume

and

sodium

treatment groups.

balance

were

similar

between

the

control

and

In conscious rats maintained on a sodium-deficient,

high potassium diet, the increase in potassium levels blocked the rise
in PRA after sodium depletion.

~

In 1976, Kotchen

al. found similar

results using a low sodium chloride diet supplemented with potassium
bicarbonate.
bicarbonate,

If
not

potassium
only

was

chloride was
there

a

used

blockade

instead of potassium
of

the

sodium-induced

increase in PRA but a further suppression of PRA was observed.

le.

Chloride
Since potassium chloride produced a greater suppression of PRA,

Kotchen et al.
potassium
chloride

in
as

(1976)

suggested a

regulating
a

new

renin

modulator

role for chloride in addition to

release.
for

renin

This

spurred

secretion.

interest

Not

only

in
did

potassium chloride inhibit renin secretion when compared with potassium
bicarbonate but sodium chloride inhibited renin release when compared
with sodium bicarbonate (Kotchen et al., 1976).
et al.

Furthermore, Kotchen

(1978) and Kirchner et al. (1978) demonstrated that both sodium

chloride and sodium bromide decreased PRA while sodium infusion as an
acetate, nitrate or carbonate salt did not alter renin release.
been postulated that bromide
manner

to

and

is handled by the kidney in a similar
these

ions

can

influence

tested

the

role

of chloride by

infusing choline chloride versus the bicarbonate salt.

Again, only the

secretion.

chloride,

It has

Kotchen et

either
al.

of

(1978)

chloride salt produced a suppression of renin release.
occurred independently of variations

renin

These changes

in sodium or potassium balance
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(Kotchen et al., 1978) or blood pressure or volume (Kirchner et al.,
1978).
Rostand et al. (1985) measured the quantities of chloride in the
tubules and correlated the concentration of chloride with changes in
renin release in the perfused rat kidney.

Substituting sodium nitrate

and thiocyanate salts for chloride reduced the amount of chloride in
the kidney and also produced an elevation of renin release.

Analysis

of the data revealed a negative correlation between chloride and renin
activity.
cations,

Therefore, it is possible that chloride, in addition to the
may

be

important

in

regulating

renin

release

from

the

juxtaglomerular cells.

lf.

Calcium
Calcium plays an important role in secretory and smooth muscle

cells.

It provides a signal for the release of neurotransmitters and

for muscle contraction.
may

be

an

inverse

intracellular

However, with respect to renin release, there

relationship

concentration of

between

calcium.

renin
In

secretion

1974,

and

the

Kotchen et al.

infused calcium chloride into the renal artery of dogs and observed a
fall in renin release that was accompanied by increased calcium levels
in the blood.

There was no alteration of renal blood flow or of

arterial pressure.

An increase in sodium excretion was observed while

the plasma concentration of sodium was unaffected by calcium treatment.
Addition of calcium directly to kidney cortical cells produced a dosedependent suppression of renin release whereas sodium did not alter the
spontaneous release of renin (O' Dea et al., 1984).

Kotchen et al.
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(1974) examined the effect of calcium on the generation of ANG II from
renin.

Infusion of calcium did not interfere with the renin-substrate

interaction

or

with

angiotensinase

activity.

It

was

therefore

concluded that calcium inhibited renin release by the macula densa or
by a direct effect on the juxtaglomerular cells.
Recent studies investigating the role of calcium in regulating
renin

release

concentrations.

have

used

pharmacological

dependently

to

alter

calcium

BAY K 8644 is a calcium channel agonist that activates
It has been shown that BAY K 8644

the slow inward calcium channel.
vasoconstricts

agents

smooth

(Dietz,

muscle

1986).

and

reduces

Infusion of

renal

blood

flow,

dose-

the agonist into perfused

kidney (Dietz, 1986) or addition to cortical slices (Matsumura et al.,
1985) does not alter basal levels of renin release.

However, when BAY

K 8644 was added with 15 mM potassium there was a significant decrease
in renin release from the slices (Matsumura et al.,
Peart,

1986).

1985; May and

The dose of potassium was reported to be below the

threshold level for depolarization of the cells.

The effect of BAY K

8644

a

was

reversed

by

addition

of

nifedipine,

calcium

channel

antagonist. Other investigators have indicated that addition of calcium
channel

antagonists

elevate

renin

release

from

kidney

slices

by

decreasing the amount of intracellular calcium (Henrich and Campbell,
1986; Antonipillai and Horton, 1985).
The hypothesis

that renin secretion is modulated by stores of

intracellular calcium has not been defined.

However, calmodulin, an

intracellular protein that has multiple binding sites for calcium, has
been implicated in controlling renin release (Park et al., 1986; Fray
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and Park, 1986; Fray et al., 1983).

Addition of calmodulin antagonists

such as trifluoperazine (Fray et al., 1983), calmidazolinium (Fray and
Park,

1986)

or W- 7

(Shinyama et al.,

1987)

produced dose-dependent

increases in renin release when added to the kidney.

Trifluoperazine

also increased the basal levels of renin secretion from isolated renal
cortical cells

(Fray et al., 1983).

Infusion of W- 7 into the renal

artery of rats did not alter mean arterial pressure, renal blood flow
or

urine

The

flow.

control

calmodulin antagonist actions,

compound,

W-5,

which

does

not

have

also did not affect these parameters.

W- 7 produced dose-related increases

in PRA and renin secretion rate

whereas W-5 did not produce these changes in renin release (Shinyama et
al., 1987).
calcium

These data suggest a role for calmodulin and intracellular

levels

in

the

juxtaglomerular

cells

in

modulating

renin

release.
Some

of

the

stimuli

that

inhibit

presence of extracellular calcium.

renin secretion require

the

Vanadate (Churchill and Churchill,

1980), ouabain (Cruz-Soto et al., 1984), potassium (Park et al., 1986)
and high renal perfusion pressure (Fray and Park, 1986) are dependent
on calcium in order to mediate their effect.

For example,

ANG II

suppressed renin release when added directly to the kidney via the
renal

artery

(Bunag

et

al.,

1967).

Removal

or

lowering

of

the

concentration of calcium in the perfusate medium prevented the effect
of ANG
Horton,

II

on renin release

1985).

In

addition,

aldosterone

production

addition

BAY K 8644

of

(May and Peart,

from

the

ANG

glomerulosa

1986;

Antonipillai and

II-induced

stimulation

cells

enhanced

(Hausdorff et al.,

was

1986).

These

of

after

findings
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suggest that calcium is necessary in order for ANG II

to exert an

action, and that inhibition of renin secretion by ANG II is dependent
on

a

calcium

mediated

mechanism.

Dietz

(1986)

demonstrated

that

verapamil, another calcium channel antagonist prevented the decrease in
renin

secretion

produced

supported

an

influx

needed for

is

earlier

by

increasing

proposal

by

Fray

perfusion
(1980)

pressure.

This

stating that calcium

elevated perfusion pressure to decrease renin

Overall, the evidence implies that calcium suppresses renin

release.

release and may be the mechanism by which other factors

{ANG II and

increased perfusion pressure) inhibit renin release.

2.

Volume receptors
The

early

study by

Goldblatt

et

al.

(1934)

demonstrated

that

graded constriction of the renal arteries induced hypertension in dogs.
This

was

believed

to

be

vasopressor substance.
an

inverse

due

to

the

presence

of

a

circulating

In 1959, Tobian et al. observed that there was

relationship

between

cells and perfusion pressure.

the

granulation

of

juxtaglomerular

He therefore proposed the theory that

the juxtaglomerular cells act as baroreceptors, changing the rate of
renin release as determined by changes in arterial pressure.
~

by

al.

Imagawa

(1984) showed that as arterial pressure is gradually increased

suprarenal

aortic

constriction,

PRA

decreases.

These

studies

suggest that changes in perfusion pressure may be a stimulus for renin
release.
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2a.

Intrarenal baroreceptor
The role of an intrarenal baroreceptor has been studied using the

non-filtering kidney model
developed to

(Blaine et al.,

1971).

This model was

obstruct glomerular filtration and prevent changes in

.sodium delivery to the macula densa from altering renin release (Blaine
et al.,
--

1970).

Reduction of plasma volume by hemorrhage or reduction

of renal blood flow by partial suprarenal aortic constriction produced
significant increases in renin secretion (Blaine et al., 1970; 1971;
Blaine and Davis, 1971).

Renal denervation or adrenalectomy did not

diminish the renin response to decreased blood flow.

Since glomerular

filtration ceased, the authors deduced that the change in renin release
was not

dependent on the macula densa and was

likely due to the

presence of an intrarenal baroreceptor.
The role of an intrarenal baroreceptor has also been studied using
an isolated perfused kidney (Fray, 1976).

Increased perfusion pressure

suppressed renin release from the isolated kidney.

Alteration of the

sodium concentration in the perfusion medium did not affect the renin
response to increased perfusion pressure.
hypothesis of Blaine et al.
involved

in mediating

the

increased arterial pressure.

These findings support the

(1971) that the macula densa may not be
changes

in

renin

secretion produced by

Kaloyanides et al.

(1973) demonstrated

that the increase in renin secretion produced by ureteral occlusion was
prevented by increasing renal arterial pressure.
Results have also accumulated suggesting that the juxtaglomerular
cells are

sensitive

produced by

to

papaverine

changes

in arterial stretch.

decreased

renin

release

from

Vasodilation
the

isolated
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perfused kidney

(Fray,

phenylephrine

or

vasoconstriction,

1976).

Perfusion of the kidney with either

methoxamine,

increased

two

o

agonists

renin activity.

The

that

produce

increase

in renin

secretion produced by phenylephrine was blocked by co-administration of
papaverine

or

by

increased

perfusion

pressure.

Since

juxtaglomerular cells are modified smooth muscle cells,
that

they

response

may

depolarize

seen with

in

response

to

stretch

increased plasma volume)

or

the

it is likely

(similar

to

the

increased perfusion

Depolarization may influence the membrane permeability to

pressure.

Later,

certain ions (Fray, 1976).

Fray (1980) demonstrated that the

decrease in renin release produced by increased perfusion pressure was
mediated by calcium.

Intracellular recordings from renin-containing

cells show that depolarization of the juxtaglomerular cells is produced
by

stimuli

that

inhibit

renin

release

and may be

mediated by

an

increase in calcium influx (Buhrle et al., 1985).

2b.

Cardiac mechanoreceptors
In

addition

mechanoreceptors
secretion.

to

also

Increased

the
are

intrarenal

involved

left

and

in

right

inflation of arterial balloons produces
activity

(Brennan et al.,

1971).

baroreceptor,
the

atrial

maintenance
pressure

a decrease

Kaufman

(1987)

cardiac
of

renin

produced by

in plasma renin

on the otherhand,

demonstrated that increased right atrial stretch did not alter plasma
renin

activity

conscious rats.
al.

(1971)

or

the

isoproterenol-induced

increase

in

PRA

in

Other studies have supported the results of Brennan et

indicating that the mechanoreceptors in the right atrium
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influence renin release (Sanchez et al., 1987; Julius et .5!.l., 1983).
In human studies, lower body compression produced by inflation of a
cuff around the legs, caused a significant increase in right arterial
pressure and a suppression of PRA (Sanchez et al., 1987;
1983).

Julius~

.5!.l.,

Tilting the subject upwards promoted gravitational pooling of

blood and also increased PRA.

The effect of tilting on renin was
Inversely, decreasing right

counteracted by lower body compression.

atrial pressure by induced pooling of blood in the extremities, results
in an increase in PRA (Julius et al., 1983).

These findings suggest

that the cardiopulmonary mechanoreceptors play an important role in the
integration of postural changes and renin release.

3.

Autonomic nervous system
3a.

Role of the sympathetic nervous system
The juxtaglomerular apparatus of the kidney was analyzed for the

presence of adrenergic nerve terminals.
Barajas

and

Muller

(1973)

documented

Using electron microscopy,
the

presence

of

dense

core

varicosities in the vicinity of the JGA that are generally associated
with adrenergic neurons.
cells

of

the

afferent

These nerve terminal regions synapsed on the
and efferent

arteriole

as

well

as

on

the

glomerulus and the proximal and distal tubules (Buhrle et al., 1985;
Barajas

and Muller,

1973).

Using horseradish peroxidase labelling

techniques, the origin of the renal nerves has been identified in the
celiac

and

nodose

ganglion

(Gattone

et

al.,

1986)

and

there

is

innervation extending from the dorsal root ganglia in the spinal cord
segments TlO-Ll (Ciriello and Calaresu, 1983; Kuo et al., 1982).
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Typically,

stimulation of the renal nerves results in a renal

vasoconstriction,

increased renin release and an increase in sodium

reabsorption (DiBona, 1985).

The increase in renin release occurs at

stimulation frequencies that do not alter renal hemodynamics (Osborn et
1
L·•

1981) .

Renal denervation produces a decrease

in basal renin

release (Grandjean et al., 1978) and a decrease in the amount of sodium
reabsorbed

from

the

tubules

Repollet et al., 1985).

(Bello-Reuss

et al.,

1975;

Fernandez-

The antinatriuresis produced by renal nerve

stimulation can be prevented by pretreatment with the

Q

antagonist

The beta blockers, propranolol and atenolol reduce the

phentolamine.

renal nerve-induced increase in renin secretion (Osborn et al., 1983).
It has

been hypothesized

that

the

increase

in renin release

resulting from sodium depletion is partially dependent on intact renal
nerves.

Denervation reduced the response of natriuresis to volume

expansion in sodium-depleted rats.

There was no difference in sodium

excretion in rats that were maintained on a regular sodium diet.

These

results suggest that renal nerve stimulation plays a larger role in
maintaining sodium excretion in sodium-deficient than in control states
(DiBona and Sawin, 1985).
Renal sympathetic nerve activity has been shown to influence the
onset of hypertension by changing renal arterial pressure, sodium and
water

balance

demonstrated

and
that

renin
renal

release.
denervation

Winternitz

and

decreases

blood

Oparil

(1982)

pressure

and

increases the renal excretion of sodium in spontaneously hypertensive
rats.

Renal denervation delays

the development of hypertension in

renovascular hypertension (Vari et al., 1987) and in genetic forms of
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hypertension (Kline et al., 1980; Dietz et al., 1978).

3b.

Beta receptors

3b1.

Renal beta receptors

Infusion of either epinephrine or norepinephrine into dogs with
maintained arterial pressure produces the same response with respect to
renin release and renal function as renal nerve stimulation (Vander,
Renin release increases and the renal plasma flow and sodium

1965).

excretion decreases.

Vander (1965) proposed that stimulation of the

renal nerves produced an increase in renin secretion that occurred
secondarily to
slices

have

agonist,

changes

in sodium excretion.

demonstrated

that

adminstration

Studies using kidney
of

receptor

isoproterenol, produces increases in renin release that are

prevented by pretreatment with d, 1-propranolol
1975;

the beta

Vandongen

et

al.,

1973).

Addition

of

('Weinberger et al.,
norepinephrine

and

epinephrine also produce increases in renin release that are prevented
by addition of d,1-propranolol

('Weinberger

et

al.,

1975).

These

effects are due to stimulation of beta receptors since pretreatment
with either phenoxybenzamine, an alpha-antagonist or d-propranolol, a
membrane stabilizing form of the beta antagonist propranolol, did not
prevent the catecholamine-induced stimulation of renin secretion.
Beta-adrenergic receptor subtypes were localized in rat kidney
slices

by

autoradiography

using

the

non-selective

B

antagonist,

iodocyanopindolol, in the presence of the selective antagonists for the
Bi (betaxolol) or B2 (zinterol) receptors (Healy et al., 1985).
results

The

from this study identified the renal cortex as having the
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highest

concentration

of

renal

beta-receptors.

B1

binding

occurs

primarily on the afferent arterioles and on the glomeruli; B2 binding
is predominantly on the renal tubules of the medulla.

Functionally,

the B1 adrenoceptor has been associated with renin release from the
kidney.

Himori et al.

B1 antagonist,

attenuates the increase in renin secretion produced by

isoproterenol.

A B2

antagonist,

IPS-339,

isoproterenol-induced

the

reducing

(1979) demonstrated that atenolol, a selective

was

not

increase

in

Stimulation of renal nerves at a low frequency
produces
flow,

an

increase

sodium

1981).
nerve

as

effective

renin

in

release.

(0. 5 Hz for 0. 5 ms)

in renin release without changing renal blood

excretion or

arterial

pressure

(Osborn et al. ,

1985;

Pretreatment with atenolol blocked the renin response to renal
stimulation.

In contrast,

blockade of B2

modify the increase in renin secretion.

receptors

did not

These studies suggest that the

sympathetic nervous system increases renin release by stimulating B1
receptors on the JG cells.

3b2.

Extrarenal beta receptors

Recently, data have accumulated indicating that an extrarenal beta
receptor

regulates

In 1972, Reid et al.

receptors.
agonist,
increases

renin secretion independently of

isoproterenol,
in

PRA and

denervated kidneys.

into
renin

Renal

the

the

renal beta

infused the beta adrenergic receptor
femoral

secretion

vein

rate

of dogs

in both

and noticed

innervated and

perfusion pressure was held constant by

adjusting an aortic clamp so there was no influence of renal perfusion
pressure

on

the

renin

response

to

isoproterenol.

No

changes

in
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glomerular filtration,

renal plasma flow or electrolyte excretion in

these animals were detected.

In contrast, infusion of isoproterenol

into the renal artery at similar doses produced no change in PRA or
renin secretion rate.

These results do not support the involvement of

intrarenal beta receptors in the regulation of renin secretion, and
indicate that beta adrenergic stimulation is mediated by an extrarenal
mechanism.
In 1979, Johnson et al. reproduced the findings of Reid et al.
(1972) with isoproterenol and tested the effect of epinephrine on renin
secretion

infused both

intravenously and

intrarenally.

Similarly,

epinephrine produced increases in PRA when infused intravenously but
not intrarenally.

This increase in renin secretion was independent of

renal nerves, changes in perfusion pressure and prostaglandins (Johnson
et

al. ,

1979a).

Propranolol

blocked

the

effect

of epinephrine.

Further experiments were designed to identify the location of these
extrarenal beta-receptors.

Infusion of epinephrine into splanchnic

circulation (Johnson, 1983) did not produce an increase in PRA as did
intravenous infusion.

Johnson (1982) also tested the possibility that

the beta receptors were located in the cerebral vasculature by infusing
epinephrine into the carotid arteries.

At higher doses epinephrine

produced an increase in PRA when infused into the carotid arteries and
this dose also increased the circulating levels of epinephrine.
slightly lower doses there was no change in PRA.

At

Epinephrine also

produced increases in PRA in adrenalectomized animals, indicating that
the extrarenal beta receptors are not located in the adrenal glands
(Johnson,

1985).

At

this

point

Johnson

established

a

role

for
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extrarenal beta receptors but did not address whether there was an
interaction between renal and extrarenal receptors.

A submaximal dose

of epinephrine was infused intravenously and into the renal artery.
The renin secretion rate was measured in both kidneys and the values
were not different from one another (Johnson, 1984).

It was concluded

that there is no interaction between beta receptors and that renin
secretion is regulated only by extrarenal beta receptors.

Contrary to

these findings by Johnson (1979; 1982; 1984; 1985) are the data that we
have obtained in our laboratory (Urban and Van de Kar, 1986).

We have

demonstrated that addition of the beta agonist, isoproterenol, to rat
kidney cortical slices produces significant increase in renin release
from the kidney slices.

The dose of isoproterenol that we used in the

renin release bioassay, is more concentrated than that used by Johnson.
Therefore, it may be likely that the beta receptors at the kidney level
require a higher concentration of isoproterenol in order to produce an
effect whereas extrarenal beta receptors may be more sensitive to lower
doses.

3c.

Parasympathetic nervous system
Cholinergic

Barajas (1979).
followed

the

innervation

of

the

kidney

has

been

described by

He observed that labelling for acetylcholinesterase
distribution

pattern

of

catecholamine

fluorescence.

However, when the animals were treated with 6-hydroxydopamine (6-0HDA),
a

drug

that

destroys

catecholaminergic

nerve

terminals,

both

norepinephrine and acetylcholine staining disappeared from the kidney.
This

suggested

that

the

acetylcholinesterase

and

catecholamine-
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containing neurons

may

in

fact be

the

same neurons.

Addition of

acetylcholine directly to kidney slices did not produce a significant
change in renin release (De Vito et al., 1970).

Schrier et al. (1975)

studied the effects of vagotomy on renin secretion in dogs.
produced

a

suppression

hypophysectomized

dogs

of

the

vagotomy was prevented.

renin

suppression

secretion.
of

renin

Vagotomy

However,
secretion

in

after

This result indicates that inhibition of renin

secretion is due to release of a pituitary hormone and not to a direct
innervation of the kidney by the parasympathetic fibers.
attributed this
vagotomy.

effect

Therefore,

The authors

to

an enhanced release of vasopressin after

it

appears

that

cholinergic

neurons

do

not

contribute to the innervation of the kidney or to the regulation of
renin release.

4.

Other factors that regulate renin secretion
4a.

Vasopressin
Vasopressin

hormone.
whether

(AVP)

is

a

potent vasoconstrictor and antidiuretic

In addition, vasopressin inhibits renin secretion.
this

juxtaglomerular

inhibition
cells

or

occurs

by

direct

secondarily due

action

of

AVP

However,
on

the

to AVP-induced changes

in

blood pressure has not been determined.
Vander (1968) showed that infusion of AVP produced a decrease in
basal

renin release.

However,

Vander noted

that

the

excretion of

sodium was increased and proposed that AVP may inhibit renin by acting
on the macula densa.

Another study (Shade et al., 1973) using the non-

filtering kidney model,

also demonstrated that AVP suppresses

renin

41
release after intrarenal infusion.
used did not

They reported that the doses of AVP

alter mean arterial pressure or renal blood flow.

Furthermore, since this study was performed in a non-filtering kidney,
the decrease in renin release occurred without a functioning macula
densa, suggesting a direct effect of AVP on the juxtaglomerular cells.
Addition of AVP to rat renal cortical slices produced a significant
decrease

in

renin release

(Park et al. ,

1981).

This

is

further

indication that AVP acts directly on the juxtaglomerular cells.
In addition to a direct effect on the kidney, AVP decreases renin
release secondarily to changes in blood pressure (Schwartz and Reid,
1986).

The inhibitory effect of AVP on renin release has been studied

using analogues for AVP that are selective for either antidiuresis (V2
receptor)

or

vasoconstriction

(V1

receptor).

Infusion

of

the

antidiuretic agonist, DDAVP (d-arg-vasopressin), does not modify PRA or
arterial

pressure.

[(CH2)5Tyr(Me)AVP],

Pretreatment
prevented

the

with

a

V1

receptor

AVP-induced

increase

antagonist
in

pressure and the decrease in PRA (Schwartz and Reid, 1986).

blood
These

studies indicate that AVP reflexly inhibits renin secretion through
increased blood pressure.

However, whether AVP primarily suppresses

renin release by this mechanism or by a direct action on the kidney has
yet to be established.

4b.

Adenosine
Adenosine has recently been shown to inhibit the release of renin

from the kidney.

Churchill and Churchill (1985) have described the

presence of two adenosine receptors (A1 and A2) that differentially
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regulate renin secretion.

Both receptors are coupled to adenylate

cyclase, but the Ai receptor inhibits while the A2 receptor stimulates
adenylate cyclase.

Stimulation of the Ai receptor produces suppression

of renin release while activation of the A2 receptor increases renin
release

from kidney slices.

These effects of adenosine on renin

release are anatagonized by calcium channel inhibitors and are probably
mediated by changes in intracellular calcium (Churchill and Churchill,
1985).
Adenosine produces vasoconstriction when injected into the renal
artery (Osswald, 1984).
can

also

alter

renal

Other studies have indicated that adenosine
nerve

activity.

Stimulation

of

the

renal

sympathetic nerves at different frequencies produces vasoconstriction
that is blocked, dose-dependently, by adenosine (Ekas et al., 1981).
However, Arend et al.

(1984) have demonstrated that the decrease in

renin release produced by adenosine was not influenced by changes in
renal

blood

flow

or blood pressure.

Administration of adenosine

prevents the increase in renin release produced by prostacyclin (PGI2)
and norepinephrine,

suggesting that adenosine acts directly on the

juxtaglomerular cell to inhibit renin release (Deray et al., 1987).

4c.

Prostaglandins
Administration of the prostaglandin precursor, arachidonic acid,

produces

an

(Beierwaltes

increase
et

al.,

in

renin

1982).

release

from

Superfusion

of

isolated
the

glomeruli

glomeruli

with

prostaglandins PGE1, PGE2 or thromboxane had no effect on renin release
(Beierwaltes et al., 1982).

However, if the rapid breakdown of PGI2
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was prevented, thereby increasing the concentration of PGI2, or if the
pH of

the

perfusate was

prostaglandins,

renin

increased which

release

was

favors

stimulated.

stability of

the

Inhibition of PGI2

synthesis also prevented the arachidonic acid-induced increase of .renin
release (Beierwaltes et al.,

1982).

The increase in renin release

produced by PGI2 has also been described by Kirchner (1985) and Henrich
and Campbell (1984).
Prostaglandins have been shown to mediate the increase in renin
release in response to sodium depletion.

Indomethacin, a prostaglandin

synthesis inhibitor, reduces renin release in the sodium depleted dog.
However, when the animals are maintained on a regular sodium diet,
indomethacin does not affect the basal levels of PRA (Deforrest et al.,
1980).

The role of prostaglandins in mediating the response of PRA to

changes in renal arterial pressure is more controversial.

In dogs with

either a denervated non-filtering kidney or an intact filtering kidney,
suprarenal aortic

constriction produces

an increase

in PRA.

This

increase in PRA is not blunted by treatment with indomethacin (Freeman
et al., 1982) or meclofenamate (Villarreal et al., 1984).

However, the

decreases in renal perfusion pressure in these experiments were below
the autoregulatory range (80 mmHg).

Imagawa et al. (1985) produced an

increase in renin release after suprarenal aortic constriction without
going

below

the

autoregulatory

range.

After

treatment

with

indomethacin, the renin response to aortic constriction was abolished.
It has been suggested that the difference in the prostaglandin response
to suprarenal aortic constriction following reductions in perfusion
pressure within the autoregulatory range may be dependent on renal
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prostaglandins (Freeman et al., 1984).

5.

Feedback regulation of renin release
As

controls
balance.

has been discussed,
aldosterone

the

secretion

The mechanisms

renin-angiotensin system partially
which

maintains

sodium

and

water

involved in renin secretion can also be

described in terms of a feedback control system.

The primary signals

that stimulate the renin-angiotensin system are a decrease in plasma
volume and blood pressure.

The decrease in blood pressure not only

activates the stretch receptor but also the macula densa by decreasing
glomerular pressure and sodium delivery to the distal tubule.
ANG II is the end product of the renin-angiotensin system and
plays an important role in the feedback regulation of renin secretion.
ANG II has been shown to inhibit renin release from the kidney (Vander
and Geelhoed, 1965).

This is referred to as the short feedback loop.

Receptors for ANG II have been localized on the glomerulus (Bianchi et
al.,

1986).

However,

it

is possible

that stimulation of ANG

II

glomerular receptors would affect renin release as a result of changes
that would occur as a consequence of alterations in the glomerular
capillary pressure.

Furthermore, ANG II constricts the efferent renal

arterioles which increases the pressure in the capillaries, resulting
in enhanced sodium and water reabsorption (Hall, 1986).

The increased

sodium and water reabsorption would lead to an increased plasma volume
and concomitant decrease

in renin release.

ANG II stimulates the

production of aldosterone from the adrenal gland (Aguilera et al. ,
1980; Davis and Freeman, 1976).

Aldosterone acts at the renal distal
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tubule

to

increase

tubular lumen.

the

reabsorption of sodium and water

from

the

This restores plasma volume and blood pressure, thus

completing a long feedback loop .

.F.

Central nervous system regulation of renin secretion

1.

Role of the central nervous system
There has been increasing evidence suggesting a role for central

nervous system pathways in regulating renin secretion.

The effect of

electrical stimulation of several brain sites have been electrically
stimulated on PRA have been studied.

Richardson et al. (1974) compared

the effects of ventrolateral medulla (VLM) stimulation on renin release
from control and denervated kidneys.

They observed that denervation

prevented the increase in renin release following stimulation of the
VML in cats.

Propranolol also blocked this increase.

These studies

suggest that the renal sympathetic nerves are involved in mediating the
increase in renin secretion after stimulation of the VLM.

Passo et al.

(1971) stimulated the dorsal medulla and similarly demonstrated that
destruction

of

the

renal

nerves

excitation of the dorsal medulla.

attenuated

the

PRA

response

to

In this study (Passo et al., 1971),

plasma epinephrine levels were elevated, implicating the involvement of
the sympathetic nervous system and adrenal catecholamines.
Stimulation

of

the

dorsal

periaqueductal

grey

(PAG)

in

the

mesencephalon produced a pressor response that was associated with an
increase in renin activity.

Renal denervation prevented the effect of

electrical stimulation of the PAG on blood pressure and renin secretion
(Ueda et al., 1967).
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The fastigial nucleus of the cerebellum has been implicated in
regulating autonomic functions, namely, elevating arterial pressure and
heart

rate.

This

has

been

referred

to

as

the

fastigial

pressor

response and requires an intact sympathetic nervous system (Del .Bo et
.al., 1983).

Koyama et al.

(1980) stimulated the fastigial nucleus and

observed a pressor response accompanied by a significant increase in
PRA.

This

cerebellar

increase
peduncles

was

reduced
The

(SCP).

by

transection

major

output

of

from

the

superior

the

nucleus is to the pontine and medullary areas via the SCP.

fastigial

The authors

therefore concluded that the pressor response to fastigial stimulation
may

be

mediated

by

these

cardioregulatory

centers

through

the

sympathetic nervous system.
An

increase

in

renin

activity

was

observed

after

electrical

stimulation of the lateral hypothalamus (Zanchetti and Stella, 1975).
This was associated with a transient constriction of the renal artery.
However,

the

elevation

in

PRA was

maintained

beyond

the

vascular

response and was prevented by destruction of the renal nerves.

These

data are supported in part by Frankel et al. (1976) who also observed
increases in PRA after stimulation of the lateral hypothalamus.
other hand
release

Zehr

in

dogs

hypothalamus.
site

since

and

Feigl

after

(1973)

observed a

stimulation

of

a

On the

suppression of
site

in

the

renin

lateral

This site was postulated to be a sympathetic inhibitory
both

blood

pressure

histology was presented to

and

renin

levels

decreased.

No

identify the sites of stimulation,

so a

comparison with those areas stimulated by Zanchetti and Stella (1975)
could

not

be

made.

Stimulation

of

the

posterior

hypothalamus
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(supramammillary region) produced an increase in PRA and blood pressure
(Natcheff et al., 1977).
sympathetic

system.

nervous

paraventricular

nucleus

dependent

increases

frequency

(Porter,

This effect was also dependent on an intact

of

in

Electrical

the

renin

hypothalamus
release

Blood

1986).

stimulation
(PVN)

with

pressure

produced

increased
was

of

not

the
dose-

stimulation
affected

by

These data suggest a role for the PVN in

stimulation of the PVN.

increasing renin release independently of changes in blood pressure.
The role of the renal nerves in mediating this effect has not yet been
reported.

2.

Stress-induced renin secretion
Stress

is

cardiac disease.
blood

pressure

implicated

in

the pathogenesis

of hypertension and

A variety of stress paradigms produce increases in
and

the

circulating

levels

including corticosterone, prolactin and PRA.

of

different

hormones

One of the first studies

on the effect of stress on renin secretion was conducted by Leenen and
Shapiro (1974), who subjected rats to different periods of intermittent
foot shock.
the shock.

PRA was increased in rats 15 minutes after they received
However, after the rats were exposed to this stimulus for

over 2 hours, there was an apparent adjustment to the shock since there
was no difference in PRA between the shock and control groups.
~

al.

(1987) reported that intermittent foot shock for 2, 12 and 22

minutes produced increases in PRA.
20

Paris

minutes

of

forced

swimming

In addition, PRA was increased by
in

deep

cold

water,

20

minute

immobilization and by both a 3 and 12 minute conditioned fear (CER)
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Jindra et al. (1980) also observed increases in PRA in rats

paradigm.
that

immobilized

were

for

20

minutes

or

immobilization of 150 minutes daily for 34 days.

received

repeated

Exposure to a novel

environment (open field) or to the presence of a hungry cat produced
elevations

in

environment

PRA

on

(Clamage

PRA

could

Blair et al.

propranolol.

et
be

al.,

1976).

attenuated

(1976)

The
by

effect

of novel

pretreatment

reported that baboons

with

that were

subjected to an avoidance operant conditioning paradigm had elevated
PRA values.

The baboons were taught to sit in a chair and their task

was to push a lever in order to avoid an electric shock.

This study

suggested that a psychological stimulus could evoke a stress response
as measured by an increase in PRA.
There are a variety of stress models that produce increases in
PRA.

The stress paradigm used in this laboratory consisted of a 3 or

10 minute conditioned emotional or fear response paradigm.

The rats

are placed in a chamber on three consecutive days and after either a 3
or 10 minute period, they receive a footshock.

On the fourth day the

rats are placed in the chamber and do not receive any shock.

At this

point they are anticipating the shock, which simulates anxiety or fear.
The

effect

of

CER on PRA can be

attenuated,

but

not

completely

prevented by pretreatment with the beta receptor blocker propranolol
(1.0 mg/kg i.p.; Van de Kar et al., 1984).

Administration of the same

dose of propranolol to rats that were subjected to restraint stress did
not affect
increase

the

increase

in PRA was

in PRA (Sigg et al.,

diminished with higher

1978); however,

the

doses of propranolol.

Adrenal medullectomy combined with chemical sympathectomy (peripheral
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injections of 6-0HDA)

did not prevent the stress-induced increase in

PRA (Richardson Morton et al.,
restraint stress paradigm,

unpublished observations).

With the

demedullectomy did not alter the stress-

induced increase in PRA but renal denervation did reduce the observed
.increase in PRA (Sigg et al., 1978).

These conflicting results might

suggest that different neural pathways are involved in mediating the
stress-induced increase in PRA.
studies

Pharmacological

have

indicated

that

peripheral

administration of the benzodiazepines, chlordiazepoxide and midazolam,
which enhance GABA neurotransmission, did not alter the renin response
to the GER paradigm (Van de Kar et al., 1984b).

Naloxone, an opiate

antagonist or diisopropyl fluorophosphate (DFP) an acetylcholinesterase
inhibitor, also did not prevent the stress-induced rise in PRA or alter
basal levels of renin release.
neither the cholinergic,

Therefore,

these results imply that

GABAergic or opiate systems are involved in

regulating renin release in response to the GER (stress) paradigm.
Electrolytic lesions in the dorsal raphe nucleus (DRN) prevented
the stress-induced increase in renin secretion with both the 3 and 10
minute GER paradigms (Van de Kar et al.,

1984a; Richardson-Morton et

al.,

not

1986).

serotonergic

However,
fibers

this

since

effect
5,7-DHT

was

due

injections

to
into

disruption
the

DRN

of
and

pretreatment of rats with the S-HT2 antagonist, LY53857 did not prevent
the effect of stress on renin secretion (Lorens et al., 1986).
~

al.

(1987)

electrolytic
secretion

in

and

lesions
rats

Richardson-Morton
in

the

subjected

PVN
to

et

prevented
either

al.
the

(1986)

showed

Gotoh
that

increase

in

renin

immobilization

or

GER,
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respectively.

Selective destruction of the cell bodies in the PVN with

ibotenic acid, also prevented the increase in PRA (Richardson-Morton et
~·,

1986).

In

order

to

test

the

possible

involvement

of

catecholamines in regulating the stress-induced release of renin, 6.0HDA was injected into the PVN and was found to attenuate the stress
(GER) response on PRA (Richardson Morton et al., 1987).

3.

Role of serotonin (5-HT) on renin release
3a.

Effects of peripheral administration of 5-HT
Administration

of

5-HT,

or

the

serotonin

precursor,

5-

hydroxytryptophan (5-HTP) to rats produced increases in water intake
(Kikta et al., 1981) that are mediated by the renin-angiotensin system
(Meyer et al.,

1974;

Kikta et al.,

1983).

Pretreatment with the

serotonin receptor antagonist, methysergide, prevented the dipsogenic
effect of 5-HT and 5-HTP.

In addition, rats that received either the

beta blocker, propranolol (Meyer et S!l.., 1974; Kikta et al., 1983) or
the angiotensin converting enzyme inhibitor captopril (Kikta et al.,
1983) had an attenuated drinking response to 5-HT.

These results

suggest that the renin-angiotensin system mediates the 5-HT-induced
dipsogenesis.

However, these studies did not examine whether this was

a central effect of 5-HT nor did they postulate a mechanism for 5-HT
stimulation of renin release.

A study by Bunag et al. (1966b) showed

that infusion of serotonin into the renal artery did not directly
stimulate renin release from the kidney.

Data presented in this study

(Table 9) demonstrate that addition of 5-HT to kidney slices does not
directly increase renin release.
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Barney et al.

(1981) and Meyer et al.

(1974) demonstrated that

injection of 5-HT either subcutaneously or intramuscularly to rats,
produces increases in PRA.

The effect of 5-HT on PRA is prevented by

pretreatment with metergoline,

a

5-HT antagonist.

Treatment with

propranolol or camphidonium, a ganglionic blocker, attenuated the 5-HT
induced increase in PRA (Meyer et al., 1974) indicating that both 5-HT
and the sympathetic nervous system are involved in regulating renin
release.

Zimmermann

and

Ganong

(1980)

administered

two

precursors,

5-HTP and 1-tryptophan to anesthetized dogs and observed

increases in PRA that were not due to changes in blood pressure.

5-HT

The

elevation of PRA due to the 5-HT precursors was prevented by infusion
of

the

central

aromatic

amino

acid

decarboxylase

inhibitor,

benserazide, but not by carbidopa, a decarboxylase inhibitor that does
not cross the blood brain barrier.

Pretreatment with metergoline or

renal denervation also prevented the 5-HT-induced increase in PRA.
Earlier studies by Epstein and Hamilton (1977) showed that in humans,
the 5-HT antagonist, cyproheptadine, inhibited the furosemide-induced
increase in PRA.
oral

Other studies by Modlinger et al. (1979) showed that

administration of

produced

an

increase

the
in

5-HT precursor 1-tryptophan to humans,
renin

pretreatment with cyproheptadine.

secretion

that

was

prevented

by

These were the first studies that

suggested a role for brain 5-HT in stimulating renin release.

3b.

Role of brain 5-HT neurons
Administration of the 5-HT releaser, p-chloroamphetamine (PCA) or

the 5-HT agonist quipazine, produces dose-dependent increases in PRA
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(Van de

Kar

et

al. ,

1981) .

The

effect

of PCA is prevented by

pretreatment with p-chlorophenylalanine (PCPA) a drug that inhibits 5HT synthesis.

Fenfluramine, another 5-HT releaser, also produces dose

-dependent increases in PRA that are prevented by pretreatment with
PCPA or the 5-HT reuptake inhibitors, fluoxetine or indalpine (Van de
Kar~

al., 1985b). The effect of a submaximal dose of fenfluramine on

renin secretion was

enhanced after pretreatment with 1-tryptophan.

Administration of the 5-HT2 antagonist LY53857, prevents the increase
in PRA and PRC produced by fenfluramine and the 5-HT agonist MK-212
(Lorens and Van de Kar, 1987).

LY53857 alone did not alter PRA or PRC.

The 5-HT1a agonist 8-0H-DPAT (8-hydroxy-2- [ di-N-propylamino] tetralin)
did not produce any change in either PRA or PRC.

Ipsapirone, another

5-HT1a agonist, produced increases in PRA and PRC only at higher doses
(Lorens and Van de Kar, 1987).

Administration of buspirone, a non-

benzodiazepine

also

anxiolytic

that

has

5-HT1a

agonist

activity

produces a decrease in renin secretion at relatively low doses ( 1. 0
mg/kg i. p.; Van de Kar et al., 1985c).

These findings suggest that

stimulation of 5-HT2 receptors enhances renin release whereas the 5-HT1
receptors may not have a role in the control of renin secretion.
Injection of the 5-HT neurotoxin 5,7-DHT (5,7-dihydroxytryptamine)
into

the

dorsal

raphe

nucleus,

a

serotonergic

cell

midbrain, prevented the PCA-induced increase in PRA.

group

in

the

Injections of

5, 7-DHT into the median raphe nucleus were without effect on renin
secretion (Van de Kar et al., 1982b).
significantly
definitive

reduced

findings

brain

for a

5-HT

Both of these lesion treatments

content.

These

were

the

role of brain serotonin neurons

first
in the
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regulation

of

hypothalamus,

renin

secretion.

either

destroying

Destruction
or

sparing

of

the

the

mediobasal

median

eminence,

prevents the increase in PRA produced by PCA (Karteszi et al., 1982).
Posterolateral

knife

cuts

through

the

mammillary bodies

destroyed

neuronal inputs to and from the hypothalamus, also blocked the increase
in PRA produced by PCA.

However, anterolateral deafferentation did not
Hypophysectomy did not prevent the

reduce the PRA response to PCA.

PCA-induced increase in PRA 4 days after surgery (Karteszi et al.,
1982). Since the dorsal raphe nucleus is known to send projections to
the hypothalamus it is likely that a serotonergic pathway stimulates
renin secretion by some structure within the hypothalamus.
Gotoh

et

al.

(1987)

reported

paraventricular nucleus

(PVN)

that

electrolytic

lesions

Recently,
of

the

in the hypothalamus prevent the PCA-

induced increase in PRA.
In the study by Zimmermann and Ganong (1980), renal denervation
prevents the

increase in PRA produced by 5-HTP or tryptophan.

To

investigate the role of the sympathetic nervous system in mediating the
PCA-induced increase in PRA, beta blockers were administered before
PCA.

Alper and Ganong (1984) showed that pretreatment with the beta-

receptor antagonists propranolol and sotalol prevented the increase in
PRA produced by PCA.
Richardson-Morton

These results were confirmed by Van de Kar and

(1986).

Both

the

selective

beta1

receptor

antagonist, atenolol, and the non-selective beta antagonist, sotalol,
completely prevented the

effect of PCA.

However,

more conclusive

studies indicated that the sympathetic nervous system was not involved.
Treatment of rats with the catecholamine blocker, bretylium tosylate,
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or the cholinergic muscarinic antagonist, methyl atropine did not alter
the PCA-induced increase in PRA (Van de Kar and Richardson-Morton,
Transection of the spinal cord proximal to the exit of the

1986).

renal nerves, between the T1 or T2 vertebrae, did not modify the renin
response to PCA.
combined
secretion.

with

In addition,

peripheral

the effect of adrenal medullectomy

sympathectomy

was

also

tested

on

renin

The adrenal medulla was removed from rats and one week

later they received weekly injections of 6-hydroxydopamine (6-0HDA) for
4 weeks.

This treatment decreased the renal content of norepinephrine

to levels that were below the sensitivity limit of the assay (Van de
Kar

and Richardson-Morton,

1986).

Administration of PCA produced

significant increases in PRA in both the sham-operated rats and the
rats

that were sympathectomized.

These

results

indicate that the

sympathetic nervous system does not mediate the PCA-induced increase in
renin release.

These results appear to contradict the data obtained

with the beta blockers.

However,

it should be considered that beta

blockers have been shown to cross the blood brain barrier and compete
with 5-HT for receptor sites.

Propranolol, for example, is known to

interact at the 5-HT receptor (Middlemiss et al., 1977) and has been
shown to decrease the rate of 5-HT synthesis in the hypothalamus,
midbrain and frontal cortex (Giarcovich and Enero, 1984).
it is

possible

that

Therefore,

the beta blockers may be acting centrally to

influence serotonergic transmission and that a central site of action
for these beta blockers cannot be discounted.
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G.

Role of humoral factor in regulating renin release
The existence of an extrarenal humoral factor was presented by

oeVito

al.

g,!;;

in

nephrectomized
hemorrhage.

Plasma

1971.

dogs

that

were

was

collected

made

from

bilaterally

by

controlled

hypotensive

When the plasma from hypovolemic dogs was injected into

unanesthetized control dogs, there was a significant increase in PRA.
This elevation of PRA was not observed after injection of plasma from
normotensive dogs.
findings.

Polomski et al.

(1974) could not reproduce these

No further studies on this factor were performed.

Since the effect of PCA on renin secretion is not mediated by
either the parasympathetic or the sympathetic nervous systems, another
possibility is that the hypothalamus may release a factor into the
circulation that can stimulate renin release from the kidney.

A study

by Van de Kar et 5!.l. (1982a) tested the hypothesis that PCA induces the
release

of

a

nephrectomized
surgery.

factor
and

received

produced a

injection.

the

blood.

either

saline

A

group

or

PCA

of
24

rats
hours

were
after

Their plasma was collected and administered at different

times to recipient rats.
rats

into

Administration of the plasma from PCA-treated

significant

increase

in PRA at

30 minutes

after

These results suggest that brain serotonin stimulates renin

secretion by releasing a factor into the blood.
experiments have

Further transfusion

indicated that the renin-releasing factor

is heat

stable and is present in the plasma of PCA-treated rats within the
molecular weight range of 500-10,000.

CHAPTER III

MATERIALS AND METHODS

A.

Animals
Male Sprague-Dawley rats (150-300 g) were purchased from Sasco-

King Animal Laboratories (Oregon, WI) and were housed, two per cage, in
a temperature (22°C), light (12:12 light/dark cycle) and humidity (45%
- 55%) controlled room.

Rat chow (Wayne Lab Blox, Allied Mills Inc.,

Chicago,IL) and water were available ad libitum.

B.

Analytical methods

1.

In vitro renin release kidney slice bioassay for measurement of RRF

activity
A rat (150-200 g) was perfused under halothane anesthesia, with
cold saline through the left cardiac ventricle. The abdomen was opened
to expose the kidneys which were removed and immediately placed in cold
saline (0.9% NaCl).
and decapsulated.

The kidneys were palpated to remove excess blood
The poles (2-3 mm) were dissected and removed from

the kidneys, and the kidney was cut in half through the papilla, glued
to a 1-inch square piece of Plexiglas, and mounted on an Oxford Model G
vibratome (10° angle,

settings of 0 for vibration and speed).

The

kidney was always maintained in cold saline, and saline ice cubes were
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added during the slicing to maintain the temperature at 4°c.

Coronal

slices (400 µm) were cut, and the first slice was discarded.

Once the

slice was cut, it was placed on ice in a petri dish containing cold
saline, and the medullary tissue was excised from each slice w.ith a
scalpel.

The renal medulla does not contain renin and the highest

density of renin secreting cells is in the outer cortex.

Therefore,

using coronal slices of cortical tissue ensures that the slices were
homogenous with respect to renin content (Katz and Malvin, 1982a; Jones
~al.,

1979).

Each slice was cut in half and randomly placed, two

kidney slice halves per vial, in 10.0 ml vials that were siliconized
(Prosil-28; Scientific Products, Specialty Chemicals, Gainesville, FL).
Two ml of a Krebs-Ringer buffer were added to each vial.

The Krebs-

Ringer solution has a composition of 118.0 mM NaCl, 1.22 mM KH2P04, 4.7

mM KCl, 2.5 mM CaCl2, 1.2 mM MgS04, 10.0 mM glucose, and 25.0 mM NaHC03
and was used throughout the experiments.

The vials were placed in a

water bath and the kidney slices were incubated at 37°C.

Each vial

received its own supply of a 95% 02-5% C02 gas mixture via a needle
(20-gauge) that was attached to plastic tubing (Scientific Products,
3/32 in. O.D., 1/32 in. I.D.) and inserted into plastic snap-on caps
which fit snugly onto the vials.

This allowed proper oxygenation of

the vials without bubbling the medium.
that bubbling of the

Cho and Malvin (1979) reported

incubation medium in which the kidney slices

incubated inactivates renin at the air-water interface.

This would

result in low and variable values for renin release and the assay for
renin would not indicate real changes in renin release over time.

A

few small holes in the caps relieved the pressure inside the vials.
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The other end of the tubing was attached to a 12 place pipette manifold
which was fitted to the hose that supplied the 95% 02-S% C02 gas.

This

system, when set up with 4-5 manifolds, could oxygenate a total of 4860 vials.
The slices were placed in the vials with 2. 0 ml of Krebs-Ringer
buffer for a 30 minute preincubation period.

After 30 minutes, a 0.2

ml sample was withdrawn from the vials for the determination of renin
concentration.

The vials were refilled with 2. 0 ml of Krebs-Ringer

solution and test solutions (plasma fractions, plasma samples, drugs or
brain and peripheral tissue extracts) were added to the vials.
As a routine for each kidney slice bioassay, six vials received
the vehicle

(usually saline or Krebs-Ringer buffer) and another six

vials received a dose of isoproterenol (10-6M - l0- 5M).
two controls for
levels

of

renin

the bioassay:
release

and

This served as

the vehicle was a control of basal
isoproterenol

demonstrated

maximal

stimulus-induced renin release or the upper limit of the bioassay.
The vials incubated for 1 hr; 0.2 ml was saved for renin assay,
and the Krebs-Ringer solution was decanted and saved for measurement of
pH and, on occasion, lactate dehydrogenase (LDH) activity.
cytosollic enzyme that is used as an indicator of cell lysis.

LDH is a
The LDH

assay were performed to ensure that the increases observed in renin
release from the kidney slices were due to the applied stimulus and not
due to lysis of the kidney cells.

A final 2.0 ml was added for a 30

minute postincubation period and a final 0. 2 ml sample was taken for
determination of renin concentration.
blotted dry and weighed.

The slices in each vial were

All samples were stored at

-40°C until
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determination of renin concentration.
For each bioassay, in addition to the incubation values, samples
were

also

measured

for

renin

release

during

incubation and post-incubation periods.
controls for each kidney slice vial.

the

30

minute

pre-

These were used as quality

After each incubation, the post-

incubation value for renin release should have returned back to the
levels seen in the pre-incubation.

This indicated: (1) if the increase

seen during the incubation period was truly due to the applied stimulus
and (2) whether the kidney cells were dying.
the

pre-incubation

and

post-incubation

Using the comparisons of
periods

along

with

the

measurement of the pH and LDH enabled checks on the bioassay that would
validate the viability of the kidney slices.

2.

Specificity of the bioassay for RRF
2a.

Test for non-specific activation of renin by plasma fractions
Krebs-Ringer samples (2.0 ml) were preincubated with kidney slices

for 1 hour.
pooled.

The kidney slices were removed and the Krebs-Ringer was

Samples

(0.2 ml)

of either saline,

saline-plasma

(M.W.

5,000-10,000) or PCA-plasma (M.W. - 5,000-10,000) fractions were added
to 2. 0 ml of the Krebs -Ringer solution.

These samples incubated at

37°C for 1 hour and afterwards, 0. 2 ml aliquots were taken and saved
for the determination of renin concentration (Method section B part
3b).
2b.

Test for non-specific generation of angiotensin I from renin

substrate by plasma fractions and brain extracts
The

samples

that

were

used

in

the

previous

studies

(plasma
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fractions

and brain extracts)

were

activity

that

in

would

result

tested for possible
the

non-specific

renin-like

generation

angiotensin I in the incubation for the radioimmunoassay.

of

A volume of

2.0 µl of either rat hypothalamic, cerebellar, and pituitary extracts,
or the saline-plasma and PCA-plasma fractions

(M.W. -

5,000-10,000)

were added to 0.2 ml of the Krebs-Ringer solution containing PMSF, 8HQ, phosphate buffer and nephrectomized plasma, which corresponded to
the dilution of these test substances in the kidney slice bioassay.
The samples

incubated for

1 hour at 37°C,

and the

incubation was

terminated by addition of 0. 2 ml of distilled water and immersion of
the samples in a boiling water bath.

The samples were then assayed for

ANG I.

3.

Determination of renin concentration and plasma renin activity
Renin activity of the kidney slices samples and plasma is measured

by radioimmunoassay for generated ANG I

according to the method of

Haber et al. (1969) and Stockigt et al. (1971).
3a.

Preparation of renin substrate (angiotensinogen)
Renin substrate (angiotensinogen) was obtained from the plasma of

nephrectomized, male Sprague-Dawley rats (retired breeders, 450-500 g).
Removal

of

the kidneys

(the major source of renin)

prevented the

enzymatic reaction between renin and angiotensinogen in the plasma and
allowed the plasma concentration of substrate to increase (Radziwill et
al. , 1986).
Approximately 40 animals were used for the preparation of renin
substrate.

The rats were anesthetized with halothane (Burns, Glenview,
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IL) and care was taken to avoid any undue stress to the rats.

The

kidneys were palpated and a dorsal incision was made through the skin
at the kidney level.

The muscles of the back were teased apart by

blunt dissection and the kidneys were removed through the openings in
the body wall.
were removed.

The renal artery and vein were ligated and the kidneys
The ligatures were placed back into the body cavity and

the incision was sutured closed.
of

dexamethasone

(0.2

Each rat then received an injection

mg/rat,

s.c.;

Sigma,

St.

Louis,

MO).

Dexamethasone treatment increases the amount of angiotensinogen in the
plasma (Reid, 1977).
The rats were decapitated 24 hours after surgery.
was

collected

in

a

beaker

containing

0. 3

The trunk blood

M ethylene

tetraacetate (EDTA, pH 7.4; approximately 0.5 ml per rat).

diamine
The blood

was centrifuged at 1500 x g, and the plasma was collected and stored at

-40°c.

3b.

Determination of renin concentration in the Krebs-Ringer medium

after incubation with kidney slices and in plasma.
Renin concentration was measured by determining the amount of
angiotensin I (ANG I) generated by incubating the sample (0.2 ml KrebsRinger from kidney slices or plasma) for 1 hour with a saturating
concentration of renin substrate.

Renin substrate was 0.1 ml of plasma

from nephrectomized rats that received an injection of dexamethasone
(0.2 mg/rat, s.c.) 24 hours before sacrifice.
The converting enzyme

inhibitors

8-hydroxyquinoline

(8-HQ,

10%

suspension in 0.3 M EDTA; final concentration: 0.86 mM; Mallinckrodt,
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St. Louis, MO) and phenylmethylsulfonyl fluoride (PMSF, 5 g in 150 ml
ethanol; final concentration: 2.3 mM; Sigma, St. Louis, MO) were added
(5 µl each) to the samples to prevent the degradation of ANG I to ANG
II.

PMSF inhibits the angiotensin converting enzyme by sulfonating the

active site of the enzyme (Fahrney and Gold, 1962).

8-HQ prevents the

action of converting enzyme by chelating divalent metals
1956) which are necessary for its activity (Fitz,
1971).

(Phillips,

Boyd and Peart,

A volwne of 0.1 ml of sodiwn phosphate buffer (0.5 M, pH 6.0)

was added to the samples to maintain the pH at 6. 0-6. 5 during the
incubation.

This pH range has been determined by us to be optimal for

renin activity.

The

samples

incubated at

37°C

for 1 hour.

The

reaction was halted by addition of 1.6 ml cold distilled water to the
Krebs-Ringer samples, or 0.2 ml of cold distilled water to the plasma
samples, and subsequent immersion of the samples in a boiling water
bath for 3 minutes.

3c.

Plasma renin activity
Plasma renin activity was measured by radioimmunoassay of ANG I

generated

in

the

plasma

sample

after

a

3 hour

incubation.

The

converting enzyme inhibitors, 8-HQ and PMSF were added (25 µl and 20
µ1) to 1.0 ml of plasma at the same final concentration (0.86 mM 8-HQ
and 2.3 mM PMSF).

Sodiwn phosphate buffer (0.5 ml; 0.5 M pH 6.0) was

added to the plasma samples to reduce the pH of the samples to 6.0-6.5.
The samples were incubated for 3 hours at 37°c to generate ANG I from
endogenous

angiotensinogen

(renin

substrate).

The

incubation was

stopped by addition of 0. 5 ml distilled water and immersion of the
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samples in a boiling water bath for 3 minutes.

3d.

Radioimmunoassay for generated angiotensin I (ANG I)
After the

incubation,

the samples

(renin concentration,

plasma

renin activity and plasma renin concentration) were centrifuged (13,000
x g for 10 minutes; Fisher microcentrifuge Model M235A) and aliquots of
the supernatant (20 µl and 50 µl) were diluted to a final volume of 0.5
ml with Tris-HCl (pH 8. 0) and added to tubes (polystyrene, 12 x 75)
with a 0.3 ml solution of an ANG I antibody in a Tris buffer (0.1 M pH
8.0 containing 0.1% gelatin; Sigma, St.Louis, MO).
0.8 ml.
from Dr.

The final volume is

The ANG I antisera (Reid #3 and Brownfield Tl351) were a gift
M. S.

Brownfield,

University of Wisconsin.

These ANG

I

antis era were used at dilutions of 1: 100, 000 (Reid #3) or 1: 40, 000
(T1351) with 35% binding and a sensitivity limit of 10 pg per tube.
After a 24-48 hour incubation period at 4°c with the antiserum, an 1251
labelled ANG I tracer was added to the tubes (10,000 counts per minute
per tube) for an overnight incubation at 4°C.
0.5

ml

of

a

charcoal-dextran

(TSOO;

On the following day,

Pharmacia,

Piscataway,

NJ)

suspension and 1.5 ml of cold distilled water were added to the tubes.
The tubes were then centrifuged at 2000 x g for 15 minutes.

This

separated the unbound 1251-ANG I from the antibody-bound tracer in the
supernatant which was decanted.

The charcoal pellets, containing the

free 1 251-ANG I, were counted on a Micromedic gamma counter.

The data

were reduced by RIA_AID computer program (Robert Maciel Associates,
Inc., Arlington, MA).
variability was 11. 9%.

Intra-assay variability was 4.6% and interassay
The values for renin release from the kidney
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slices are reported as ng ANG I generated/hr.

These values were then

divided by the weight of the kidney slices to obtain ng ANG I/mg
kidney/hr.

PRA and PRC values were reported as ng ANG I/ml/3 hr and ng

ANG I/ml/hr, respectively.
ANG I (Beckman, Arlington Heights, IL) was radiolabelled with 125I
(New England Nuclear,
(Sigma,

St.

Louis,

MO)

North Bellerica,

MA)

using the chloramine T

method of iodination (Greenwood,

Hunter and

Phosphate buffer (0.05 M; 0.02 ml), 12 µl ANG I (0.5

Glover, 1963).

µg/µl) and 20 µl chloramine T (3.5 mg/ml phosphate buffer) were added
to the vial containing the 12 5 I and mixed for 3 seconds.

This was

immediately followed by addition of 25 µl of sodium metabisulfite (4.5
mg/ml phosphate buffer; J.T. Baker Chemical Co., Phillipsburg, NJ) to
halt the reaction.
acetic

acid

on

a

Radiolabelled ANG I was first eluted with 0 .1 N
Bio-Rad AG

Laboratories; Richmond,

l-X4

anion

exchange

resin

(Bio-Rad

CA) column that was made from a siliconized

disposable pasteur pipette (5 3/4"; Scientific Products) with a small
amount of glass wool placed in the tip to support the anion exchange
resin.

Fractions (12 drops per tube) were collected from the column

and the radioactivity in each tube was measured.

The radioactive peak

fractions eluted off this column (usually tube numbers 4-5) were then
placed on a
Piscataway,

Sephadex Gl5 column (Kl5/90,
NJ)

90 x 1.5 cm;

Pharmacia,

and eluted with 0. 05 N acetic acid containing 0 .1%

bovine serum albumin (BSA; Sigma, St. Louis, MO).

Fractions (2.0 ml)

were collected off the Sephadex column and measured for radioactivity.
The tubes

that contained the radioactive ANG I

(approximately five

tubes, numbers 35-39) were pooled and stored at -10°C.

65

c.

In vivo studies of the renin-releasing factor

1.

The effect of a serotonin releaser, PCA and serotonin agonists (MK-

212 and TFMPP) on PRA, PRC and plasma RRF concentration
PCA is a drug that exerts its action by inducing the release of
serotonin

from

Administration

the
of

nerve
PCA

has
To

concentration of RRF.

endings
been
test

(Sanders-Bush
shown

to

et

al.,

1975).

the

plasma

increase

if direct activation of serotonin

receptors would induce the release of RRF into the blood, the serotonin
agonists MK-212 [6-chloro-2-phenyl-(l-piperazinyl)-pyrazine] and TFMPP
(m-trimethylphenyl

piperazine)

were administered to

rats

and their

plasma was collected and assayed for RRF concentration, PRC and PRA.
PCA (10 mg/kg,

i.p.) was administered 1 hour before sacrifice.

The serotonin agonists, MK-212 (Merck, Sharp and Dohme, Rahway, N.J.)
and TFMPP

(m-trifluoromethyl-phenylpiperazine;

Aldrich

Chemical

CO.

Inc.; Milwaukee, WI) were administered, at a dose of 10 mg/kg i.p, to
rats

30

minutes

before

sacrifice.

Saline

administered at a volume of 2.0 ml/kg i.p.

and

the

drugs

were

The rats were decapitated

and their plasma was collected in chilled centrifuge tubes containing
20 units of heparin.
minutes.

The samples were centrifuged at 1,500 x g for 30

The plasma from each rat was divided into 3 aliquots.

One

aliquot of 1. 0 ml was saved for the determination of plasma renin
activity

and

the

second

aliquot

(0. 2

ml)

was

determination of plasma renin concentration (PRC).

saved

for

the

The third aliquot

(2.0 ml), was saved for the determination of plasma RRF concentration.
It was diluted with 2.0 ml distilled water, placed in a boiling water
bath (to denature renin) for 20 minutes and centrifuged at 13,000 x g

66
for 20 minutes.

The supernatant was lyophilized to dryness.

The dry

peptide residues were resuspended in 0.25 ml saline and 0.2 ml of the
resuspended plasma was added to vials containing 2. 0 ml Krebs-Ringer
and kidney slices to test for renin-releasing activity as desc;ribed
above (section B part lb).

2.

Effect of a stressor on PRA and plasma RRF concentration
2a.

Description of the conditioned emotional response

(stress)

paradigm
Rats were subjected to a conditioned emotional response (CER), or
fear paradigm.

The CER was performed in a rectangular chamber (49 cm

long x 23 cm wide x 28 cm high) with a grid floor composed of stainless
steel rods (7.6 mm diameter) spaced 1.3 cm apart. The front wall of the
chamber was constructed from clear Plexiglas.

The remaining walls and

ceiling of the chamber were made of white Plexiglas.

Illumination was

provided by a fluorescent lamp (20 W) mounted on the outside of the
rear wall.

The chamber was located in a sound attenuated room 7. 5

meters from the animal quarters.

Scrambled constant current shock was

delivered through the grid floor by a Grayson-Stadler shock generator.
The rats were carried to the stress room in a plastic cage that was
identical to their home cage.

Three minutes following their placement

in the chamber, the experimental animals received an inescapable foot
shock (1. 0 mA DC for 10 seconds).
were returned to their home cage.
day for three consecutive days.

Immediately thereafter, the rats
This procedure was repeated once a

Control rats were treated the same,

except that shock was not administered at any time.

By the third day,

67

it was quite apparent that the stressed rats had learned that placement
in the chamber would be followed by a shock.

In contrast to control

animals, the stressed rats defecated, urinated and alternated between
freezing and jumping behaviors.

On the fourth day,

placed in the chamber for three minutes.

the rats were

Instead of receiving the

shock, they were removed and immediately sacrificed by decapitation in
a room located 3.0 meters from the stress room.

2b.

Preparation of plasma from stressed and unstressed rats
Blood from

the decapitated rats was collected into centrifuge

tubes containing 0.5 ml of a 0.3 M EDTA (ethylene diamine tetraacetate,
pH 7.4; Sigma, St. Louis, MO) solution.

The plasma was divided: 1.0 ml

for determination of PRA and 0. 2 ml for determination of PRC.

The

third

RRF

aliquot

(2.0

ml),

saved

for

determination

of

plasma

concentration, was diluted with 2. 0 ml distilled water, placed in a
boiling water bath (to denature renin) for 20 minutes and centrifuged
at 13,000 x g (Fisher microcentrifuge Model 235A) for 20 minutes.
supernatant was lyophilized to dryness.

The

The dry peptide residues were

resuspended in 0.25 ml saline and 0.2 ml of the resuspended plasma was
added to vials containing 2.0 ml Krebs-Ringer and kidney slices to test
for renin-releasing activity as described above.

3.

Role of disulfide bonds in RRF: In vivo study with cysteamine and

PCA
3a.

In vivo study with PCA and cysteamine pretreatment
It is possible that since the RRF is a peptide, it may be contain

68

disulfide bonds that stabilize the molecule and maintain its active
conformation.

Administration of cysteamine (2-aminoethanethiol) has

been shown to destroy somatostatin (Palkovits,

1982)

and prolactin

(Sagar et al., 1985) immunoreactivity by reducing the disulfide .bonds
present in these molecules.

To determine if RRF contained disulfide

bonds, cysteamine was administered 3 hours before PCA.

The rationale

behind this experiment was if RRF contained disulfide bonds, cysteamine
would reduce the disulfide bonds and render RRF inactive and prevent
the PCA-induced increase in plasma renin activity.
Male

rats

were

injected with

cysteamine

(300

mg/kg;

Aldrich

Chemical Co, Inc., Milwaukee, WI) or saline (2.0 ml/kg), subcutaneously
(s.c.), 4 hours prior to sacrifice.

This was followed 3 hours later,

by injection of PCA (10 mg/kg) or saline at a volume of 2.0 ml/kg i.p.
The rats were decapitated 1 hour after PCA injection, and trunk blood
was collected in centrifuge tubes containing 0.5 ml of 0.3 M EDTA
(pH 7 .4).

The plasma was stored at -40°c until PRA and PRC were

determined.

3b.

Lack of an effect of cysteamine in the renin assay
The generation of ANG I from angiotensinogen has been found to be

increased when the sulfhydryl reagents, cysteamine or dithiothreitol,
were

added

during

the

incubation period

Funae, Sasaki and Yamamoto, 1979).

(Poisner

and Hong,

1977;

To ensure that the values for PRA

in this experiment were not influenced by treatment with cysteamine,
control plasma pools were incubated with and without cysteamine to test
for interference in the assay.
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Cysteamine was added to plasma samples for a final concentration
of 3.8 x 10- 3 M.

This value was calculated to be the hypothetical

distribution of cysteamine per body weight
water)

after

mixing.

High and normal

(allowing 70% for body

PRA samples

( 1. 0 ml)

were

prepared with 8-HQ and PMSF (25 µl and 20 µl; final concentration 0.86
mM 8-HQ and 2.3 mM PMSF) and sodium phosphate buffer (0.5 ml of a 0.5 M

solution, pH 6. 0).

In addition, 0.01 ml of cysteamine (0.38 M) was

added to the samples for incubation for 3 hours at 37°C.

The assay for

generated ANG I was performed as previously described (Method section B
part 3).

4.

Role of parathyroid hormone

(PTH) as the mediator of the PCA-

induced increase in renin release (a possible RRF)
Parathyroid hormone (PTH) was investigated as a possible reninreleasing factor.

It has been shown that PTH produces increases in

plasma renin activity (Powell et al., 1978; Smith et al., 1979) and the
molecular weight of PTH is approximately 9,000 which is similar to the
molecular weight of RRF.

To test the involvement of PTH in PCA-induced

increase in PRA, parathyroidectomized rats were injected with PCA to
test if removal of the parathyroid gland prevented the increase in PRA.
Thyroparathyroidectomized and sham-operated rats were purchased
from

Kurt

Johnson

Laboratories

(Bridgeview,

IL).

Rats

were

anesthetized with ether and a ventral incision was made on the ventral
surface of the neck and the muscles were teased apart.

The thyroid and

parathyroid glands

sutured.

were

thyroparathyroidectomized

removed and
rats

the

received

wound was
daily

injections

of

The
tri-
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iodothyronine (T3; 5 µg/kg s. c., dissolved in 1. 0 M NaOH and saline;
calbiochem-Behring Corp., La Jolla, CA) after surgery and their water
was supplemented with 2% calcium lactate and 10% glucose.
available

ad

libitum.

Sham

operated

animals

Rat chow was

underwent

the

same

surgical procedure only without removal of the parathyroid and thyroid
glands.

They received daily vehicle injections.

water were available ad libitum.

Rat chow and tap

On the fourth day after surgery, the

rats received either an injection of PCA (10 mg/kg, i.p.) or saline 1
hour before sacrifice.

The rats were decapitated and trunk blood was

collected into centrifuge tubes containing 0.3 M EDTA (pH 7.4).

Plasma

was stored at -40°C until determination of PRA.

5.

A dose-response study for possible renin-releasing activity of

neurophysin II (NPII)
Neurophysin

II

(NPII ;

bovine) ,

the

vasopressin

associated

neurophysin, was tested as a possible renin-releasing factor.

Male

Sprague-Dawley rats received intraperitoneal injections of neurophysin
II (0.1, 0.5, 2.0, 10.0 or 20.0 µg/kg;

Sigma, St. Louis, MO).

The

peptide was dissolved in 0. 9% saline and administered at a volume of
2.0 ml/kg i.p., 20 minutes before sacrifice.

The rats were sacrificed,

and trunk blood was collected in centrifuge tubes containing 0.5 ml of
0.3 M EDTA (pH 7.4).
were determined.

The plasma was stored at -40°c until PRA and PRC
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o.

In vitro characterization of RRF
Preparation

1.

of

PCA-plasma

and

saline-plasma

fractions

with

molecular weights of 1,000-5,000; 5,000-10,000 and 10,000-20,000
To determine the approximate molecular weight range of RRF, plasma
from either PCA-treated or saline-treated rats was pooled and filtered
to obtain plasma fractions

of different molecular weights.

These

fractions were tested for renin-releasing activity in the renin release
bioassay using kidney slices.
In each of the following experiments, approximately 40 rats were
nephrectomized under halothane

(Burns;

Glenview,

IL)

anesthesia 20

hours before administration of p-chloroamphetamine (PCA; Regis, Morton
Grove,

IL)

or

saline.

PCA

(12

mg/kg,

i.p.)

and

saline

administered at a volume of 2.0 ml/kg, 1 hour before decapitation.

were
The

blood was collected in centrifuge tubes containing 20 units of heparin
(Upjohn;

Kalamazoo,

MI)

and

was

centrifuged

centrifuge (1, 500 x g) for 30 minutes at 4°c.

in

a

refrigerated

The plasma was pooled

into either PCA-plasma (plasma from rats that were injected with PCA)
or saline-plasma

(plasma from

approximately 150 ml each)
received.

rats

treated with saline) pools

(of

depending on which treatment the animal

Ultrafiltration of

the

plasma was

performed

in a

low

pressure stirred cell (Nuclepore, Pleasanton,CA) at 4°c.
For this fractionation procedure, the PCA-plasma and saline-plasma
pools

were

placed

in

a

boiling water

bath

centrifuged at 13, 000 x g for 20 minutes.

for

20

minutes,

and

Ultrafiltration of the

supernatant of the plasma pools was performed at 4°C in a low pressure
stirred cell first with a low adsorption membrane with a molecular
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weight cut-off of 20, 000.

The filtered fraction containing solutes

with molecular weights below 20,000 was refiltered through a membrane
with a molecular weight cutoff of 10,000.

The latter fraction was then

refiltered through a membrane with a molecular weight cutoff of 5,000.
'l'he remaining fraction containing solutes with molecular weights below
5,000 was refiltered through a membrane with a molecular weight cutoff
of 1,000.

The material that was retained on the respective membranes
Thus,

was resuspended in 3-4 ml saline.

3 separate fractions were

obtained, one that contained solutes in the molecular weight range of
1,000-5,000, one that contained solutes with a molecular weight range
of 5,000-10,000

and the

last fraction

molecular weights of 10,000-20,000.

that contained solutes with

All the fractions were stored at

-40°c.
The

PCA-plasma

and

saline-plasma

fractions

(M.W.-1,000-5,000;

5,000-10,000 and 10,000-20,000) were added to the kidney slices (nonbubbled method) at a volume of 0.2 ml for the 1 hour incubation period
to test for renin-releasing activity.

2.

Evaluation of possible renin releasing activity of 5-HT and PCA in

vitro
Since PCA, a 5-HT releaser, was used to release RRF, it was also
possible that the plasma that was tested for renin releasing activity
contained some residual PCA molecules.

In addition, since PCA releases

5-HT, the 5-HT content in the plasma could also have been increased.
PCA and 5-HT were added to the kidney slice bioassay to test if these
drugs could have altered renin release.

Fenfluramine (another 5-HT
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releaser)

and saline, were also added to kidney slices to test for

renin-releasing activity.
Sigma,

St.

Louis,

MO)

The drugs PCA (M.W. 206), 5-HT (M.W. 176;
and

fenfluramine

(M.W.

249;

A.H.

Robins,

Richmond, VA) were dissolved in saline for an initial concentration of
10-4M.

A volume of 0.02 ml of each drug was added to the kidney slices

for the incubation period.

The final dilution of the drug in the vials

was l0- 6M; this corresponded to the calculated distribution of the drug
in body water.

This

calculation was performed by estimating the

concentration of the drug in body water (which was assumed to be 70%
body weight).
the drug

This value was then divided by the molecular weight of

to obtain the

concentration of the

substance within the

animal.

3. Incubation of the PCA-plasma and saline-plasma fractions with
Pronase
In order to test whether or not RRF is a peptide, a fraction of
PCA-plasma and a fraction of saline-plasma (M.W. - 5,000-10,000) were
incubated with pronase, a mixture of non-specific proteases (Narahashi,
1970).

If RRF were a peptide or a protein,

then incubation with

pronase should destroy its renin-releasing activity.
Pronase

E

(a

non-specific

protease,

type

XIV,

isolated

from

Streptomyces griseus that has an activity of 4 units per mg; Sigma, St.
Louis,

MO)

was

added

releasing activity
weights

between

to

(the

the

fraction

that had

renin-

fraction containing solutes with molecular

5,000-10,000)

saline-treated rats.

PCA-plasma

and

to

the

equivalent fraction

from

Pronase was dissolved in a 0.1 M borate buffer pH
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7.5 containing 5 mM CaCl2, at a concentration of 20 µg/200 µl and was
added to a volume of 1.6 ml of PCA-plasma and saline-plasma fractions

(M.W.

5,000-10,000).

The borate buffer vehicle that was used to

dissolve pronase was added at the same volume (0. 2 ml) to an equal
aliquot (1.6 ml) of the PCA-plasma and saline-plasma fractions (M.W. 5,000-10,000).

All of the samples were incubated at 37°c for 4 hours.

After incubation, all aliquots were placed in a boiling water bath for
20 minutes (to denature the pronase) and centrifuged at 13,000 x g for
30 minutes.

The plasma fractions were added to the kidney slices at a

volume of 0.2 ml per vial to test for renin-releasing activity.

E.

Studies of RRF in rat brain

1.

Dissection technique
Rats were sacrificed by decapitation and the brains were removed

immediately

and

placed

on

dissection.

The brains were dissected by the procedures outlined by

Glowinski and Iversen (1966).

a

cold

glass

plate

kept

on

ice

for

The pituitary gland was removed from the

sella turcica with the aid of a spatula.

The cerebral cortices were

gently dissected apart and removed from the rest of the brain.

The

hippocampus,

the

caudate-putamen

cortical tissue.

and

amygdala

were

removed

from

The hippocampal formation was easily removed from the

cortex by blunt dissection with a spatula. The amygdala was cut from
the cortex at a site rostral to the hippocampus.

The corpus callosum

and lateral ventricle formed the boundaries for the caudate-putamen
which was carefully dissected with a curved scissors.
The hypothalamus was delineated rostrally by the optic chiasm and
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caudally by the mammillary bodies.

A transverse cut made at the level

of the mammillary bodies separated the hypothalamus from the midbrain.
The anterior commissure (located at the level of the optic chiasm) was
the horizontal reference for the separation of the thalamus from the
hypothalamus.
The midbrain was separated from the pons by a diagonal knife cut
just caudal to the inferior colliculi.

The cerebellum was removed from

the remaining brain tissue by blunt dissection and severing of the
cerebellar peduncles.

The pons was separated from the medulla by a cut

caudal to the transverse fibers of the pons.

After dissection, the

brain parts were wrapped in aluminum foil and placed on dry ice.

The

samples were stored at -70°c.

2.

Extraction of the peptide from rat brain
2a.

Comparison of different extraction media from whole brain tissue
Whole rat brains were cut sagittally and each half was homogenized

(1 g/10 ml) with either: (1) cold 0.1 N hydrochloric acid, (2) hot 0.1
N hydrochloric acid, (3) cold 0.1 N hydrochloric acid/absolute ethanol
mixture (20:80 vol:vol), (4) cold 0.1 N perchloric acid, (5) hot 0.1 N
perchloric

acid or

(6)

boiling distilled water.

The

tissue

was

homogenized with a Potter-Elvehjem tissue grinder (Scientific Products,
McGaw Park, IL), and centrifuged for 30 minutes at 18, 000 x g.
supernatant was transferred to polypropylene tubes,

The

lyophilized and

stored at - 70°c until they were tested for renin-releasing activity.
The samples were reconstituted in 2.0 ml of Krebs-Ringer buffer and the
pH of the samples was readjusted to 7. 0- 7. 4 with 1. 0 M NaOH before
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addition to the kidney slices.

The extract (0.20 ml) was added to the

kidney slices for the 1 hour incubation period.

2b.

Comparison of extraction with cold 0.1 N perchloric acid and

boiling distilled water from rat hypothalamus
The extraction media that yielded the best results with whole
brain tissue were the 0.1 N cold perchloric acid and boiling distilled
water.

Hypothalamic

tissue

was

homogenized

with

either

0.1

N

perchloric acid or boiling distilled water to test which medium was
more

effective

in

extracting

RRF

from

hypothalamic

tissue.

Rat

hypothalami (6 hypothalami, approximately 0.11 g) were homogenized in
either cold 0 .1 N perchloric acid or boiling distilled water in a 1
g/10 ml ratio with a pyrex glass tissue homogenizer.
were centrifuged for 30 minutes at 18,000 x g.
transferred to polypropylene tubes,

The homogenates

The supernatants were

lyophilized and stored at - 70°c

until they were tested for renin-releasing activity.
were

resuspended

in

0.1

ml

of

Krebs-Ringer

buffer,

These samples
the

pH

was

readjusted (pH 7. 0- 7. 4 with 1. 0 M NaOH) and 0. 02 ml was added to the
kidney slices during the incubation period.

3.

Preparation of hypothalamic, cerebellar and pituitary extracts
Hypothalamic tissue was dissected from 10 rat brains immediately

after decapitation and stored at -70°c.

The brain was placed, dorsal

surface down, and the hypothalamus was excised from the ventral surface
with fine curved scissors.

The rostral border was the decussation of

the optic tracts and the decussation of the anterior commissure.

The
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caudal border was the mammillary bodies.
from

the

sella

brainstem.

and

the

cerebellum was

removed

from

the

A volume of 10 ml/g of boiling water was added to the

hypothalamic
~issue.

turcica

The pituitary was removed

(0.97

g),

cerebellar

(0.85

g)

or

pituitary

(0.74

g)

The tissue was homogenized with a glass tissue grinder, placed

in a boiling water bath for 20 minutes and centrifuged at 13,000 x g
for 30 minutes.

An aliquot of 4. 5 ml of the supernatant from each

tissue was lyophilized to dryness and resuspended in 0.2 ml of saline.
A volume of 0.02 ml was added to the kidney slices to test for reninreleasing activity.

4.

Dose response of hypothalamic tissue extracts
Rat hypothalamic tissue (5.8 g, approximately 280 hypothalami) was

homogenized in boiling distilled water (1 g/ml) with a pyrex tissue
grinder.

The homogenate was placed in a boiling water bath for 20

minutes and centrifuged at 13,000 x g for 30 minutes.

The supernatant

was collected, 0.4 ml of the extract was saved for serial dilutions and
1.6 ml of the supernatant was lyophilized (Savant Speed-Vac).

The

straight, non-lyophilized, hypothalamic extract was serially diluted
with saline (1: 15, 1: 10, 1: 5, 1: 2 and 1: 1) to obtain the equivalent
volume of the content of 0.07, 0.1, 0.2, 0.5 and 1 hypothalamus when
added (0. 2 ml) to the kidney slices, respectively.

The lyophilized

pellet was resuspended in 0.4 ml of 0.9% saline and diluted (1:2 and
1:1) to yield extracts that were equivalent to the content of 2 and 4
hypothalami.

Aliquots

(0. 02 ml)

of the hypothalamic extracts were

added to the kidney slices for the 1 hour incubation.
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Distribution of RRF in rat brain

5.

Rat brains were dissected as described in section E part 1.

The

brain areas that were analyzed for renin-releasing activity were the
pituitary
midbrain,
and

gland,
amygdala,

cerebellum.

pons,

thalamus,

hypothalamus,
The

brain

caudate-putamen,

cerebral cortex,

tissues

were

hippocampus,

medulla oblongata

homogenized

distilled water (1 g/ml) with a glass tissue grinder.

in

boiling

Afterwards, the

homogenates were placed in a boiling water bath for 20 minutes and then
centrifuged at 13,000 x g for 30 minutes.

The extracts were added to

the kidney slices at a volume of 0. 02 ml for the incubation period.
This volume corresponded to the equivalent of 1 hypothalamus using the
1

g/ml

dilution.

different extracts

Standardizing
allowed direct

the

dilution

and

volume

comparison of the

of

the

renin-releasing

activity of the different brain areas.

6.

Distribution of RRF in colchicine-treated rat brains
In order to identify the cell bodies of origin of RRF, rats were

treated with

colchicine,

a

drug

that

inhibits

axonal

transport

of

materials from the cell body, to prevent the movement of RRF from the
cell

body.

The

results

from

the

renin

release

colchicine-treated brain parts would indicate where
that contain RRF were located.

bioassay

of

the

the cell bodies

After colchicine treatment, the areas

that have high renin-releasing activity would indicate RRF contained in
cell bodies.
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6a.

Animals
Rats were prepared for stereotaxic surgery by anesthetizing them

with pentobarbital

(50

mg/kg

i.p.;

Butler

Co.,

Columbus,

OH)

and

pretreating them with methyl atropine bromide (0.4 mg/kg i.m.; Regis
Chemical

Co. ,

secretions.

Morton Grove,
After

IL)

surgery,

ampicillin (50 mg/kg,

i.m.;

which minimized respiratory tract

the

rats

received

an

injection

of

Sigma, St. Louis) to prevent infection.

care was taken to avoid undue discomfort to the animals.

6b.

Intracerebroventricular injections of colchicine
The rats were secured in a Kopf stereotaxic apparatus with the

incisor bar 5. 0 mm below the intra-aural line.

The injection needle

was placed bilaterally, 1.4 mm lateral to the midsagittal suture, 0.5
mm caudal

from bregma and 4. 5 mm ventral from the skull surface.

Colchicine (Sigma, St. Louis) was administered bilaterally (150 µg/20
µl saline;

10 µl

into each side over a 10 minute period) into the

lateral cerebral ventricles.

The needle was

left in place for 5

minutes to prevent dorsal diffusion of the drug.
The rats were decapitated 48 hours after injection of colchicine
and the brains were dissected as indicated in section E part 1.

The

brain

and

parts

centrifuged.

were

homogenized

in

boiling

distilled

water

The supernatant (0.02 ml) was added to the kidney slices

to test for renin-releasing activity.
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6c.

Verification that colchicine does not interfere in the renin

release bioassay
In a test that preceded the determination of RRF in the brains of
colchicine-treated rats, colchicine was added to the kidney slices to
test

whether

colchicine

would

alter

renin

release.

colchicine was added to three test substances saline,
(10-SM)

or cerebellar extract,

distilled water) .

(homogenized as

Saline

or

isoproterenol

1 mg/ml in boiling

The concentration of colchicine was calculated as

the approximate dilution of colchicine in the treated rat brains (150
µg colchicine into one brain (1. 80 g) homogenized in 1. 8 ml boiling
distilled water,
sample].

which

corresponded

to

0.083

mg

colchicine/ml

of

This calculation did not take into account any diffusion of

colchicine from the brain.

The samples were added to the kidney slices

at a volume of 0.02 ml for the incubation period.

F.

Distribution of RRF in peripheral tissues
After decapitation, the adrenal gland, spleen, liver, kidney and

skeletal muscle (from the abdomen) were dissected from normal rats.
The tissues were homogenized (1 g/ml) with boiling distilled water in
glass tissue homogenizers.

The homogenates were placed in a boiling

water bath for 20 minutes and centrifuged at 13,000 x g for 30 minutes.
The supernatant of each extract
slices for the incubation period.

(0. 02 ml) was added to the kidney
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G.

Effect of nephrectomy on the hypothalamic content of RRF
Rats were bilaterally nephrectomized as previously described in

the Method section B part 3a.

Another

group

of control or sham-

operated rats were treated identically except that their kidneys were
.not

removed.

decapitated.

Twenty-four

hours

after

surgery

the

rats

were

The brains were quickly removed and the hypothalami were

dissected

and

stored

at

bioassay,

the

hypothalami

- 70°C.

On

were

the

day

of

the

kidney

individually homogenized

1

slice

g/ml

in

boiling distilled water, placed in a boiling water bath and centrifuged
(13, 000 x g)

for 20 minutes.

Each hypothalamic extract (20 µl) was

tested individually in the RRF bioassay.

H.

Stimulation of RRF from hypothalamic neurons
Superfusion of hypothalamic explants was performed to determine

whether neurons in the hypothalamus could release RRF in response to
depolarization.

The

method

used

for

the

superfusion

of

rat

hypothalamus was adapted from that used by Gallardo and Ramirez (1977).

1.

Preparation of hypothalamic explants
Rats (175-200 g) were decapitated and the hypothalami were quickly

dissected
buffer

and placed

that

was

in

bubbled

a

petri
with

superfusion buffer used for

dish containing cold Krebs-Ringer

95%

02-5%

C02.

The

Krebs-Ringer

this study had a composition of 117 mM

NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.2 mM MgS04, 1.2 mM KH2P04, 11.5 mM
glucose

and 25 mM NaHC03

boundaries

for

the

(final pH

hypothalamus

7 .4).

were

the

The

rostral and caudal

optic

chiasm

and

the
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mammillary bodies, respectively.

The anterior commissure was used to

define the dorsal limit of the hypothalamus.
In some cases rat hypothalamo-hypophyseal explants were used, in
others,

the hypothalamic explants were used without the hypophysis.

The brain was removed from the caudal approach and the pituitary was
carefully removed away from the sella while still attached to the
hypothalamus.
brain

and

the

The hypothalamus was then dissected from the rest of the
hypothalamo-hypophyseal

oxygenated Krebs-Ringer.

explant

was

placed

in cold

A total of four explants were placed in each

superfusion chamber.

2.

Superfusion of rat hypothalamic explants
The superfusion chambers

(0. 5 ml) were constructed from 3. 0 ml

plastic disposable syringes that were cut in half.

The hypothalamic

tissue was placed at the bottom of the chamber and rested on a few
strands of glass wool.

Superfusion buffer entered the chamber from the

bottom through a hypodermic needle (18 gauge) that was attached to the
syringe

(superfusion chamber;

refer to Figure 2).

The needle was

inserted into rubber stoppers on a Plexiglas stand and the apparatus
(stand with superfusion chambers) was placed in a water bath maintained
at 37°C.

The buffer was continuously delivered into the chamber by a

Gilson peristaltic pump (Gilson Medical Electronics, Inc., Middleton,
WI) at a flow rate of 0.08 ml/minute.

A PE90 tubing (Becton Dickinson

and Co., Parsippany, N.J.) led the buffer through a silastic manifold
tubing (0. 065 inch I. D.) and another length of PE90 tubing connected
the silastic tubing to the needle on the chamber.

The Krebs-Ringer
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Inlet for

Sample
outflow

Oz/COz

Plexiglas
stand

Figure 2.

Illustration of superfusion chamber.
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buffer entered the chamber from the bottom and filled the chamber as it
filtered up through the tissue.

The chamber was closed with a rubber

stopper containing two 20 gauge needles;

one was fitted with PE90

tubing that allowed the inflow of the 95% 02 - 5% C02 mixture and the
other needle was fitted with tubing (PE90) that served as the outlet
for the liquid (sample) and oxygen.

As the gas entered the chamber,

it formed bubbles that expelled the liquid sample through the tubing.
This also kept the volume of the chamber constant at 0.5 ml.
After a 30 minute equilibration period, samples were collected over
a

30

minute

control

maintained on ice.

period

into

polypropylene

tubes

that

were

To test for the potassium stimulated release of RRF

from the hypothalamus, the Krebs-Ringer buffer was replaced with a high
potassium Krebs-Ringer buffer containing 60 mM KCl.
the high potassium Krebs-Ringer buffer was

The composition of

61. 7 mM NaCl, 60 mM KCl,

1.25 mM CaCl2, 1.2 mM MgS04, 1.2 mM KH2P04, 11.5 mM glucose and 25.0 mM
NaHC03 (final pH 7 . 4) .

The sodium concentration of the buffer was

reduced to maintain the proper osmolarity.

Samples were collected for

30 minutes into polypropylene tubes that were kept on ice.

For both

the control and experimental (high potassium) periods, the pH of the
buffer was monitored to confirm that the pH did not fluctuate over
time.

3. Preparation of superfusate samples
After the samples were collected (approximately 3 ml), they were
filtered and concentrated by ultrafiltration on a micropartition system
(MPS I, Amicon, Danvers, MA) through a membrane that had a molecular
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weight cutoff of 500.

The samples that were collected with the high

potassium buffer were further washed with 0. 9% saline to remove the
excess potassium ions.
concentration

on

the

The final volume for all the samples after
filter

was

0.3

ml.

This

approximately a 10 fold increase in concentration.

corresponded

to

A volume of 0.2 ml

was added to the kidney slices to test for the renin-releasing activity
of the hypothalamic superfusates.

I.

Statistical analysis of the data

1.

Representation of the data
The data were represented as mean

mean).

The

sample

mean was

experimental group (n).

the

±

S.E.M. (standard error of the

average

of

the

numbers

in

the

The standard error of the mean (S.E.M.) was

reported along with the mean to establish a confidence interval for the
population mean.

The S.E.M. was calculated from a formula relating the

standard deviation and the number of samples in the test group (n).

2.

Statistical tests
2a.

Student's t-test
The Student's t-test was used to compare two means either from the

same

sample

population

(paired

populations (unpaired t-test).
data,

t-test)

or

from

different

sample

As a rule for the analysis of these

the significance levels used for the t-test and other tests

(ANOVA and Duncan's new multiple range test) were 5% and 1%.
t-tests used were all two-tailed.

The

Two-tailed t-tests are indicated

when looking for a difference between the means (mean1 not equal to
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mean 2 ) rather than testing the probability that one mean is greater
than the other (one-tailed t-test).

2b.

Analysis of variance
The analysis of variance (ANOVA) was designed to compare several

groups (means) after a treatment or to compare the same group using
different treatments.

The one way ANOVA was used to compare the effect

of different treatments between relatively homogenous, random groups.
The F value is calculated and defined as the ratio of two independent
estimates of the variance (Steel and Torrie, 1960).
compared to values

in a

table

for

the

The F value is

level of significance.

A

significant F value indicates that there is less than 5% or 1% that two
or more means are not different between the treatment groups.

However,

the ANOVA does not show which means are significantly different from
one another.
The two way ANOVA is used when there are two or more ways of
grouping the data (Steel and Torrie, 1960).

The individuals in the

experiment are grouped into blocks according to characteristics.

For

example, animals that are subject to surgery before receiving a drug
treatment would comprise one block.
be

treated

conditions.

identically,

minimizing any variations

in techniques or

This assures that the differences observed will be due to

the effects of treatment.
obtained:

The units within the block should

one

indicates

For a two way ANOVA,
if

there

is

a

three F values are

treatment

effect;

another

indicates a difference between the blocks and the third indicates if
there is an interaction between the treatment and block effects.
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zc.

Duncan's new multiple range test
The Duncan's new multiple range test was applied in addition to

the ANOVA to determine which means are statistically different (Duncan,
Generally,

1955).

tests of comparison should be performed only when

the F values are significant, however, a Duncan's multiple range test
can be performed without a significant F value.
a

protection

level

within

the

computation

determined by the degrees of freedom.

The Duncan's also has
of

statistic

Null

hypothesis

when

comparison tests have
sample sizes.

a

it

is

is

The protection guards against

the possibility of finding a false positive (Type I
the

that

true).

Other

error;

multiple

rejecting
range

protection level that is the same for

or
all

The data necessary to perform a multiple range test are

the mean squared error obtained from the ANOVA, the number of samples
in

the

group

(n)

and

significant ranges.

being

value

that

is

obtained

from

a

table

of

The value obtained from the table is dependent on

the degrees of freedom,
means

a

tested.

the level of significance and the number of
The

desired range

is

then multiplied by the

standard error of the mean (obtained by taking the square root of the
mean squared error divided by the number of samples) to make a shortest
range of significance.

If the distance between two means is greater

than the shortest range of significance then the difference between the
means is significant.

CHAPTER IV

RESULTS

A. Development of a renin release bioassay
Table 1 compares the values for renin release after a 30 minute
incubation between the bubbled and unbubbled kidney slice methods.
The unbubbled method yields renin values that were higher and more
consistent (5.0 ± 0.6 to 7.5 ± 0.5 ng ANG I/mg kidney/hr) than those
obtained with the bubbled method (0. 23 ± 0. 04 to 1. 90 ± 0. 30 ng ANG
I/mg kidney/hr).
The values for pH, kidney slices weight and renin release in one
experiment are presented in Table 2.

All these values were measured

after a 30 minute incubation period.

The kidney slice weights were

within a small range of distribution with a mean of 18.3 ± 0.5 mg.

The

pH values of the incubation medium of the 24 vials ranged from 7.4 to
7. 5 with a mean of 7. 45 ± 0. 01.

Both the values for pH and kidney

slice weight were within a close range indicating that the method of
oxygenation
reliable.

and

method

of

slicing

the

kidneys

(vibratome)

were

The values for renin release from the slices ranged from 3.4

to 11.1 ng ANG I/mg kidney tissue/hr with a mean value of 5.9 ± 0.37 ng
ANG I/mg kidney/hr.

This is a much smaller range than that observed

with the bubbled kidney slice method.
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The small range of distribution
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TABLE 1 Comparison of interexperimental variation of renin release (ng
ANG I/mg kidney/hr) from kidney slices between the bubbled and improved
unbubbled in vitro methods.

Experiment
1
2
3
4

Bubbled Method
1. 90 ± 0. 30 (24)
1. 80 ± 0 .15 (24)

0.23 ± 0.04 (24)
0.53 ± 0.07 (24)*

Experiment
5
6
7
8
9
10
11

Unbubbled Method
7.2 ± 0.6 (24)
5.0 ± 0.6 (24)
7.5 ± 0.5 (24)
6.4 ± 0.4 (24)
6.7 ± 0.4 (24)
5.9 ± 0.4 (24)
7.1 ± 0.4 (36)

* This value for renin release (experiment 4) was obtained from
kidney slices that were cut on a vibratome, but were incubated in
Krebs-Ringer that was bubbled with the 95% 02-5% C02 gas. The kidney
slices used in experiments 1,2 and 3 were cut using a hand-held razor.
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TABLE 2
lntraexperimental variability for renin release from kidney
slices during incubation with Krebs-Ringer Bicarbonate solution for 30
minutes.
Weight of the slices
Vial

!!!!

.L!W..

1
2
3
4
5
6
7
8
9
10

7.4
7.5
7.6
7.4
7.4
7.6
7.5
7.4
7.5
7.4
7.5
7.4
7.4
7.5
7.5
7.5
7.5
7.4
7.5
7.5
7.4
7.4
7.4
7.5
7.45 ± 0.01

17.9
19.0
16.0
16.3
20.1
18.l
19.8
15.6
19.6
14.2
17.2
19.7
17.2
16.9
16.6
17.3
22.0
22.8
22.0
18.5
15.3
20.2
14.1
22.8
18.3 ± 0.5

11

12
13
14
15
16
17
18
19
20
21
22
23
24
Mean ± S.E.M

Renin release
(ng ANG I/mg kidney/hr)
4.9
6.7
6.2
3.6
5.0
3.3
3.4
4.4
6.5
8.7
5.1
5.7
5.2
5.7
7.0
6.0
6.1
5.8
6.6
8.4
3.4
7.6
11.1
6.2
5.9 ± 0.4
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of renin release, both intraexperimentally and interexperimentally, is
is an indicator of the reliability of the new kidney slice method.
Addition

of

isoproterenol

(Student's unpaired t-test,

produced

a

significant

increase

two-tailed, t=2.460, df-14, p < 0.05) in

renin release from the kidney slices (Table 3).

As can be seen in the

following experiments, the values for renin release in the slices that
received

either

saline

or

isoproterenol

are

reproducible

between

experiments.

B. Check for specificity in the bioassay for RRF
1. Test for non-specific activation of renin by plasma fractions
(Table 4)
This control experiment was performed to verify that the effect of
the

PCA-plasma

fraction

(M.W.

5,000-10,000)

was

not

due

to

non-

specific activation of inactive renin that could have been released by
the kidney slices.

Kidney slices were removed from the Krebs-Ringer

medium after a 1 hour incubation, and the Krebs-Ringer solutions were
pooled and then divided into 2. 0 ml aliquots.
(M.W.

5,000-10,000)

or

PCA-plasma

(M.W.

Saline, saline-plasma

5,000-10,000)

samples were

added to the Krebs-Ringer aliquots for a 1 hour incubation at 37°C.
The concentration of renin was measured as the ability to generate ANG
I from a saturating concentration of renin substrate.

As can be seen

from Table 4, there was no activation of renin by the plasma fractions.
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TABLE 3
Effect of saline or isoproterenol (10- 7M) on renin release
from kidney slices using the unbubbled method.

Renin release
(ng ANG I/mg kidney/hr)
Saline (n-10)

10.6 ± 0.9

Isoproterenol lo-7M (n-6)

19.7 ± 3.4*

Data represent mean± S.E.M.
Significant difference from the saline group, p < 0. 05 (Student's
unpaired t-test, two tailed: t=2.460, df=l4).

*
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TABLE 4 Test for non-selective activation of renin in the incubation
medium (Krebs-Ringer) by the fractions (M.W.
5,000-10,000) of plasma
from saline-treated or PCA-treated rats.

Fraction added

Renin activity
(ng ANG I/ml/hr)

PCA-plasma fraction
(M.W. 5,000-10,000)

231.2 ± 19.0

Saline-plasma fraction
(M.W. 5,000-10,000)

276.0 ±

Saline

238.6 ± 22.8

8.8

Each data point represent mean± S.E.M. of 6 determinations.
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z.

Test

for

non-specific

generation

of

angiotensin

I

from

renin

substrate by plasma and brain fractions (Table 5)
Another

control

experiment

was

performed

saline-plasma and PCA-plasma fractions

(M.W.

to

verify

that

5,000-10,000)

the

and the

different brain extracts did not have renin-like activity that would
have

resulted

in

the

non-specific

generation

of

ANG

I.

Rat

hypothalamic, cerebellar, and pituitary extracts and the PCA-plasma and
saline-plasma fractions

(M.W.

5,000-10,000) were added to the Krebs-

Ringer buffer and incubated with renin substrate for 1 hour.
seen in Table 5,

As can be

the values for the amount of generated ANG I were

below the sensitivity limit of the assay indicating that the effect of
the test substances on renin release from the kidney slices was not due
to non-specific generation of ANG I in the bioassay.

The normal rat

plasma was tested at the same concentration as the other substances and
produced detectable amounts of ANG I.

C. In vivo studies of the renin-releasing factor
1. The effect of the serotonin releaser, PCA and serotonin agonists
(MK-212 and TFMPP) on PRA, PRC and plasma RRF concentration (Table 6)
The 5-HT releaser PCA (10 mg/kg, i.p.) and two 5-HT agonists, MK212 (10 mg/kg, i.p.) and TFMPP (10 mg/kg, i.p.) were administered to
rats to test if stimulation of serotonin receptors would increase PRA,
PRC and the concentration of RRF in the blood.
all

significantly

F(3,36)-22.741,

increased

p < 0.001;

plasma

PCA, TFMPP and MK-212

renin

ac ti vi ty

[ANOVA:

Duncan's multiple range test:

shortest

range of significance between means - 9.6, p < 0.01] and plasma renin
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TABLE 5
Test for non-specific generation of angiotensin I from
angiotensinogen
(renin substrate)
by hypothalamic,
cerebellar,
pituitary and plasma extracts and fractions.

Substance added

ng ANG I generated/ml/hr

Rat hypothalamic extract

N.D.

Rat cerebellar extract

N.D.

Rat pituitary extract

N.D.

PCA-plasma fraction
(M.W. 5,000-10,000)

N.D.

Saline-plasma fraction
(M.W. 5,000-10,000)

N.D.

Unfractionated normal rat plasma

3.75 ± 0.15

Each point represents mean ± S. E .M. of 6 determinations.
The
extracts and fractions were incubated with renin substrate (20 µl/2.0
ml) without renin in the medium to test if these extracts possessed
renin-like activity.
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TABLE 6 The effect of saline or PCA, MK-212 or TFMPP (10 mg/kg i.p.)
on plasma renin activity (PRA), plasma renin concentration (PRC) and
plasma concentration of renin-releasing factor (RRF) in conscious rats.

PRA
(ng ANG ILmlL3hr)

PRC
RRF
(ng ANG ILml/hr) (ng ANG ILmg kidne:;x::/hr)

Treatment
saline
(n=l2)

3.5 ± 0.4

5.1 ± 0.5

12.0 ± 0.8

PCA
(n=ll)

20.1 ± 2.2**

23.5 ± 3.4**

18.9

± 1. 5*

MK-212
(n=ll)

40.7

± 3.8**t

56.3

± ll.7**t

19.3

± 3.0*

TFMPP
(n=6)

17.2

± 2.5**

21.4

± 3.4**

18.8

± 2.8*

Data represent mean ± S.E.M. The number of rats (n) in each group is
represented in parentheses.
One way ANOVA for: PRA; F (3,36)-22.741, p < 0.001.
PRC; F (3.36)-12.394, p < 0.001.
RRF; F (3,36)- 3.147, p < 0.05.
Duncan's new multiple range test:
* Significant difference from saline group, p < 0.05.
** Significant difference from saline group, p < 0.01.
t Significant difference from all other groups, p < 0.01.
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concentration [ANOVA:

F(3,36)=12.394, p < 0.001;

Duncan's multiple

range test: shortest range of significance between means
0.05;
The

=

=

13.5, p <

18.0, p < 0.01] when compared with the saline control group.

PRA

and

PRC

values

in

the

group

that

received MK-212

were

significantly elevated over the other treatments (PCA and TFMPP) groups
(Duncan's multiple range test: p < 0.01).

The plasma concentration of

RRF was significantly increased in the rats that received either PCA,
MK-212 or TFMPP [ANOVA: F(3,36)=3.147, p < 0.05;

Duncan's multiple

range test: shortest range of significance between means - 6. 4, p <
0.05].
treated

There were no significant differences between any of the druggroups

for

RRF

activity.

These

results

stimulation of 5-HT receptors can increase PRA,

indicate

that

PRC and the plasma

concentration of RRF.

2. Effect of stress on PRA and plasma RRF concentration (Table 7)
It has been shown that rats that were stressed using a conditioned
emotional response (CER) or fear paradigm had significantly elevated
levels of PRA (Van de Kar et al, 1985; Richardson-Morton et al, 1987).
Therefore,

the plasma from stressed rats was

tested in the kidney

slices bioassay to determine whether stress could be a physiological
stimulus that would increase the plasma concentration of RRF.

Table 7

shows the effect of stress on plasma renin activity (PRA) and on the
plasma concentration of RRF.
paradigm had

significant

Rats that were subjected to the CER

increases

in PRA

(Student's

t-test,

two-

tailed; t-3.380, df=l9, p < 0.01) and also in the plasma concentration
of RRF (Student's unpaired t-test, two-tailed; t-2.711, df-19, p <
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TABLE 7 The effect of stress (conditioned emotional response or fear
paradigm) on plasma renin activity (PRA) and the plasma concentration
of renin-releasing factor (RRF).

PRA
(ng ANG I/ml/3 hr)
control (n=9)
stress (n=12)

4.5

± 0.8

29.l ± 6.2**

RRF
(ng ANG I/mg kidney/hr)
12. 7

±

1.1

16.0 ± 0.7*

Data represent mean± S.E.M.
** Significant difference from corresponding saline control group,
p < 0.01, (Student unpaired t-test, two-tailed; t-3.380, df-19).
* Significant difference from corresponding saline control,
p < 0.02 (Student unpaired t-test, two-tailed; t-2.711, df-19).
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0.02).

These results indicate that stress can act as a physiological

stimulus to induce the release of RRF into the blood.

3.

Presence of disulfide bonds in RRF: Study with cysteamine and PCA

(Table Ba and Bb)
Since

RRF was

characterized

as

a

heat

stable

peptide,

it

is

possible that this peptide contains disulfide bonds that stabilize the
molecule

and

maintain

activity.

Therefore,

cysteamine,

a

drug

the

conformation

destruction

that

reduces

of

for

these

disulfide

its

renin-releasing

disulfide

bonds,

might

bonds

with

change

the

conformational change of RRF and destroy its renin-releasing activity.
To

test

this hypothesis,

rats

were pretreated with cysteamine

mg/kg, s.c.) before administration of PCA (10 mg/kg, i.p.).

(300

Tables Ba

and Bb show the effect of cysteamine and PCA and cysteamine on plasma
renin

activity

respectively.
way

ANOVA:

(PRA)

and

plasma

renin

concentration

(PRC),

Cysteamine did not increase in resting PRA values [Two
F(l,20)-3.345,

p

>

0.05].

Administration

of

PCA

significantly increased PRA [Two way ANOVA: F(l,20)-17.016, p < 0.001;
Duncan's multiple range test:
means= 6.9, p

< 0.05].

shortest range of significance between

The two way ANOVA indicates that there was no

interaction between cysteamine and PCA [Two way ANOVA: F(l,20)-0.0371,
p > 0.1].
PCA group.

The cysteamine-PCA group was not different from the salinePCA did not produce an increase in PRA after cysteamine

when compared with its cysteamine-saline control group.
The effects of cysteamine and PCA on plasma renin concentration
(PRC) were very similar to the data obtained for PRA.

Cysteamine
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TABLE Ba Effect of pretreatment with cysteamine (300 mg/kg s. c.) on
the p-chloroamphetamine (PCA; 10 mg/kg i.p.)-induced increase in plasma
renin activity (PRA)
Plasma renin activity (ng ANG I/ml/3 hr)

saline
PCA

saline

cysteamine

6.0 ± 1.1

11.8 ± 2.6

13. 5 ± 1. 8*

16.9 ± 3.0

Data represent mean± S.E.M. n-8.
Two way ANOVA: Factor A (cysteamine): F(l,20)-3.345, p > 0.05, N.S.
Factor B (PCA): F(l,20)= 17.016, p < 0.001.
Factor Ax B: F(l,20)= 0.0371, p > 0.10, N.S.
Duncan's new multiple range test:
Significant difference from saline-saline control group,
* p < 0.05, shortest range of significance between means - 6.9.

TABLE Sb Effect of pretreatment with cysteamine (300 mg/kg s.c.) on
the p-chloroamphetamine
(PCA) - induced increase in plasma renin
concentration (PRC)
Plasma renin concentration
(ng ANG I/ml/hr)

saline
PCA

saline

cysteamine

7.3±1.2

14.6 ± 4.5

22.7 ± 3.8**

21.5 ± 3.5

Data represent mean± S.E.M. n=8.
Two way ANOVA: Factor A (cysteamine): F(l,20)= 0.585, p > 0.100, N.S.
Factor B (PCA): F(l,20)= 19.811, p < 0.001.
Factor Ax B: F(l,20)= 1.325, p > 0.100, N.S.
Duncan's new multiple range test:
Significant difference from saline-saline control group,
** p < 0.01, shortest range of significance between means
11.9.
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treatment did not increase PRC when compared with the saline-saline
control

F(l,20)-0.585, p > 0.100].

[Two way ANOVA:

PCA produced a

significant increase in PRC [Two way ANOVA: F(l,20)-19.811, p < 0.001].
Treatment with cysteamine did not block the effect of PCA [Two way
ANOVA: F(l,20)-1.325, p > 0.100].

For both PRA and PRC, the values for

the cysteamine-saline and cysteamine-PCA groups were not statistically
different from each other.
increase

in

the

However, PCA did not produced a significant

cysteamine-PCA

corresponding control.

group

when

compared

with

its

There is no difference between the saline-PCA

and cysteamine-PCA groups.
The generation of ANG I from angiotensinogen was reported to be
increased when disulfide reducing agents,

such as cysteamine,

added to the incubation media (Poisner and Hong, 1977).

To test for

the possible interaction of cysteamine in the renin assay,
plasma pools
calculated

were

as

incubated with

cysteamine,

theoretical

distribution

the

at

were

a

dose

within

control
that was

body

water.

Cysteamine did not modify the amount of ANG I generated in either the
normal [Student's t-test (unpaired), two-tailed: t-0.7612, df-10, p >
0.05]

or

high

[Student's

t-test

(unpaired),

two-tailed:

t=0.4155,

df-10, p > 0.50] plasma renin activity pools (Table 9).
These

results

indicate

that

cysteamine

was

not

preventing the PCA- induced increase in renin secretion.
the

concentration

of

cysteamine

used

in

this

capable

of

Furthermore,

experiment

did not

influence the generation of ANG I from the renin substrate and thus did
not bias the results.
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TABLE 9
assay.

Lack of cysteamine interference in the plasma renin activity

Plasma renin activity
(ng ANG I/ml/3 hr)
saline

cysteamine

normal
plasma renin activity

9.3 ± 0.9

10.2 ± 0.8

high
plasma renin activity

23.7 ± 1.6

23.0 ± 0.7

Data represent mean± S.E.M. n-5 in each group.
Student's unpaired t-test (two-tailed):
for normal PRA: t-0.7612, df-10, p > 0.50, N.S.
for high PRA: t=0.4155, df=lO, p > 0.50, N.S.
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4.

Test for parathyroid hormone

(PTH) as the mediator of the PCA-

induced increase in renin release (Table 10)
Several laboratories have demonstrated that parathyroid hormone
(PTH)

increases

PRA

(Powell

et

al.,

1978;

Smith

et

al.,

Therefore, PTH was tested as a possible renin-releasing factor.

1979).
PCA

was administered to thyroparathyroidectomized rats to test if removal
of the parathyroid gland would prevent the PCA- induced increase in
plasma renin activity.
Basal

levels

parathyroidectomy

of

plasma

[Two

way

renin
ANOVA:

activity

were

F(l,28)-2.154,

unaffected
p

>

by

0.100].

Administration of PCA produced a significant increase in plasma renin
activity in the sham-operated rats [Two way ANOVA: F(l,28)-22.774, p <
0.001;

Duncan's multiple range test: shortest range of significance

between means - 33.2, p < 0.05].
PCA-induced

increase

in

Parathyroidectomy did not prevent the

plasma

renin

activity

[Two

way

ANOVA:

F(l,28)-1.736, p > 0.100; Duncan's multiple range test: shortest range
of significance between means

=

44. 9, p < 0. 01] .

The sham- PCA and

parathyroidectomy-PCA groups were not significantly different from each
other.

RRF.

These results suggest that the parathyroid hormone is not the
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TABLE 10 Effect of p-chloroamphetamine (PCA; 10 mg/kg i.p.) on plasma
renin activity in sham and thyroparathyroidectomized rats.

Plasma renin activity (ng ANG I/ml/3 hr)
saline

PCA

Sham-operated

15.2 ± 2.6

52.3 ± 9.5*

Parathyroidectomized

16. 8 ± 1. 7

82.2 ± 19.0**

Data represent mean± S.E.M. n = 8.
Two way ANOVA:
Factor A (PCA): F(l,28)=22.774, p < 0.001.
Factor B (parathyroidectomy): F(l,28)=2.154, p > 0.1, N.S.
Factor Ax B: F(l,28)-1.736, p > 0.1, N.S.
Duncan's new multiple range test:
Significant difference from corresponding saline group,
33.2.
* p < 0.05, shortest range of significance between means
** p < 0.01, shortest range of significance between means 44.9.
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5,

Test for possible renin-releasing activity of neurophysin II

(Table 11)
Lesions in the paraventricular nucleus (PVN) prevent both the PCAinduced

(Gotoh

et

al.,

1987)

and

the

stress-induced

increases

(Richardson Morton et al., 1986; Gotoh i l al., 1987) in plasma renin
activity.

Neurophysin II (NPII), is synthesized in the PVN, released

from the neural lobe,

10,000.

and has a molecular weight of approximately

There is no known physiological action for the neurophysins

and therefore, NPII was tested as a possible renin-releasing factor.
Intraperitoneal injection of increasing doses of neurophysin II did not
alter PRA [One way ANOVA: F(5,39)=0.2291, p > 0.100] or PRC [One way
ANOVA: F(5,39)-0.4959, p > 0.100] levels indicating that neurophysin II
does not have any renin-releasing activity and is probably not the RRF.

D.

Summary of data using unbubbled kidney slice method

1. Effect of saline-plasma or PCA-plasma fractions (M.W. 1,000-5,000;
5, 000-10, 000 and 10, 000-20, 000) on renin release from kidney slices
(Table 12)
Table 12 shows

the effect of the PCA-plasma and saline-plasma

fractions (M.W. 1,000-5,000; 5,000-10,000 and 10,000-20,000) on renin
release from the kidney slices.
renin-releasing

activity.

All of the fractions exhibited some
The

PCA-plasma

fraction

containing

substances with molecular weights 5,000-10,000 produced a three-fold
increase in renin release when compared with any of the other plasma
fractions;

0.001;

this increase was significant [ANOVA:

F(6,55)-10.48, p <

Duncan's multiple range test: shortest range of significance
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TABLE 11
Failure of increasing doses of neurophysin II (bovine) to
alter plasma renin activity (PRA) and plasma renin concentration (PRC)
in conscious rats.

PRA
(ng ANG I/ml/3 hr)

PRC
(ng ANG I/ml/hr)

saline

7.9 ± 0.9

10.2 ± 0.6

0.1

9.0 ± 1.0

11.9 ± 1.6

0.5

9.1 ± 1.1

11.0 ± 1.2

2.0

9.1 ± 1.0

12.4 ± 1.2

10.0

8.9 ± 0.7

11.0 ± 1.0

20.0

8.2 ± 1.2

10.2 ± 1.6

Dose of Neurophysin II
(ug/kg. i.p.)

Data represent mean± S.E.M. n-8 per group.
One way ANOVA: PRA; F(5,39)- 0.229, p > 0.1, N.S.
PRC; F(5,39)- 0.495, p > 0.1, N.S.
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TABLE 12 The effect of saline or plasma fractions from saline-treated
or PCA-treated (10 mg/kg i.p) nephrectomized rats on renin release from
kidney slices.

PCA-plasma fractions
M.W.
1,000-5,000 (10)
M.W. - 5,000-10,000 (17)
M.W. = 10,000-20,000 (6)

Renin Release
(ng ANG I/mg kidney/hr)
12. 0 ± 1. 8
32.0 ± 4.1*
12. 3 ± 1. 6

Saline-plasma fractions
M.W.
M.W.
M.W.

=
=

1,000-5,000 (5)
5,000-10,000 (10)
10,000-20,000 (5)

Saline (9)

11.3 ± 1.5
9.5 ± 1.3
10.9 ± 1. 9
6.2 ± 1.0

Data represent mean± S.E.M., n is represented in parentheses.
One way ANOVA F(6,55)-10.48, p < 0.001.
Duncan's new multiple range test:
* Significant difference from all other groups, p < 0.01; shortest
range of significance between means = 18.0.
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between means -

18.0,

p < 0.01].

Lactate dehydrogenase was also

measured in the incubation medium and was determined to be 0. 034 ±
O. 006 µmol pyruvate/ml/min for the saline-plasma group (M. W.

5, 000-

10, 000) and 0.032 ± 0.006 µmol pyruvate/ml/min for the PCA-plasma group
(M.W. 5,000-10,000).

The LDH values were lower than those reported in

the literature for kidney slices (Fray et al., 1983), and indicate that
the increase in renin release from the group that received the PCAplasma fraction (M.W. 5,000-10,000) was not due to cell lysis.

2. Test for possible renin-releasing activity of 5-HT or PCA (Table 13)
Since the PCA-plasma produced increases in renin release from the
kidney slices it could be suggested that either 5-HT or PCA molecules
in the plasma fractions could increase renin release from the slices.
Therefore,
tested

for

5-HT,

PCA and

fenfluramine,

renin-releasing

activity.

another 5-HT releaser were
None

of

these

drugs

were

effective in stimulating renin release from the kidney slices [ANOVA:
F(3,11)=0.18, p > 0.1].

These results suggest that the increase in

renin release seen with PCA-plasma was not due to either PCA or 5-HT
molecules.

3. Incubation of the saline-plasma and PCA-plasma fraction (M.W. 5,00010,000) with pronase (Table 14)
To determine if RRF is a peptide,

the PCA-plasma and saline-

plasma fractions that contained renin-releasing activity (M.W. 5,00010,000) were incubated with pronase and the samples were added to the
kidney slices.

Incubation of the PCA-plasma fraction (M.W. 5,000-
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TABLE 13
Inability of 5-HT (10-6M), p-chloroamphetamine (10-6M) and
fenfluramine (10-6M) to increase renin release from kidney slices.

Test substance
Saline (4)
10-6M 5-HT (4)
10-6M PCA (3)
10-6M Fenfluramine (4)

Renin release
(ng ANG I/mg kidney/hr)
9.4
8.8
8.6
9.5

±
±
±
±

1.0
1.2
1.1
0.4

Data represent mean± S.E.M .. n is represented in parentheses.
One way ANOVA F(3,ll)-0.18, p > 0.100, N.S.
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TABLE 14
Ability of pronase to destroy the renin-releasing activity
of the PCA-plasma fraction (M.W. 5,000-10,000).

Renin release
(ng ANG I/mg kidney/hr)

Fraction added

n

Vehicle-treated
PCA-plasma fraction

9

15.7 ± 1.2*

Pronase-treated
PCA-plasma fraction

10

5.6 ± 0.4

Vehicle-treated
Saline-plasma fraction

6

10.6 ± 1. 3

Pronase-treated
Saline-plasma fraction

6

11. 7 ± 0.9

Saline

9

6.4 ± 0.5

Isoproterenol (10-6M)

6

19.6 ± 1.9*

Data represent mean± S.E.M., n represents number of determinations.
One way ANOVA F(5,39)= 29.84, p < 0.001.
Duncan's new multiple range test:
* Significant difference from saline or the corresponding pronasetreated group, p < 0.01; shortest range of significance between means 4.2.
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10,000) with pr-0nase completely eliminated its renin-releasing activity
[ANOVA:

p < 0.001;

F(S,39)-29.84,

Duncan's

multiple

range

shortest range of significance between means - 4.2, p < 0.01].

The low

renin-releasing activity of the saline-plasma fraction (M. W.
10, 000) was not affected by treatment with pronase.

test:

5, 000-

These data suggest

that RRF present in the PCA-plasma is a peptide and that the increase
in renin release seen with the saline-plasma is not due to a peptide
Saline and

factor.

isoproterenol were

tested in

the bioassay as

representative values for the low and high (stimulus induced) renin
release.
The proteolytic activity of pronase was verified using a casein
agar plate.

Casein is one of the substrates for pronase.

The pronase

was mixed with the plasma fractions and a sample was added to a casein
agar plate.
ring,

The proteolytic activity showed up on the agar as a clear

indicating

that

pronase

had

digested

the

incubation of the pronase with the plasma fraction,
boiled.

casein.

After

the samples were

Boiling inactivated the pronase and prevented any further

proteolysis; this was also verified using the casein agar plate.

E. Studies of the renin-releasing factor in rat brain
1. Extraction of RRF from rat brain tissue
la. Test of different extraction media on the recovery of reninreleasing activity from whole brain (Table 15)
One of the preliminary studies for the distribution of RRF in rat
brain

included

the

testing

of

different

extraction media

recovery of renin-releasing activity from whole rat brain.

on

the

Whole rat
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brains were extracted as

described in Method section E part 1 in

different extraction media, and added to the kidney slices. The hrains
that were extracted with cold perchloric acid (0.1 N) had the highest
renin-releasing activity (One way ANOVA:

F(6,59)-4.428,

p < 0.001].

This increase was statistically significant from the saline control and
the hot and cold hydrochloric acid extract groups (Duncan's multiple
range test: shortest range of significance between means
0.01).

5.9, p <

Brains that were extracted with either cold 0.1 N HCl/ethanol
or

(20:80)

with

hot

distilled

water

also

had

a

significant

concentration of renin-releasing activity when compared with the saline
group (Duncan's multiple range test:
between means

=

4.5, p < 0.05).

shortest range of significance

Hot perchloric acid (0.1 N) extract

and hot and cold hydrochloric acid (0.1 N) extracts had renin-releasing
activity that did not differ from the saline control values.
these

results

it

appears

that

cold

perchloric

acid,

cold

From
0.1

N

HCl/ethanol and boiling distilled water were the most effective in
recovering renin-releasing substances from whole rat brain.

lb. Comparison of extraction with cold 0 .1 N perchloric acid and
boiling distilled water on the recovery of RRF from rat hypothalamus
(Table 16)
Rat hypothalamic tissue was
releasing

substances

using

tested for the recovery of renin-

cold 0.1

N perchloric

distilled water as the extraction media.

acid or boiling

The extracts were added to

the kidney slices and the renin-releasing activity of the two extracts
were compared.

The hypothalamic tissue that was homogenized in the

113

TABLE 15 Comparison of different extraction media on renin-releasing
activity from whole rat brains.

Extraction media

!l

Renin release
(ng ANG I/mg kidney/hr)

Cold hydrochloric acid (0.1 N)

9

7.9 ± 0.3

Hot hydrochloric acid (0.1 N)

9

7.2 ± 0.3

Cold 0.1 N HCl/ethanol (20:80)

9

11.9 ± 2.2*

Cold perchloric acid (0.1 N)

10

13.8 ± 2.1**

Hot perchloric acid (0.1 N)

10

10.4 ± 1.6

8

11.0 ± 0.6*

12

6.2 ± 0.6

Hot distilled water
saline

Data represent mean± S.E.M.
One way ANOVA: F(6,59)- 4.428, p < 0.001.
Duncan's new multiple range test:
Significant difference from saline control group,
* p < 0.05, shortest range of significance between means - 4.5.
** p < 0.01, shortest range of significance between means
5.9.
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TABLE 16 Comparison of 0.1 N perchloric acid and distilled water on
the recovery of renin-releasing factor (RRF) from rat hypothalamus.

Renin release
(ng ANG I/mg kidney/hr)
cold 0.1 N perchloric acid

11.1±1.7

hot distilled water

22.4 ± 4.2*

Data represent mean± S.E.M. n-4.
Significant difference from cold perchloric acid extract group, p <
0.05 (Student's unpaired t-test, two-tailed, t-2.516, df-6).

*
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boiling distilled water had significantly more renin-releasing activity
than the hypothalamic tissue extracted with perchloric acid extract
[Student's t-test (unpaired),

two-tailed:

t-2.516,

df-6,

p < 0.05].

These data differ from the data obtained in the previous study that
indicated that perchloric acid was more effective in recovering reninreleasing activity from whole rat brain.

This suggests that the renin-

releasing substance in the hypothalamus and that (those) in whole rat
brain may be different.

One advantage in using boiling distilled water

for the extraction medium is that the hypothalamic homogenates do not
need the pH readjusted before addition to the kidney slices.
following

studies

on RRF

the

tissues

were

For the

homogenized in boiling

distilled water.

2. Renin-releasing activity of hypothalamic, cerebellar and pituitary
extracts (Table 17)
The

hypothalamus,

cerebellum

and

pituitary

tissues

were

homogenized in boiling distilled water (see Method section E part 3)
and the extracts were added to the kidney slices to test for reninreleasing activity.
increase

The hypothalamic extract produced a significant

in renin release

from the kidney slices

[One way ANOVA:

F(4,46)-ll.474, p < 0.001] when compared with either the saline control
(Duncan's multiple range test: shortest range of significance between
means -

8. 5,

p < 0. 05)

multiple range test:
10.9, p < 0.01).

or the pituitary extract values

(Duncan's

shortest range of significance between means -

The cerebellar extract significantly increased renin

release from the kidney slices when compared with the pituitary extract
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TABLE 17 Effect of rat hypothalamic, cerebellar and pituitary extracts
on renin release from kidney slices.

Substance added
Saline (13)

Renin Release
(ng ANG I/mg kidney/hr)
9.7 ± 0.6

Hypothalamic Extract (16)

19.1 ± 2.l**t

Cerebellar Extract (10)

15.3 ± 2.1*

Pituitary Extract (8)
Isoproterenol 10-6M (5)

5.7 ± 0.6
19.7 ± 2.6**t

Each data point represents mean± S.E.M. The number of determinations
(n) is represented in parentheses.
One way ANOVA: F(4,46)- 11.474, p < 0.001.
Duncan's new multiple range test:
t Significant difference from the saline group, p < 0. 05, shortest
range of significance between means
8.5.
Significant difference from pituitary extract
* p < 0.05, shortest range of significance between means
** p < 0.01, shortest range of significance between means

8.5.
10.9.
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(Duncan's

multiple

range

test;

p

< 0.05) but the effect was not

significant when compared with the saline group.

Pituitary extract

produced a small, but statistically insignificant,

decrease in renin

release when compared with the saline values.

Saline and isoproterenol

(10-6 M) were added to the kidney slices to demonstrate the high and
low values of renin release for the bioassay.
the

that

hypothalamus

and

cerebellum

These results suggest

contain

renin-releasing

The pituitary may contain substances that inhibit renin

substances.

release in vitro.

3. Dose-response effect of the renin-releasing activity of hypothalamic
tissue (Figure 3)
The hypothalamus has been shown in the previous study to contain
renin-releasing

substances.

Rat hypothalami

were

prepared

(Method

section E part 4) and added to the kidney slices in dilutions that
corresponded to the content of 0.07, 0.1, 0.2, 0.5, 1.0, 2.0 and 4.0
hypothalami.

Addition of hypothalamic extract to the kidney slices

produced a dose-dependent increase in renin release.

The content of

0.5 hypothalamus produced a significant increase in renin release that
was

also

significantly

hypothalamus

(Duncan's

different
multiple

significnce between means and maximal,

increase

from
range

the
test:

6.3, p < 0.05).

equivalent
shortest

of

0. 2

range

of

There was a significant,

in renin release when the equivalent of the

content of one hypothalamus was added to the kidney slices (One way
ANOVA:

F(B,50)-10.520,

p

< 0.001;

Duncan's

multiple

range

shortest range of significance between means - 8.2, p < 0.01].

test:

The
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FIGURE 3 Dose-response effect of rat hypothalamic tissue extract on
renin-releasing activity.
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maximal response was also obtained when the equivalents of 2 and 4
hypothalami

were

significantly

added

different

to
from

the

slices.

the

These

equivalent

of

values
0.5

were

also

hypothalamus.

Saline and isoproterenol were added as low and high (stimulus-induced)
controls for the bioassay.

These results indicate that the kidney

slices can respond with a maximal stimulation of renin release when the
equivalent of the content of one hypothalamus is added to the kidney
slices.

For subsequent studies,

tissue extracts were added to the

kidney slices in the volume that corresponded to the equivalent of the
content of one hypothalamus (0. 02 ml of tissue extract in a 1 g/ml
dilution with boiling distilled water).

4. Distribution of RRF in rat brain (Figure 4)
Rat brains were dissected and the individual parts were prepared as
indicated in Method section E part 5.

The extracts were added to the

kidney slices to test for renin-releasing activity.

Figure 4 shows the

distribution of renin-releasing activity in different brain regions.
The data are arranged in order of increasing renin-releasing activity
[ANOVA: F(l4,110)-4.693, p < 0.005].

Saline and isoproterenol (lo-5 M)

were tested along with the samples to control for the low and high
levels of the bioassay.

The following brain regions had RRF activity

that

different

was

statistically

pituitary extract groups:
multiple range test:
6.2, p < 0.05),

from

the

saline

control

or

the

the hypothalamus, cerebral cortex (Duncan's

shortest range of significance between means -

medulla oblongata and cerebellum (Duncan's multiple

range test: shortest range of significance between means - 7.0,
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FIGURE 4 Distribution of renin-releasing activity in different regions
of the rat brain.
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by Duncan's new multiple range test:
* p < 0.05, shortest range of significance between means - 6.2.
** p < 0.01, shortest range of significance between means - 7.9.
List of abbreviations:
s
saline
Iso isoproterenol 10- 5M
Pi
pituitary
Po
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Th
thalamus
Cd
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Hi
hippocampus

Mb
Am
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Cx
Md
Cb

midbrain
amygdala
hypothalamus
cerebral cortex
medulla oblongata
cerebellum
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p

< 0. 01).

There were no

significant differences

releasing activity between these groups.

pons,

thalamus,

caudate,

renin-

The pituitary had the least

amount of renin-releasing activity followed by,
the

in the

hippocampus,

in increasing order,

midbrain,

and amygQ.ala.

These values were not significantly different from the saline control
value.

These data demonstrate that there is an unequal distribution of

renin-releasing activity in the rat brain.

The areas that contain the

highest amounts of renin-releasing activity are the cerebellum followed
by the medulla, cerebral cortex and hypothalamus.

5. Distribution of RRF in brains of colchicine-treated rats (Figure 5)
Sa. Test of colchicine-treated brain extracts
The results from Figure 4, cannot distinguish RRF in cell bodies
from RRF in nerve terminals.

In order to identify RRF in the cell

bodies, a group of rats were treated with colchicine (48 hours), a drug
that

inhibits

terminals.

axonal

transport

of cell products

toward the nerve

Therefore, treatment of rats with colchicine would prevent

the movement of peptides, such as RRF, from the cell body to the nerve
terminals.

The brains from colchicine-treated rats were dissected,

homogenized and added to the kidney slices to test for renin-releasing
activity as was performed with the control brains.
Figure 5 shows the distribution of renin-releasing activity in
colchicine-treated rat brains.
a

redistribution

of

When compared with Figure 4, there was

renin-releasing

activity.

The

most

visible

difference after colchicine-treatment was that the hypothalamus was the
only brain region that exhibited significant renin-releasing activity
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FIGURE 5
Distribution
colchicine-treated rats.
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Data represented as mean± S.E.M. n-8.
One way ANOVA: F(l3,78)- 2.997, p < 0.005.
Significant difference from saline, caudate, cerebellum, midbrain and
muscle controls as determined by Duncan's new multiple range test:
** p < 0.01, shortest range of significance between means= 10.8.
Significant difference from pituitary, hippocampus, amygdala cortex and
medulla as determined by Duncan's new multiple range test:
t p < 0.05, shortest range of significance between means = 8.3.
List of abbreviations:
s
saline
Iso isoproterenol 10-5M
M
skeletal muscle
Pi
pituitary
Po
pons
Th
thalamus
Cd
caudate

Hi
Mb
Am

Hy
Cx
Md
Cb

hippo campus
midbrain
amygdala
hypothalamus
cerebral cortex
medulla oblongata
cerebellum
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[One

way

ANOVA:

F(l3,78)-2.997,

p

< 0.005].

This

activity

was

significantly different from saline, caudate-putamen, midbrain, muscle
and cerebellar extracts (Duncan's multiple range test: shortest range
of significance between means - 10.8, p < 0.01) and from the pituitary,
hippocampus, amygdala, cortex and medulla extracts (Duncan's multiple
range test: shortest range of significance between means - 8. 3, p <
0.05).
slightly,

The
but

renin-releasing activity of
not

significantly,

isoproterenol-stimulated

renin

the hypothalamus was also

increased

release.

above
In

the

value

addition

to

for
the

hypothalamus, the renin-releasing activity of the pituitary, pons and
thalamus in colchicine-treated rats was slightly but not significantly
increased when compared with the corresponding areas from the brains of
non-treated rats (Figure 4).

The renin-releasing activity previously

observed in the cerebral cortex, medulla and cerebellum was reduced,
and the value for renin-releasing activity in the cerebellum was at the
level of saline control values.

The renin-releasing activity of the

caudate-putamen, hippocampus, midbrain and amygdala was also decreased
slightly after colchicine treatment in comparison with the non-treated
controls.

Saline and isoproterenol (lo-5 M) were run as controls for

the bioassay.

Skeletal muscle extract was also tested in the bioassay

as a tissue control.

These results suggest that RRF cell bodies are

located in the hypothalamus and that the renin-releasing activity that
was

observed

in

the

cerebral

cortex,

medulla

and

probably due to the presence of RRF in nerve terminals.

cerebellum was
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Sb. Test for colchicine interference in the renin release bioassay
(Table 18)
Before

the

actual bioassay was performed with the colchicine-

treated brain parts, a preliminary kidney slice assay was performed to
test for the possible interference of colchicine in the release of
renin from the kidney slices.

Colchicine (0. 083 mg/ml extract) was

added to either saline, isoproterenol (lo- 5 M) or cerebellar extract to
test if colchicine would interfere in either basal or stimulus-induced
renin release from the kidney slices.

lsoproterenol (Duncan's multiple

range test: shortest range of significance between means - 6. 2, p <
0.05) and cerebellar (Duncan's multiple range test: shortest range of
significance

between

means

8.4,

<

p

0.01)

extract

produced

significant increases in renin release from the kidney slices when
compared with the saline control group [One way ANOVA: F(S,23)-7.330, p

< 0. 001).

There were no significant differences in renin-releasing

activity between
substance.

the

colchicine

and

saline

groups

for

each

test

This dose of colchicine (0.083 mg/ml) was calculated as the

theoretical dilution of drug in the brain.

This theoretical value

maybe larger than the actual distribution since this calculation did
not

take

into

(cerebrospinal
demonstrate

account
fluid)

that

the

the
to

the

dose

of

leakage

of

periphery.
colchicine

the

drug

from

Therefore,
used

in

the

the

CSF

the

data

brain

scan

experiment would not have interfered with renin release from the kidney
slices in the RRF bioassay.
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TABLE 18
slices.

Failure of colchicine to alter renin release from the kidney

Renin release Cng ANG I/mg kidney/hr)
saline

colchicine

saline

13.5 ± 1.6

13.4 ± 1.4

isoproterenol 10-5M

21. 7 ± 2.4*

19.7 ± 1.1*

cerebellum extract

25.5 ± 2.0**

24.4 ± 2.6**

Data represent mean± S.E.M. n-5.
One way ANOVA: F(5,23)-7.330, p < 0.001
Significant difference from saline-saline or colchicine-saline control
groups Duncan's new multiple range test:
* p < 0.05, shortest range of significance between means
6.2.
** p < 0.01, shortest range of significance between means 8.4.
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F.

Distribution

of

renin-releasing

activity

in peripheral

tissues

{Figure 6)
Since a number of peptides are distributed in the central nervous
system and in peripheral tissues, some peripheral tissues were tested
for

renin-releasing activity.

spleen,

The adrenal gland,

liver and kidney were homogenized in boiling water and the

extracts were added to the kidney slices.
releasing
muscle,

skeletal muscle,

activity

of

different

Figure 6 shows the renin-

peripheral tissues.

The

skeletal

spleen and liver extracts did not exhibit any significant

renin-releasing

activity.

The

adrenal

gland

extract

produced

a

significant decrease in renin release from the kidney slices (ANOVA:
F(5,28)-6.318, p < 0.005;

Duncan's multiple range test: shortest range

of significance between means - 4. 5, p < 0. 05] .

The kidney extract

produced a significant increase in the amount of ANG I detected.
It was possible that not all the renin in the kidney extract was
inactivated by the boiling procedure.

Therefore addition of kidney

extract to the kidney slices may have increased the amount of renin in
the

sample.

To

test

this

possibility,

kidney

extract,

at

a

concentration that equalled the dilution of the kidney extract in the
Krebs-Ringer
sample/2.0

buffer
ml),

during

was

nephrectomized plasma).
ng ANG I/ml.

the

incubated

kidney
with

slice
renin

bioassay

(0.02

ml

substrate

(0.1

ml

The kidney extract was able to generate 73.1

When this value was divided by the average weight of the

kidney slices for that bioassay (15.7 mg), this resulted in an addition
of approximately 4.6 ng ANG I/mg kidney/hr.

Subtracting this number

from the value for renin release with kidney extract (14.6 ng ANG I/mg
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FIGURE 6
tissues.

Distribution

of
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determined by Duncan's new multiple range test:
* p < 0.05, shortest range of significance between means - 4.5.
List
SAL
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of abbreviations:
saline
adrenal
muscle
spleen
liver
kidney

as
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kidney/hr)

would have

yielded

a

final

value

of

10

ng ANG

I/mg

kidney/hr, and this value would not have been statistically different
from

the

saline

control group.

Therefore

it is

likely that

the

increase in ANG I with the kidney extract was due to the presence of
renin in the extract.

G. Effect of nephrectomy on the hypothalamic content of RRF (Figure 7)
The colchicine experiment indicated that the hypothalamus contains
RRF cell bodies.

If there were

a

feedback loop involved in the

regulation of RRF release, then removal of the kidneys should result in
a change of hypothalamic RRF.

The hypothalami from nephrectomized

(NEPHX) and sham-operated rats were homogenized in boiling water and
the extracts were added to the kidney slices for the incubation period.
The

hypothalamic

extract

from

nephrectomized

rats

produced

a

significant increase in renin release from the kidney slices [ANOVA:
F(3,22)-8.09, p < 0.005) when compared with either the saline control
(Duncan's multiple range test: shortest range of significance between
8.7, p < 0.01) or the hypothalamic extract from sham-operated

means

=

rats

(Duncan's multiple range test:

between means

6.5, p < 0.05) groups.

shortest range of significance
The hypothalamic extract from

sham-operated rats produced a small increase in renin release, however,
this increase was not statistically significant when compared with the
saline control.

Saline and isoproterenol (lo-6 M) were also added as

controls for the bioassay.

The data show that removal of the kidneys

from rats results in an increase in the hypothalamic content of RRF.
These findings may suggest that the kidney may be involved in a
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FIGURE 7
Effect of bilateral nephrectomy (24
hypothalamic content of renin-releasing factor (RRF).
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One way ANOVA: F(3,22)=8.09, p < 0.005.
Duncan's new multiple range test:
p < 0.05, significant difference from sham-operated control group,
shortest range of significance between means - 6.5.
* Significant difference from saline control group, p < 0.01, shortest
range of significance between means - 8.7.
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feedback loop that regulates the production and release of RRF from the
hypothalamus.

H.

Test

for

the

neuronal

release

of

RRF:

Study

with

superfused

hypothalami (Figure 8)
The study with the colchicine-treated rats suggest that RRF cell
bodies

are

localized

neuroendocrine system,
should

be

able

to

in

the

hypothalamus.

If

this

is

be

stimulated

to

release

the

factor.

followed

by a

30 minute

solution

to

30 minute

test period with

stimulate

the

This

Hypothalami or

rat hypothalamic-pituitary explants were superfused for a
period

true

then the neurons containing the peptide (RRF)

possibility was tested by using hypothalamic explants.

control

a

high-

potassium

Krebs-Ringer

peptide.

The samples were collected, concentrated by ultrafiltration

and the fraction that was retained on the filter

release

a

of

the

(molecular weights

greater than 500) were added to the kidney slices to assay for reninreleasing activity.
The samples from the hypothalamic explants that were superfused
for the 30 minute control period with regular (control) buffer had a
value

for

renin

significantly

release

different

that
from

was
the

slightly
saline

increased,

control

but

value.

not
The

superfusates from the hypothalamic explants that were superfused with
the high potassium Krebs-Ringer solution had a

significantly higher

renin-releasing

superfused with

control buffer

activity

than

[One way ANOVA:

when

they

were

F(3,26)-9.894,

p

< 0.001;

the

Duncan's

multiple range test: shortest range of significance between means -
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FIGURE 8
Secretion of renin-releasing factor (RRF) from superfused
hypothalamus: Effect of high potassium (60 mM).
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One way ANOVA: F(3,22)= 9.894, p < 0.001.
Duncan's new multiple range test:
p < 0.05, significant difference from control buffer group, shortest
range of significance between means - 4.7.
* Significant difference from saline, p < 0. 01, shortest range of
significance between means - 6.4.

132
4.7,

p

< 0.05].

potassium

The

stimulated

value

for

hypothalamic

renin-releasing
explant

different from the isoproterenol group.

was

activity
not

of

the

statistically

Both of these groups had renin

release values that were significantly increased over the saline and
control

range

test:

shortest range of significance between means - 6.4, p < 0.01).

As a

routine
controls.

buffer

saline

superfused

and

This

groups

isoproterenol

result

indicates

(Duncan's

were

added

that

the

stimulated to secrete renin-releasing substances.

multiple

to

kidney

slices

hypothalamus

can

as
be

CHAPTER V

DISCUSSION

A. Summary
The results of this dissertation support the hypothesis for the
existence of a renin-releasing factor (RRF) that is released from the
brain into the circulation.

Using an improved and reliable method for

measuring renin release from kidney slices, these studies indicate that
RRF is a heat stable peptide having a molecular weight between 5,00010,000.

These data support previous

in

vivo studies indicating that a

factor in the plasma (M.W. 500-10,000) of PCA-treated rats is capable
of increasing plasma renin activity (PRA) in recipient rats (Van de Kar
et al. ,

1982a).

Stimulation of serotonergic receptors and stress

triggers the release of RRF into the blood.

These studies suggest that

the hypothalamus contains RRF which produces a dose-dependent increase
in renin release from kidney slices.

Further investigation revealed

that RRF is unevenly distributed within the brain with the cerebellum,
medulla oblongata, cerebral cortex and the hypothalamus exhibiting the
highest concentration of RRF.
treated

rats

suggest

hypothalamus.

It is

that

RRF

Studies using brains from colchicinecell

bodies

are

localized

in

the

also noted that the renin-releasing activity

previously observed in the cerebellum, medulla and cerebral cortex was
133
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reduced which suggests that RRF in these brain regions is present in
nerve terminals.

Superfusion of rat hypothalamus explants with high

potassium medium demonstrated that RRF neurons in the hypothalamus can
be stimulated to release RRF.
significantly
possible

increased

presence

of

The hypothalamic content of RRF was

after bilateral
a

feedback

nephrectomy suggesting

the

from

the

loop

the

kidneys

to

hypothalamus which is responsible for the maintenance of RRF at a
homeostatic level.
Bioassay of several peripheral tissues indicated that the spleen,
liver, skeletal muscle and kidney do not contain RRF.

Adrenal extract

produced a decrease in renin release from kidney slices which may be
due to the presence of inhibitory peptides or transmitters
adrenal gland.

in the

The study further determined that parathyroid hormone

(PTH) and neurophysin II (NPII) are not RRF.

B. Renin release bioassay
1. In vivo bioassay
The first investigations on RRF were performed in conscious rats
in a

series of cross - transfusion experiments

1982a).
into

(Van de Kar et al. ,

The plasma from PCA-treated rats was concentrated and injected

conscious

recipient

rats.

Plasma

renin

activity

(PRA)

was

measured in the recipient rats to determine whether there was a factor
in the blood from PCA-treated rats that increased renin secretion.

The

results from these experiments indicated the presence of a blood-borne
factor with a molecular weight between 500-10,000.

Injecting plasma

fractions into conscious rats could have altered either sodium balance,
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plasma osmolarity or even blood pressure which,
altered plasma

renin

activity.

Therefore,

in turn, would have

it was

possible

that

physiological changes in the recipient rats could have interfered with
the effect of RRF.

To eliminate these influences, an in vitro renin

release bioassay was developed so that the effect of RRF could be
observed directly on the kidney.

2. In vitro kidney slice bioassay
In vitro kidney slice methods have been used to study the direct
effects of various stimuli on renin release (Henrich and Campbell,
1984; O'Dea et al.,
1982a).

1984; Fray and Laurens, 1981; Katz and Malvin,

The kidney slice method used in these studies was based on the

method used by Katz and Malvin (1982a).

After experimenting with the

methods of slicing and oxygenation, the resulting method of measuring
renin release in vitro was an improvement over the other methods.
Cutting the tissue by hand (Churchill and Churchill, 1982; Henrich and
Campbell,

1984)

or with a Stadie-Riggs microtome

(Katz and Malvin,

1982a) could cause variation in slice thickness and deformation of the
kidney due to changes in the amount of pressure that is put on the
kidney during slicing.

Using a vibratome to slice the kidney tissue

ensured that each slice was of uniform thickness, primarily because the
vibratome cuts
tissue

or

the kidney without applying pressure to the kidney

deforming

it.

The uniformity

in slice

size

could be

correlated with the kidney slice weight (Table 2).
Another modification of the method involved coronal sectioning of
the kidney.

By cutting the kidney coronally instead of sagittally each
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slice contained equal amounts of cortical tissue (both outer and inner
cortex) and medullary tissue.

The highest content of renin secreting

cells is located in the outer cortex (Katz and Malvin, 1982b; Jones et

_ru..,

1979).

The renal medulla however, has virtually no renin activity

(Katz and Malvin, 1982b) and thus, was removed.
contained

primarily

inner

and

outer

The kidney slices then

cortical

tissue.

Medullary

dissection ensured that the slices were homogenous with respect to
renin content.

Using this coronal method of slicing more than 30

slices per kidney could be obtained which was far more than the 2-4
slices which were previously obtained using sagittal cuts (Katz and
Malvin, 1982a; Churchill and Churchill, 1982; Cho and Malvin, 1979).
Proper oxygenation of the vials is important to the viability of
the slices.

Cho and Malvin (1979) demonstrated that direct bubbling of

the Krebs-Ringer buffer surrounding the kidney slices decreased the
amount or activity of renin present in the medium and also prevented
the accumulation of renin activity over time.

The decrease in renin

was due to inactivation of the enzyme at the air-liquid interface.

The

values for renin release using the bubbled kidney slice method were
lower and less

consistent

than those presented using the modified

(unbubbled) method (Table 1).

By changing to the unbubbled method the

values for renin release became more consistent and reproducible.
Histological

and

immunocytochemical

studies

were

performed to

verify the viability of the kidney slices both before and after the
incubation periods (Van de Kar et al., 1987).

Histological analysis

revealed that the glomerulus and adjacent juxtaglomerular apparatus
appeared healthy both before and after incubation.

Immunocytochemical
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staining for immunoreactive renin was localized to segments of the
afferent arterioles.
staining

in

incubation.

the

Again,

slices

there were no differences between the

either prior

to,

or

after,

2.5 hours

of

These findings suggest that the content of renin was not

depleted during the incubation period.

Other reports indicate that the

renal content of renin is not depleted by a similar incubation period
(De Vito et al., 1970).

These analyses of the kidney slices indicate

that the juxtaglomerular cells in the kidneys remain healthy during the
RRF bioassay.
An indicator for a viable kidney slice method is the determination
of lactate dehydrogenase (LDH)
slices.

LDH is

in the medium surrounding the kidney

a cytoplasmic enzyme that

is commonly used as a

indicator for the leakage of cell contents into the medium.
Churchill

(1979)

and Lyons

(1980)

Reports by

showed that LDH activity in the

medium did not parallel the release of renin from the slices.

LDH did

accumulate during the incubation, however, the rate of accumulation was
not affected by factors that increased renin release.

The values for

LDH reported for the unbubbled kidney slice method discussed above were
(Fray~

lower than reported in the literature

J!.l., 1983) and were not

different between the treatment groups that received the PCA-plasma or
saline-plasma fraction (M.W.

5,000-10,000).

Even though the kidney

slices that received the PCA-plasma fraction released more than two
times as much renin as

the vials

that received the

saline-plasma

fraction, the LDH values were the same.
An additional precaution taken with the kidney slice bioassay was
to use young rat kidneys for the slices.

The kidneys used for the
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bioassay were taken from rats that weigh less than 250 g.

It has been

noted in our laboratory that as the rats age their kidney slices often
hypersecrete

renin

into

the

Krebs-Ringer

treatment effect during the incubation.

medium

which

masks

any

Using rats between 150-250 g

increases the probability that the kidneys will be responsive to a
stimulus.

Corman

~

al. (1985) saw that as the rats grew older their

kidneys increased in weight.

They noticed that the increase in kidney

size is due to enlargement of the glomerulus and proximal tubules.
Furthermore, the filtering capabilities of the kidney is decreased in
older rats.
rats

Fray (1978) noted that the kidneys from sodium-depleted

had higher basal

controls rats.

It

levels

of

renin release

than kidneys

from

is possible that there are alterations in the

handling of sodium that causes the kidneys to release more renin.

The

aging of the kidney may not be related to a change in one function but
may be the result of changes in several processes.

It is possible that

the alterations in renin release, in Yi..t!:,Q, from older kidneys are due
not only to changes in the renin-angiotensin system but to age related
nephropathies.
To test the reliability of the kidney slice bioassay isoproterenol
was added to the kidney slices.
M)

is

known

Addition of isoproterenol (10-5-10-6

to cause renin release

from the kidney

(Henrich and

Campbell, 1984; O'Dea et al., 1984; Katz and Malvin, 1982a; Churchill
and

Churchill,

Vallotton,

1976;

1982)

by

stimulating

Weinberger et al.,

beta
1975).

receptors

(Capponi

An increase

and

in renin

release was observed using the unbubbled kidney slice method (Table 3)
after a 1 hour incubation with isoproterenol.

Using the new method, a
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10-7M dose of isoproterenol was able to produce a significant increase
in renin release whereas, with the bubbled kidney slice method, a 10-5
M dose did not produce a statistically significant increase.
literature
values

for

incubation.

generally

cites

increases

of 1.3-2.2

isoproterenol-induced renin

times

the

The

control

release after 1-2 hours

of

Addition of 10- 7 M isoproterenol produced more than a

three - fold increase in renin release over a period of 3 hours in the
unbubbled renin release bioassay (Urban and Van de Kar, 1986).

When

compared with the values in the literature, this is a larger increase
in renin release produced with a smaller dose of isoproterenol; this
illustrates that the bioassay is sensitive and responds to a stimulus.
One limitation to this bioassay is the narrow dynamic range for
assessing renin release.

It is not often that values for renin release

are larger than 25 ng ANG I/mg kidney/hr.

It is likely that there is

more renin being released than can be detected by this bioassay.

One

possibility is that renin may be degraded in each of the kidney slice
vials during the incubation period, since we have not measured the rate
of accumulation and degradation of renin in these vials.

C. In vivo studies on plasma RRF
1. Effect of 5-HT agonists on PRA, PRC and plasma RRF concentration
Since PCA stimulates the release of RRF, the serotonin agonists
MK-212 and TFMPP were administered, in addition to PCA, to conscious
rats to test if these 5-HT agonists could stimulate the release of RRF.
PCA, MK-212 and TFMPP increased PRA, PRC and plasma RRF levels.

For

both PRA and PRC, the levels produced by MK-212 were higher than the

140
PCA- and TFMPP-treated groups (Table 6).
known to bind to 5-HT receptors.
the

receptor

subtypes
1979)

(Clineschmidt,

However, their relative potency at

differ.
that

Both MK-212 and TFMPP are

also

MK-212

is

has

been

phosphoinositol turnover in cortical slices

a

serotonin
shown

to

agonist
increase

(Conn and Sanders-Bush,

1985).

The serotonin-induced increase in phosphoinositol turnover is

coupled

to

5-HT2

receptors

whereas

stimulation of 5-HT1

receptors

results in an increase of adenylate cyclase activity (Sanders-Bush and
Conn,

1985).

The selective 5-HT2 antagonist LY53857 prevented the

increase in PRA after either treatment with MK-212 or fenfluramine
supporting the

hypothe~is

that 5-HT2 receptors regulate renin secretion

(Lorens and Van de Kar, 1987).

Studies by Clineschmidt et

Al.

(1978)

showed that MK-212 can inhibit the serotonin uptake system at the dose
that was used in this study (10 mg/kg, i.p.).

They demonstrated that

pretreatment of rats with MK-212 prevents the depletion of serotonin
observed 72 hours after treatment with PCA.
neuron via the reuptake pump.

PCA gains access to the

Pretreatment with an uptake inhibitor

prevents PCA from entering the nerve terminal and thus inhibits its
action.

It is possible that by blocking the serotonin uptake pump, MK-

212 increases the amount of serotonin available at the synapse (Wong
al., 1985).

~

Assuming that the renin response, seen with the 10 mg/kg

dose of MK-212 is not due to maximal occupation of the receptors, it is
likely that by a combination of both stimulating 5-HT2 receptors and
increasing the synaptic availability of serotonin, MK-212 could produce
a potentiation of the renin response.
Administration of the 5-HT1B receptor agonist, TFMPP,

produces
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significant increases in PRA and PRC, although the increase in PRC is
not as elevated as that produced by either MK-212 or PCA.

A number of

studies have demonstrated that TFMPP binds preferentially to 5-HT1B
receptors

(McKenney and Glennon,

1986; Asarch et al. , 1985).

This

result is in disagreement with the theory that only 5-HT2 receptors are
involved in the regulation of renin secretion.

However, administration

of RU24969, a non-selective 5-HTlA&B agonist, produces dose-dependent
increases

in PRA and PRC that are

LY53857 (Van de Kar et al., 1987).
HT1 agonist,

inhibited by pretreatment with

This indicates that the putative 5-

RU24969 also has affinity and activity at the

receptor or that LY53857 also blocks the 5-HT1B receptor.
by

Pettibone

and

Williams

containing compounds,

(1984),

TFMPP

and

similar

5-HT2

In a study
piperazine-

were found to act as serotonin releasers and

displace endogenous stores of serotonin.

Fuller~

al.

(1981), have

reported that TFMPP can act as an uptake inhibitor since it prevented
the

depletion of brain serotonin by PCA.

Furthermore ,

Conn and

Sanders-Bush (1985) have indicated that TFMPP can produce an increase
in phosphoinositol hydrolysis, an effect that is associated with 5-HT2
receptors.

It is possible that TFMPP produces an increase in PRA, PRC

and RRF levels by an action that is not attributable to its 5-HT1
activity.

TFMPP could release enough serotonin to increase renin

secretion, or it is even possible that TFMPP may have activity at the
5-HT2 receptor site in addition to its 5-HT1B activity.
Administration of the serotonin agonists MK-212 and TFMPP and the
serotonin releaser, PCA, all increased the plasma concentration of RRF.
The difference in the mechanism of action of the drugs can be noticed
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in

the

PRA

and

PRC

values,

however,

the

values

for

plasma

RRF

concentration are equally elevated, indicating that each drug released
about the same amount of RRF.

It is difficult to explain why the RRF

values do not reflect the difference PRA and PRC values.

It is evident

that

RRF into

serotonin receptors

plasma.

were

stimulated

to

release

the

One reason for the consistent values for RRF concentration is

that the kidneys may have been stimulated maximally with the addition
of the plasma samples so that any difference

in RRF concentration

between the drug treatments (measured as renin release from the kidney
slices) was not detectable by the bioassay.

Isoproterenol was not

added in this bioassay so it is difficult to define the dynamic range
of this bioassay.

It is not likely that the activity of RRF was

digested by proteases since the plasma samples were boiled for 20
minutes and the larger proteolytic enzymes would not have survived the
boiling process.

Another possibility is that some RRF was inactivated

by brush border enzymes present in the proximal tubule of the renal
cortex.

A study by Ward and Johnson (1978) showed that kidney extracts

inactivated substance P faster than the extracts of either liver or
lung.

The highest activity of substance P degradation occurred in the

brush border of the proximal tubules.

The bioassay is performed on

renal cortical slices that contain a high concentration of proximal
tubules (Van de Kar et al., 1987).
RRF

could

have

been

catabolized

Therefore, it is likely that some
during

the

bioassay

precautions were taken to inactivated these enzymes.

since

no
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2. Role of stress on plasma RRF concentration
Rats that are subjected to a variety of stress paradigms have
increased levels of corticosterone, prolactin and renin (Paris i l !ll.,
1987; Richardson-Morton et al., 1986; Van de Kar et al., 1984; 1985;
Eljarmak et al., 1982).

The effect of a stressor such as conditioned

emotional response (Richardson-Morton et al., 1986) and immobilization
(Gotoh

et

al.,

1987)

on

renin

secretion

can

be

prevented

by

electrolytic lesions in the hypothalamic paraventricular nucleus (PVN).
This result does not appear to be due to decreased levels of renin
substrate

that

would

occur

as

a

result

of

interrupting

the

adrenocortical axis since the corresponding PRC values, measured with a
saturating
decreased

concentration

of

exogenous

(Richardson-Morton et

al.,

renin

1986).

substrate,

are

also

Further studies have

indicated that cell bodies in the PVN are responsible for mediating the
stress-induced
1987).

increase

in PRA and PRC

(Richardson-Morton et !ll.,

Furthermore, electrolytic lesions in the PVN also prevented the

increase in PRA after administration of PCA (Gotoh i l !ll.,

1987).

Since the PVN contains neurons that can release peptides into the
circulation, it is likely that the release of RRF may be stimulated by
stressful conditions.

Stress produces an increase in PRA and plasma

RRF concentration when compared with the renin-releasing activity of
plasma from control (non-stressed) rats (Table 7).

That the increase

in PRA was about four times greater than the change observed with the
RRF concentration.

There are many factors that can influence the PRA

values in stressed rats.

PRA is a measurement that reflects changes in

central and peripheral sympathetic nerve activity, changes in sodium
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levels and blood pressure, in addition to increases due to RRF.

When

measuring the plasma concentration of RRF, only the direct effect of
the factor is being detected at the kidney level which is evaluated by
incubating

the

plasma

fraction

with

renal

cortical

slices.

Furthermore, the renal cortical slice is only a fraction of the total
renin-releasing ability of the kidney.

If more kidney tissue were

added to the bioassay, the increase in renin-releasing activity could
have been greater.

D. Characterization of plasma RRF in vitro
Administration of PCA to rats produced an increase in plasma renin
activity that was due to the presence of a blood-borne renin-releasing
factor (RRF;

Van de Kar, et al., 1982a).

RRF was identified to be

present in the plasma fraction with molecular weights of 500-10,000.
The PCA-plasma fraction (M.W. 500-10,000) was also tested in the renin
release
release.

bioassay

and

produced

dose-dependent

increases

in

renin

Further studies using the PCA-plasma fraction with smaller

molecular weight ranges indicated that RRF is within the 5,000-10,000
molecular weight range.

RRF is also heat stable.

These studies were

performed using the bubbled kidney slice method (Urban et al., 1985).
Although there were fairly large increases in renin release among the
treatment groups (0.1 ± 0.06 and 0.66 ± 0.38 ng ANG I/mg kidney/hr),
these differences were not significant.

This was due in part to the

fact that there was a low number of samples in each group (n-3), and
there was also a large variation among the values for renin release
within each group.

This was reflected in the relatively large standard
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error of the mean (S.E.M.).

The large S.E.M. values indicated the need

for a more reliable method for measuring renin release.
unbubbled method,

that proved to be

Therefore, the

reliable and reproducible was

developed and used for the rest of the experiments.
The studies using the plasma fractions were repeated using the new
unbubbled method.

The results indicate that the 5,000-10,000 molecular

weight PCA-plasma fraction had the highest amount of renin-releasing
activity.

This replicates the results found using the previous bubbled

bioassay method.

Thus, we obtained similar results using both the

bubbled and unbubbled in vitro renin release bioassays and an in
renin release bioassay (Van de Kar et .5!.l., 1982a).

~

This suggests that

even though the bubbled method was not very reliable for measuring
renin release,
importantly,

it showed a response to an applied stimulus.

replication

of

the

results

using

different

More

methods,

reinforces the validity of the observation.
Nephrectomy is known to increase plasma angiotensinogen (renin
substrate) levels (Carretero and Gross, 1967).

Therefore plasma from

nephrectomized rats would be expected to contain increased amounts of
angiotensinogen.

It is not likely that angiotensinogen would influence

renin release from the kidney slices since the molecular weight of
angiotensinogen

is

approximately

60,000

(Tewksbury,

1983)

and

the

plasma fraction that increased renin release contained solutes with
molecular weights from 5, 000-10, 000.

Furthermore, angiotensinogen is

denatured by heat and would not have survived the boiling process prior
to fractionation of the plasma.

For the same reasons, renin would not

be present in the plasma fractions: renin is heat labile and also has a
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larger molecular weight (40,000).

Moreover, the plasma renin activity

values in rats that are anephric are at the sensitivity limit of the
assay indicating that there is little, if any, renin present in the
plasma.

In addition, if renin or angiotensinogen were responsible for

the renin-releasing activity, these substances would be expected to be
present in the saline-plasma fraction and would have produced a similar
increase in renin release.
Serotonin (5-HT) and PCA were not capable of directly producing an
increase in renin release from the kidney slices indicating that these
drugs are not renin-releasing factors.

Furthermore, these molecules

are small (PCA: M.W.-206; 5-HT: M.W.-179) and would have been filtered
through

the

lower

molecular

weight membrane

(M.W.

cutoff 5,000).

Circulating catecholamines which are known to alter renin release are
also not likely to be the renin-releasing factor since they also have
low molecular weights and are heat labile.
The

renin-releasing activity of the

PCA-plasma fraction

(M.W.

5,000-10,000) is destroyed by incubation with pronase; in addition with
the heat stability of RRF these studies suggest that RRF is a peptide.
Pronase non-selectively digests peptide bonds (Narahashi, 1970).
renin-releasing

activity

of

this

PCA-plasma

fraction

(M.W.

The

5,000-

10,000) is lower than in the previous experiment (Table 12 versus Table
14).

This difference in potency may be partially due to the presence

of calcium chloride (5 mM) that was present in the pronase vehicle
(borate buffer).

The final concentration of the calcium chloride that

was added to the kidney slice buffer was approximately 5.5 x lo-5 M.
The presence of calcium at this dose has been shown to inhibit renin
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secretion

(Park

et

al.,

1986;

Antonipillai

and

Horton,

1985).

Therefore, this increase in the calcium content of the kidney slice
buffer may have altered the response of the kidneys to the PCA-plasma
fraction.

The renin-releasing activity of the corresponding saline-

plasma fraction (M.W. 5,000-10,000) was not affected by treatment with
pronase, suggesting that the substance in this fraction that increases
renin release is not a peptide.

The substance present in the saline-

plasma fraction might therefore be different from the factor present in
the PCA-plasma fraction.
1,000-5,000
activity.

and

Furthermore, the other plasma fractions (M.W.

10,000-20,000)

also

exhibited some

renin-releasing

It is possible that the increase in renin release seen with

these other plasma fractions may be due to incomplete fractionation of
RRF or due to a change in the osmolali ty of the buffer bathing the
kidney slices.
method

for

The ultrafiltration method employed is not an absolute

determining molecular weight but

is

primarily used to

concentrate solutes within different molecular weight ranges.

Some of

RRF may have been retained in the large molecular weight fraction and,
if the molecular weight of RRF is closer to 5,000, it could have been
filtered
fraction.

through

into

the

lower

(1,000-5,000)

This explanation may account for

molecular

weight

some of the activity

present in the other PCA-plasma fractions (M.W. 1,000-5,000 and 10,00020,000).

However, in the saline-plasma fractions there is also some

renin-releasing activity.

Administration of PCA stimulates release of

RRF, but it is also likely that there may be a small basal release of
the peptide that would be detected in the plasma of the saline-treated
rats.

However, this possibility is not supported by the data obtained
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from the pronase experiment.
5,000-10,000)

contained

the

If the saline-plasma fraction
same

substance as

(M. W.

the PCA-plasma then

pronase should have destroyed the renin-releasing activity present in
the saline-plasma fraction.
Since these fractions contain solutes with different molecular
weights it is difficult to conceive that one substance produces these
increases.

One possibility may be that these fractions change the

osmolality of the Krebs-Ringer buffer when they are added to the kidney
slices which would affect renin release.
decreases

in

osmolality

stimulate

the

Studies have indicated that
release

of

renin

in vitro

suggesting that the release of renin may be regulated by the cell
volume of the juxtaglomerular cells (Skott, 1986; Frederikson
1975).

et~ .•

If the plasma fractions do alter the osmolality of the Krebs-

Ringer buffer, it would most likely result in a relative increase in
osmolality since these fractions are concentrated plasma and contain
high

concentrations

Frederikson et al.

of

protein.

According

to

the

hypothesis

(1975) and Skott (1986) these concentrated plasma

fractions should decrease renin release from the kidney slices.
and Guyton (1976)
albumin

increased

of

Hall

reported that infusions of hypertonic dextran or
renin

secretion

rate

in

anesthetized

dogs.

Similarly, Fray and Laurens (1981) reported that addition of albumin to
juxtaglomerular cells increases renin release from the cells probably
by sequestering, and lowering, the extracellular calcium concentration.
It could be possible that there may be substances in the PCA-plasma and
saline-plasma fractions that could lower the amount of extracellular
calcium

thereby

increasing

renin

release

over

the

saline control
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values.
Recent evidence has indicated that in addition to active renin, an
inactive form of renin is present in the plasma (Bouhnik
Inagarni et al.,

1983).

Inactive renin,

or prorenin,

produced in the kidney (Taugner et Sl].., 1987; Bouhnik
circulates in the plasma where it is activated.
conditions

that

can

activate

prorenin,

such

~

~

Sl].., 1985;

is primarily

Sl].., 1985) and

There are a variety of
as

cold

activation

(Wilczynski and Osmond, 1983), proteolysis with trypsin (Takada

~al.,

1986; Wilczynski and Osmond, 1986), and acidification (Wilczynski and
Osmond, 1983).

The actual stimulus for activation of prorenin in the

plasma in vivo has not been identified.

One possibility for the

increased amount of renin activity seen with the addition of the PCAplasma (M.W.

5,000-10,000) could have been that the plasma fraction

contained an activator

that would convert prorenin

surrounding the kidney slices to active renin.

in the medium

PCA-plasma and saline-

plasma fractions (M.W. 5,000-10,000), when added to the pooled KrebsRinger buffer that was previously incubated with kidney slices, did not
produce an increase in renin activity above the saline control group
(Table 4).

This indicates that the increased amount of renin release

from the kidney slices was not due to activation of prorenin by the
plasma fractions.
The plasma fractions were also tested for possible renin-like
activity that would have resulted in higher values for ANG I generated
in the renin assay.

The PCA-plasma and saline-plasma (M. W.

5, 000-

10, 000) fractions were incubated with renin substrate to test if they
could generate ANG

I.

The plasma fractions were not capable of
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producing any measurable amounts of ANG I, which demonstrates that
there

was

fractions.

no

renin-like

enzyme

activity

present

in

these

plasma

These two tests verify that the increase in the amount of

ANG I generated from the samples was due to the release of renin from
the kidney slices and not to activation of prorenin or the presence of
renin-like enzymes in the plasma fractions.

This conclusion is logical

since the molecular weights of renin and cathepsin D,

a renin- like

enzyme, have molecular weights around 40,000.

E. Studies of RRF in rat brain
1. Extraction media
Rat hypothalami that are homogenized with boiling distilled water
yield a higher amount of renin-releasing activity than hypothalami that
are homogenized with cold perchloric acid (0.1 N).

Since RRF is a heat

stable peptide, the brain tissue could be homogenized in boiling water
to denature other larger proteins, leaving the renin-releasing activity
of RRF unaffected.
and hypothalamic

It would be expected that the whole brain extracts
extracts would exhibit similar values

releasing activity with the different extraction media.

for

renin-

The comparison

of extraction media with whole brain homogenates indicate that the cold
perchloric acid (0 .1 N) is the better solution for extracting reninreleasing

activity.

Boiling

distilled

water

and

cold

0 .1

N

hydrochloric acid/ethanol (20:80) were equally effective in recovering
renin-releasing substances from whole brain tissue.

The results from

the whole brain versus hypothalamic tissue homogenates are not in total
agreement.

These data imply that extraction of whole brain with cold
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perchloric

acid

may

extract

or

activate

other

renin-releasing

substances not located in the hypothalamus.

2. Central nervous system (CNS) distribution of RRF
Rat

hypothalamic

extract

produces

dose-dependent

renin-release from the kidney slices (Figure 3).

increases

in

The equivalent of the

content of one hypothalamus, when added to the kidney slices, produces
a maximal stimulation of renin release.

This indicates that there are

receptors on the kidney that can respond to different concentrations of
RRF.

This also is an important finding because it made it possible to

standardized the amount of tissue extract that was added to the kidney
slices so that the relative concentration in renin-releasing activity
of different brain regions could be compared.

The renin-releasing

activity of other brain regions were compared to the renin-releasing
activity present in one hypothalamus.
Bioassay of rat brain regions showed a differential distribution
of

renin-releasing

activity

(Figure

4).

In

addition

to

the

hypothalamus and cerebellum which have been shown previously to contain
renin-releasing substances

(Van de Kar i l 1!l,., 1987b), the cerebral

cortex and medulla oblongata also have significant amounts of reninreleasing substances.

Other brain regions (pons, thalamus, caudate,

hippocampus,

and

midbrain

amygdala)

do

not

contain

significant

concentrations of RRF although there is some renin-releasing activity
present in these regions.
Addition of pituitary extract produced a small decrease in renin
release from the kidney slices.

Since the whole pituitary (both neural
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and anterior lobes) was homogenized, the decrease in renin release may
be due to the presence of vasopressin in the neural lobe.

Vasopressin

is known to inhibit renin secretion (Schwartz and Reid, 1985; Vander,
1968).

The high vasopressin content in the pituitary may have masked

any renin-releasing activity.

The hypothalamic PVN and SON (supraoptic

nucleus) contain vasopressin cell bodies, however, an increase in renin
release is still observed when the hypothalamic extract is added to the
kidney

slices.

synthesized
glycoprotein.

Within

and

the

processed

PVN
along

and
with

SON

neurons,

neurophysin

vasopressin
and

a

is

smaller

Vasopressin is separated from the neurophysin as they

are transported down the axon to the nerve terminals where they are
released (Gamier et al.,

1985; Masse et al., 1982; Russell et al.,

1982).

It can be hypothesized that when vasopressin is bound to the

carrier

protein

(neurophysin)

it

may

not

interact

receptor and thus will not suppress renin release.

at

the

kidney

Therefore, based on

this conjecture, the renin-releasing activity of the hypothalamus would
not be masked by the inhibitory action of vasopressin.
Colchicine is known to inhibit microtubule transport (Andreu and
Timasheff, 1986).
the

axonal

Treatment with colchicine has been used to prevent

transport

of peptides

from the

cell body in order to

concentrate the peptide within the cell body (Emanuele t l ll·, 1985;
Kawata et al., 1985).

Therefore brain areas that have increased renin-

releasing activity should indicate the presence of RRF in cell bodies.
The brain areas that have a decrease in activity would indicate the
presence of RRF in nerve terminals.

After intracerebroventricular

injections of colchicine, the renin-releasing activity in the rat brain
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was redistributed.
renin-releasing
other brain
suggest

The hypothalamus was the only brain region that had

activity

regions

that

the

that was

except

cell

the

bodies

significantly

pons

and

increased over

thalamus.

containing

RRF

These

are

located

all

results
in

the

hypothalamus.
Using an HPLC
column)

system

hypothalamic
fractions

and

a

G50

extract was

and

determined.
activity

(high performance

the

Sephadex

liquid chromatography,
gel

separated

into

renin-releasing

GPC-100

chromatography column,

rat

different molecular weight

activity

of

the

fractions

was

There was a significant concentration of renin-releasing

in

three

approximately

peaks

4,800-6,000

unpublished observations).

within
(Van

the
de

molecular
Kar,

weight

Brownfield

range

and

of

Urban,

These fractions have not been tested for

susceptibility to pronase digestion.
In

addition

to

the

presence

of

RRF

in

the

rat

hypothalamus also contains renin-releasing substances
al.,

1987b).

Bovine

hypothalamic

extract

was

CNS,

bovine

(Van de Kar i l

filtered

to

obtain

different molecular weight fractions which were tested in the renin
release bioassay for the presence of RRF.
with

pronase

substances
hypothalamus

to

in

test

the

whether

hypothalamus.

contains

there
We

These fractions were treated
were

similar

determined

renin-releasing peptides

renin-releasing
that

the

bovine

within the molecular

weight ranges of approximately 1,000-5,000 and 5,000-10,000 (Van de Kar
et al.,

1987b).

Discovering the presence of renin-releasing peptides

in bovine hypothalamus with a similar molecular weight range as the rat
plasma fractions, suggests that the rat may not be the only species to
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have RRF.

The bovine hypothalamic fraction (M.W. 5,000-10,000) may

contain the same or similar renin-releasing peptides as the rat plasma
fraction.

One

dissimilarity

between

the

rat

plasma

and

bovine

hypothalamus fractions is that the bovine hypothalamus contains reninreleas ing activity in a fraction with a molecular weight range of
1,000-5,000.

Renin-releasing activity was only present in the rat

plasma fraction within the 5,000-10,000 molecular weight range.

It is

possible that in the bovine hypothalamus, the smaller peptide may be a
metabolite of the larger peptide that does not reach the bloodstream,
or it may even be a different substance altogether.

F. Distribution of RRF in peripheral tissues
Many neuropeptides are not only localized to the brain but also
exist

in

peripheral

tissues.

For

example,

vasoactive

intestinal

polypeptide (VIP), neurotensin, substance P, neuropeptide Y (NPY) and
atrial natriuretic factor (ANF) are peptides that can be identified in
neurons in the brain and also are distributed in different peripheral
tissues.

The test for renin-releasing activity in various peripheral

tissues indicated that only the kidney extract produced an increase in
the amount of ANG I detected in the RRF bioassay.

This effect was

likely due to excess ANG I that was generated by renin in the kidney
extract which escaped denaturation before it was added to the kidney
slices.
Addition of adrenal extract to the kidney slices inhibited renin
release.

The

catecholamines.

adrenal

medulla

contains

a

high

content

of

These are not likely to be involved in the decrease in
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renin release since catecholamines are not heat stable and are likely
to be

destroyed by addition of water and heating at

minutes.

lOOoc for

However, if the catecholamines did survive the treatment

20

• it

could be likely that they would decrease renin release by stimulating
alpha receptors.
Glucocorticoids
adrenal

cortex.

glucose

and

and

mineralocorticoids

These hormones play a

sodium

balance

and

plasma

are

role

localized

in

the

in the maintenance of

volume.

Administration of

steroids decreases the elevated levels of plasma renin activity that
occurs after adrenalectomy (Nasjletti and Masson, 1969).
prednisolone,
also

a

decreases

suppression

of

Infusion of

glucocorticoid with some mineralocorticoid activity,
plasma
renin

renin

activity

after

in

normal

administration

of

subjects.

The

glucocorticoids

in

conscious animals probably occurs secondarily to the increase in plasma
volume.

Receptors

aldosterone

for

corticosterone

(Scholer et al.,

1979)

(Lee

~ .•

et

1983)

and

have been identified by binding

studies to be localized along the nephron and on distal segments of the
cortical tubules,

respectively.

De Vito et al.

(1970) reported that

addition of aldosterone to kidney slices produces about a 30% decrease
in

renin

from

release

the

slices

whereas

addition

of

deoxycorticosterone has no effect on renin release.
In addition

to

catecholamines

and steroids,

immunocytochemical

methods have identified other transmitters and peptides in the adrenal
medulla.
al.,

1981;

Serotonin (Holzwarth and Brownfield, 1985), VIP (Hokfelt et
Holzwarth,

1984),

substance P (Hokfelt et al.,

neurotensin

(Lundberg t l al.,

1982),

1977), neuropeptide Y (NPY; Varndell fil
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al., 1984; Majane et al., 1985), somatostatin and enkephalin (Lundberg
gt al.,

VIP,

1982) were identified in the adrenal medulla.

some

fibers were also found

In the case of

in the adrenal cortex.

In our

studies, 5-HT has been demonstrated not to alter the release of renin
from the kidney slices, therefore 5-HT would not produce the decrease
in renin release produced by the adrenal extract.

VIP stimulates the

secretion of renin both in yivo (Porter et §1., 1985) and in vitro
(Porter et al. , 1983) .
adrenal

homogenate

Therefore any VIP that is present in the

would not

release from the kidney slices.

be

responsible

for

decreasing

renin

On the otherhand, NPY (Hackenthal and

Taugner, 1986), substance P (Gullner and Bartter, 1979; Gullner §.!:al.,
1979) and somatostatin (Izumi et al., 1979) have been shown to decrease
renin release .in vitro.

Substance P,

even though it is a potent

vasodilator which would reflexly increase PRA, produced a decrease in
PRA at doses that do not alter blood pressure (Izumi et §1., 1979).
NPY slightly decreases

plasma renin activity in conscious

animals

(Pfister et al., 1986) at doses that do not influence mean arterial
pressure or heart rate.

Neurotensin also produces hypotension like

substance P, but may not affect renin release (Gullner and Bartter,
1979).

Based on these findings it is probable that the decrease in

renin release from the kidney slices produced by adrenal extract may be
due to the presence of NPY, substance P or somatostatin which are known
to suppress renin release.
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G. Evidence for a RRF neuroendocrine system
1. Superfusion of rat hypothalamus
Since the main grouping of RRF cell bodies have been localized to
the hypothalamus, hypothalamic explants were stimulated to test for the
release RRF.

Superfusion of the hypothalamic explants with a high

potassium solution (60 mM), which depolarizes the neurons, results in
increased release of RRF.

This observation indicates that RRF neurons

can respond to a stimulus and that the nerve terminal regions are
likely to be present in the hypothalamus.

For a neuropeptide to be

released from the hypothalamus there are essentially three pathways:
1.) The neuron may send a projection down the pituitary stalk to the
posterior pituitary lobe,

2.) the neuron may terminate in the region

of the median eminence where the peptide is released into the portal
blood and

3.) the peptide may be released into the third ventricle

where it will enter the cerebrospinal fluid (CSF).

Based on the

earlier in vivo studies of the PCA-induced increase in renin secretion,
the role of the pituitary in the release of the peptide still needs to
be resolved.

Hypophysectomy prevented the PCA-induced increase in PRA

after 22 days but did not affect PRA 4 days after surgery (Karteszi et
al., 1982; Van de Kar et .5!.l., 1982).
hypothalamic-hypophyseal
infundibulum attached,

explants

were

used

Both hypothalamic explants and
that

for

the

had

the

pituitary

superfusion study.

and
The

results suggest that there was no need for the hypothalamus to have an
intact pituitary stalk in order to release RRF.

This suggests that the

terminals involved in the release of RRF were intact and may terminate
in the median eminence which would not have been destroyed in the
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dissection procedure.

These results do not rule out the involvement of

the pituitary gland in the release of RRF.

However,

they do lend

credibility to the hypothesis that RRF is part of a neuroendocrine
system.

2.

Effect of bilateral nephrectomy on hypothalamic content of RRF
Another characteristic of a neuroendocrine system is that the

release of the factor may be regulated by the end product or hormone.
The release of corticotropin releasing factor (CRF) is regulated by
circulating levels of corticosterone.

High levels of corticosteroids

will inhibit the release of ACTH and CRF from the hypothalamus to
control the plasma levels of CRF (Keller-Wood and Dallman, 1984).

When

the adrenal gland is removed, thereby removing corticosterone feedback,
the hypothalamic content of CRF is increased (Plotsky and Sawchenko,
1987;

Piekut and Joseph,

1986;

Sawchenko and Swanson,

1985).

The

studies by Piekut and Joseph (1986) and Sawchenko and Swanson (1985)
were performed in rats that were adrenalectomized for at least seven
However,

days.
indicate

the

recent study by Plotsky and Sawchenko

that 24 hours

(1987)

after adrenalectomy there is a significant

increase in CRF, as determined by radioimmunoassay, and in CRF staining
in the PVN.

This study suggests that nephrectomy performed 24 hours

before sacrifice may also be a long enough time to observe an increase
in the hypothalamic concentration of RRF.
The

data

suggest

that

removal

of

the

kidneys

inhibitory input for RRF secretion and production.
kidneys,

eliminates

an

By removing the

there is a reduced capacity to inhibit the synthesis and
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possibly, the release of RRF from the hypothalamus.

Therefore, RRF

cells will continue to synthesize and secrete RRF as long as there is
no feedback stimulus from the kidney to reduce their activity.
feedback factor
possibly ANG

may be

This

a product of the renin-angiotensin system,

II or aldosterone.

Based on these results we could

speculate that ANG II may be the mediator of the feedback loop from the
kidney

to

the

brain.

The

subfornical

organ

(SFO)

is

a

circumventricular organ that is located in the third ventricle and is
responsive to changes in the circulating levels of ANG II (Gross et
al., 1985).

The SFO has been documented to send projections to the PVN

(Tanaka et al.,

1986)

that are implicated in the control of blood

pressure (Gutman et al., 1985).

In an earlier study, Tanaka et Sll.

(1985) demonstrated that stimulation of the neurons in the SFO produced
an inhibition in the activity of 50% of the PVN neurons tested.

This

suggests that the SFO sends projections to the PVN that can regulate
the

firing

rate of neurons

in the PVN.

More studies need to be

performed to characterize this RRF feedback loop.

However,

it is

probable that elevated levels of ANG II produce by increased renin
release, may stimulate neurons in the SFO which project to the PVN to
maintain the release of RRF at a homeostatic level.
It is important to note that in the bilateral nephrectomy and the
colchicine

studies,

the

levels

of renin-releasing activity in the

hypothalamus is elevated over the isoproterenol control values.

Even

though these increases are not significantly different, this may give
an

indication

receptor.

as

to

whether

or not RRF

stimulates

a

renal

beta

It is probable that isoproterenol is maximally stimulating

160
the renal beta receptors since different doses of isoproterenol c10-5_
10-7 M) produce similar increases in renin secretion.

This indicates

that the beta receptors may be saturated since the more concentrated
dose (lo- 5 M) does not produce a further increase in renin release from
the slices when compared with the 10- 7 M dose of isoproterenol.

The

elevations observed with isoproterenol usually produce increases in
renin release around 20-23 ng ANG I/mg kidney/hr.

However, with the

PCA-plasma fraction (M.W. 5,000-10,000; Table 8) and the hypothalamic
extracts, increases in renin release from the kidney slices range from
23-32 ng ANG I/mg kidney/hr.

These results are not sufficient evidence

for the existence of separate RRF receptors, but may give hint on the
possibility of selective RRF receptors in the kidney.
When the beta antagonist, d,1-propranolol, is added to the kidney
slices prior to addition of the PCA-plasma fraction or plasma from
stressed rats,

there is a slight inhibition of both basal and RRF-

stimulated renin release which may be due to the membrane stabilizing
effects

of

d-propranolol.

However,

there

still

is a

significant

increase in renin release when the PCA-plasma fraction is added to the
kidney slices.

Other beta blockers have been tested.

Nadolol and

atenolol, on the otherhand, prevented the renin-releasing activity of
the PCA-plasma fraction (Urban and Van de Kar, unpublished results).
These data are conflicting and do not conclusively state whether or not
RRF

stimulates

renal

beta

receptors.

Clearly,

the

receptor

that

mediates the effect of RRF on renin release from the kidney needs to be
studied further.
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H. Possible renin-releasing peptides
There are a number of peptides that stimulate renin release.
few of them are within the 5,000-10,000 molecular weight range.

A

At the

time that these studies were performed, the molecular weight of RRF was
identified to be in the range of 5,000-10,000.

It was not until after

these studies were performed that the molecular weight of RRF was
identified

to

be

within

the

4,800-6,000

molecular

weight

range.

Insulin (M.W. 6000) and parathyroid hormone (PTH, M.W. 9000) are two
hormones that are within the molecular weight range of 5,000-10,000 and
are known to increase renin release.
Insulin is primarily synthesized in the pancreas, however, recent
evidence

has

accumulated

indicating

the

presence

of

immunoreactivity and binding sites in the brain and,

insulin-like
of particular

interest for this study, in the hypothalamus (Baskin et.§].., 1983; Van
Houten et al. , 1980) .

Induction of diabetes by alloxan injection

produces a decrease in PRA that is restored to normal when the diabetic
rats are supplemented with insulin
sodium remain normal.

(Pratt~~ .•

1985).

The levels of

However, potassium levels are increased in the

diabetic rats and it is likely that the decreased PRA values were
produced by the increased plasma concentration of potassium (Vander,
1970).

Infusion of insulin produces increases in plasma renin activity

(Otsuka et al., 1970) that is prevented by either pretreatment with
propranolol (Assaykeen et al., 1970) or by the prostaglandin synthesis
inhibitor, indomethacin (Campbell and Zimmer, 1980).
of

insulin

in the rat CNS appears

periventricular

area

(Baskin

et

The distribution

to be concentrated around the

~ .•

1983;

Dorn

et

al.,

1981).
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Considerable staining for immunoreactive insulin has been identified in
the ependymal cells lining the wall of the third ventricle and in the
hypothalamus (Dorn et !!l., 1981).

The cerebellum and brainstem contain

small, almost nondetectable concentrations of insulin as determined by
radioimmunoassay.

Before insulin is ruled out as a putative RRF,

insulin should be tested in an in vitro renin release bioassay to test
its

renin-releasing

activity without

the effects

of potassium and

increases in circulating catecholamines that can occur

in

vivo.

Parathyroid hormone (PTH) produces increases in PRA (Smith et !!l.,
1979; Powell et al., 1978; Broulik et al., 1986).

PTH infusion did not

alter plasma calcium levels or blood pressure but pretreatment with a
beta blocker

(metipranol)

attenuated the

humans (Broulik et al., 1986).

renin response to PTH in

The PCA-induced increase in PRA was not

affected by removal of the parathyroid gland indicating that PTH is not
the RRF.

If PTH were the RRF then removal of the parathyroid gland

would have blocked the effect of PCA on renin secretion.
There
secretion.

are

other

Even

peptides

that

are

known

though some of the peptides

to

regulate

renin

are not within the

molecular weight range of the PCA-plasma fraction that has reninreleasing activity, recent evidence with the sephadex G-50 and HPLC gel
filtration (GPC-100 column) indicated that there may be hypothalamic
substances with molecular weights below 5,000

that are capable of

inducing renin release from the kidney slices (Van de Kar, Brownfield
and Urban, unpublished observations).

Glucagon (M.W. 3350), has been

shown to increase renin secretion from the kidney (Ueda et al., 1978;
Vandongen et al.,

1973).

When infused into the renal artery at a
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relatively low dose,

glucagon produced increased heart rate,

blood flow and glomerular filtration rate.

renal

At a higher dose, glucagon

produced similar changes in the renal hemodynamic parameters and in
addition produced a significant increase in renin release (Ueda et al.,
1978).

Pretreatment with propranolol did not prevent the increase in

renin release produced by glucagon (Ueda t l al. , · 1978; Vandongen et
al., 1973).

Glucagon and isoproterenol stimulate adenylate cyclase in

the renal medulla (Mulvehill et al., 1976).

However, the effect of

glucagon on adenylate cyclase activity is not inhibited by propranolol,
indicating a glucagon specific adenylate cyclase.
likely

that

glucagon may

stimulate

renin

Therefore it is

secretion by activating

adenylate cyclase in the renal cortex.
Vasoactive intestinal peptide

(VIP;

M.'W.

3326)

increases renin

release both in vivo (Porter et al., 1983; 1985) and in vitro (Porter
et al., 1983).

There is a high density of VIP-immunoreactive neurons

in the hypothalamus, specifically, the suprachiasmatic nucleus (SCN) of
the rat (Loren et al., 1979; Sims t l l!.l., 1980; Samson t l al., 1979).
The SCN is known to receive serotonergic inputs from the midbrain raphe
nuclei (Azmitia and Segal, 1978; Bobillier t l .f!l., 1976; Van de Kar and
Lorens,

1979).

Reduction of serotonergic inputs

into the SCN,

by

injection with 5,6-dihydroxytryptamine (5,6-DHT), produced a decrease
in the amount of VIP but not of vasopressin in the SCN (Kawakami et
al., 1985).

These results from this study (Kawakami et ill., 1985) are

suspect because the neurotoxin 5,6-DHT produces non-specific damage to
neurons (non-serotonergic) surrounding the injection site (Baumgarten
et al., 1973).

Shimatsu et al. (1982) have shown that intraventricular
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( icv) injection of serotonin stimulates the release of VIP into the
portal blood.

The plasma concentration of VIP was also increased after

icv injection of serotonin.

It is possible that VIP could be the RRF,

based on the hypothalamic localization of the cell bodies and fibers,
and

the

fact

that

serotonin

can

stimulate

VIP

release

from

the

hypothalamus.
However, when comparing the distribution of RRF with that of VIP
in the CNS, there is a discrepancy between the distribution of VIP and
that of RRF.

One of the primary differences is that the cerebellum

dose not contain any VIP-immunoreactivity (Loren et
et al., 1979).
releasing

il.,

1979; Samson

The cerebellum, in control rats, had significant renin-

activity

that

was

reduced

in

colchicine-treated

rats.

Furthermore, the cerebral cortex contains a high concentration of VIP
cell bodies

(Loren et al.,

1979;

Sims et .ill.,

1980) but the RRF

concentration in the cerebral cortex was significantly reduced after
colchicine-treatment when compared with the hypothalamic extract.

This

decrease in renin-releasing activity suggests the presence of RRF in
nerve terminals,

not in cell bodies.

From the current data,

it is

noticeable that the patterns of distribution for RRf and VIP are not
similar, since the molecular weights of these peptides differ also, it
seems unlikely that VIP and RRF are the same peptide.
Hauger-Klevene et al.
hormone

(ACTH)

blockade

of

(1970) have shown that adrenocorticotropic

produces an increase
the

ganglionic blocker.

sympathetic

nervous

in PRA,
system

that
with

is

inhibited by

pentolinium,

a

The release of ACTH from the pituitary has been

shown to be influenced by serotonergic neurotransmission (Fuller, 1981;
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Szafarczyk et al., 1980).

However, it is not likely that ACTH is the

RRF, since hypophysectomy does not prevent the PCA-induced increase in
PRA (Karteszi et al. ,

1982).

Lesions of the dorsal raphe nucleus

prevent the PCA-induced increase in PRA, but do not alter the increase
in corticosterone levels (Van de Kar il gl., 1982b).

Posterolateral

deafferentation of the hypothalamus also blocked the effect of PCA on
PRA but not on corticosterone (Van de Karil al., 1985a; Karteszi il
al., 1982).

This indicates that the PCA-induced release of renin and

ACTH may be mediated by different pathways.
Atrial natriuretic factor (ANF) plays a role in regulating blood
pressure and sodium balance.

In 1981, De Bold et al. reported that

peptides in the cardiac atria contain a natriuretic factor.

ANF

produces an increase in sodium excretion accompanied by a decrease in
plasma volume and a decrease in blood pressure.

ANF is, therefore, the

antithesis of the renin-angiotensin-aldosterone system.

Infusion of

ANF to conscious animals results in an increase in sodium excretion
(Murray et al. ,

1985)

and a decrease in blood pressure and renin

(Burnett et al. ,

1985).

Studies by Deray et al. (1987) show that infusion of ANF into

nonfiltering canine

1984;

kidneys

Sosa et al. , 1986;

Seymour il Al.,

release

does

not

alter

the

increase

in renin

release produced by addition of either norepinephrine or prostacyclin,
whereas adenosine did attenuate the renin response to these agents.
Based on these studies the authors conclude that ANF does not have a
direct action on the juxtaglomerular cells.
Autoradiographic
receptors

studies

using

kidney

tissue

localized

ANF

to the renal outer cortex with concentrations of binding
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1986; Murphy t l al.,

sites over the glomerulus (Healy and Fanestil,
1985).

There is also a light distribution of binding sites in the

renal medulla.

In vitro studies have not clearly determined to what

extent ANF regulates renin secretion directly from the kidney.

Using a

juxtaglomerular cell culture and renal cortical slices, Kurtz t l al.
(1986) and Henrich et al. (1986) showed that addition of ANF decreases
renin

secretion.

This

effect

is

independent

of

calcium,

since

pretreatment with verapamil did not alter the ANF-induced decrease in
renin secretion ..

Other studies using similar doses of ANF indicate no

change in renin release (Rodriguez-Puyol et al., 1986).
further

potentiated

(Antonipillai

et

the ANG II-induced inhibition of renin release

al.,

1986).

Stimulation

isoproterenol was unaffected by ANF.

who

of

renin

release

by

Contrary to these findings are

the results obtained by Hackenthal et al.
(1986)

However ANF

(1985) and Hiruma et

reported that ANF stimulates renin release.

ll·

It is not

likely that ANF is the RRF since its physiological actions are directly
opposed

to

renin.

So

far,

the

stimuli

that

concentration of RRF also increase PRA and PRC.

increase

the

plasma

If ANF were the RRF,

it would most likely result in an initial decrease in PRA since the
natriuresis would reflexly inhibit renin secretion by increasing the
delivery of sodium chloride to the macula densa.
The existence of a hypertension-producing,
factor

(ASF)

aldosterone-secreting

has been reviewed by Carey and Sen (1986).

ASF is a

glycoprotein with a molecular weight of approximately 26, 000 with a
smaller active fragment of 4,000 (Sen et al., 1981).
report

that

ASF

does

not

alter

PRA,

ANG

II

Sen et
or

il.

(1986)

angiotensinogen
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concentration in the rat.
is ASF.

Therefore, it does not seem likely that RRF

Furthermore, immunofluorescence studies have localized ASF to

the anterior pituitary with no significant binding in the hypothalamus,
cerebral cortex, cerebellum, brainstem or peripheral tissues (kidney,
spleen, nerves, adrenal gland, thyroid, gastrointestinal tract; Sen et
al.,

1977).

This distribution pattern in the CNS does not parallel

that of RRF and therefore, it can be concluded that ASF and RRF are
different factors.
For

some

peptides,

such

as

prolactin

and

somatostatin,

the

presence of a disulfide bonds are necessary for these hormones to exert
their physiological effect (Wehrenburg et al., 1983; Palkovits et al.,
1982).

In an attempt to determine if RRF contains disulfide bonds,

cysteamine

was

disulfide bonds

administered

before

PCA.

in the RRF could change

Reduction
the

of

possible

configuration of

molecule and thus destroy its renin-releasing activity.

the

The results

indicate that cysteamine did not alter the PCA-induced increase in PRA
or PRC.
levels

However, PCA did not produce a significant increase in renin
either

the

corresponding cysteamine control group or the saline-PCA group.

In

these

after

same

Therefore,

cysteamine

animals,
there

cysteamine

may be

resting renin levels.
experiment,

treatment

cysteamine

when

compared

reduced prolactin

another

with

immunoreactivity.

action of cysteamine

that alters

We have shown, that at the dose used in this
does

not

alter

the

renin-angiotensinogen

interaction as described previously (Poisner and Hong, 1977).

It could

be possible that the increase in renin secretion may be due to a stress
effect.

At the time that the animals received the second injection,
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lesions were observed at the injection site in some of the animals that
received cysteamine.

By reviewing the data again,

it is seen that

there is more variability among the values for PRA and PRC in the
cysteamine groups.

This is reflected in the S.E.M.

However, the only

information this data provides is that cysteamine was not able to
inhibit thee renin-releasing activity of RRF that might be necessary
for its renin-releasing activity.
Cysteamine
prolactin

(Sagar

is

capable
et

al.,

of

1985;

reducing

the

Wehrenberg

immunoreactivity
et

al.,

1983)

of
and

somatostatin (Palkovits et al., 1982; Webb et al., 1986; Cameron and
Fernstrom, 1986) but not that of vasopressin or oxytocin (Palkovits et
al., 1982; Cameron and Fernstrom, 1986) which also contain disulfide
bonds.

Therefore it appears that the ability of cysteamine to reduce

disulfide bonds in a molecule may depend, in part, on the position of
the disulfide bond in the molecule and in part, on the importance of
the disulfide bond in maintaining a functional conformation.

A study

by Cameron and Fernstrom (1986) demonstrated that cysteamine treatment
can

affect

the

in

vivo

incorporation

somatostatin, oxytocin and vasopressin.

of

[ 35s] cysteine

into

This indicates that cysteamine

might also interfere with the synthesis of proteins which may result in
a reduction of activity.

Treatment with cysteamine did not alter the

renin-releasing activity of RRF.

Therefore it can be concluded that

either RRF does not contain disulfide bonds or that the bonds are not
necessary for RRF to maintain its activity.

Further studies should be

done to establish the presence of disulfide bonds in RRF.
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I. Role of RRF as a neurotransmitter
It is possible that in addition to its renin-releasing activity,
RRF may also function as a neurotransmitter in the central nervous
system.

This is supported in part by the fact that there are RRF nerve

terminals in the cerebral cortex, cerebellum and medulla.

Since these

brain regions are not known to be involved in releasing peptides into
the blood,

it is reasonable to think that RRF may be acting as a

neurotransmitter.
need

to

be

Werman (1966) has established eight criteria that

fulfilled

in

order

to

classify

a

substance

as

a

neurotransmitter:
1. The substance must be present in neuronal tissue with an
uneven distribution in the CNS.
2. Stimulation of identified neurons should cause release of this
putative neurotransmitter.
3. Direct application of the substance should produce responses
that are similar to those produced by stimulating the neurons.
4. & 5. Receptors should be identified that interact with the
substance and stimulation of these receptors should produce a
postsynaptic effect.
6. Precursors and synthetic enzymes must be demonstrated in the
neuronal element.
7. Inactivating mechanisms should exist that terminate the action
of the neurotransmitter.
8. A substance (agonist) should be able to mimic the natural
transmitter.
Using these criteria and applying them to the results that we have
observed for RRF,

it becomes evident that RRF fulfills some of the

First,

we have demonstrated that RRF is differentially

criteria.

distributed within the brain.

Release of RRF has been demonstrated

from hypothalamic explants in vitro and stimulation of serotonergic
neurons in vivo has increased the plasma concentration of RRF.
the

PCA-plasma

fraction

(M.W.

5,000-10,000)

and

the

Both

hypothalamic

extract produced dose-dependent increases in renin release from the
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kidney slices suggesting a direct action on renal receptors.
response

effect

agrees

with

the

occupancy

assumption

The dose-

theory

that

presumes that as more receptors on the kidney are filled there is a
larger increase in the effect of the neurotransmitter.

These results

satisfy requirements 3, and 4 & 5 (to a lesser degree), identifying
receptors that respond to application of RRF.

ALthough the kidney is

not a post-synaptic element, there are receptors on the kidney that
respond to application of RRF.

The other criteria have not been

addressed in this dissertation and have not, as of yet, been studied in
this, or any other, laboratory.

As the work continues with RRF, future

studies may address these other issues and confirm the role of RRF as a
neurotransmitter.

However, with the data that we have collected so far

it is conceivable that RRF may be part of a neuroendocrine system and
may in fact be a neurotransmitter.

1. Possible role of RRF in the CNS
The renin-releasing activity of the pons, pituitary and thalamus
was slightly elevated after colchicine treatment.

The renin-releasing

activity that was present in the cerebral cortex, medulla oblongata and
the cerebellum was decreased suggesting that RRF in these areas is
present in nerve terminals.

These data may give some indication for

possible RRF pathways outside the hypothalamus.
et al. (1987) and Richardson-Morton

~

The studies by Gotoh

al. (1986) have indicated that

lesions in the PVN prevent the PCA-induced and stress-induced increases
in renin secretion.

Since RRF cells bodies are localized in the

hypothalamus it is possible that RRF may be contained in hypothalamic
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PVN neurons and that some projections of RRF neurons may parallel those
of already identified PVN pathways.
Recent

studies

have

focussed

on

the

PVN as

an

integrator

of

neuroendocrine and autonomic responses (Sawchenko and Swanson, 1981).
It is conceivable that if RRF is contained in the PVN, it too, may act
as a regulator.

The presence of RRF in the medulla, and in the pons,

suggest that RRF may be involved in the regulation of blood pressure
since these areas of the brain also monitor blood pressure (Nakai et
al., 1982).

We have demonstrated that RRF releases renin both in vivo

and in vitro.

However,

its importance in regulating blood pressure

remains to be determined since we have not observed any increases in
blood pressure in rats that have received doses of concentrated PCAplasma fractions

(Van de Kar and Urban, unpublished results).

It is

equally likely that RRF may exert an action that is independent of
cardiovascular

regulation.

The

brainstem

also

is

the

site

of

integration of tracts and nuclei of the cranial nerves, primarily the
hypoglossal, glossopharyngeal, vagus and accessory nerves.

Therefore,

the RRF could also integrate messages from the cranial nerves that may
be

involved

with

olfaction,

taste,

muscle

movements

or

even

respiration.
The role of the cerebellum in mediating autonomic functions has
been

studied

in other

laboratories.

Stimulation of the

fastigial

nucleus of the cerebellum results in increased levels of plasma renin
activity (Koyama et al., 1980) and increases in heart rate and blood
pressure (Del Bo et al.,
heart rate

1983).

and blood pressure,

Renal sympathetic nerve discharge,
in the

decerebrate

rabbit,

are all
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increased

when

the

cerebellum

(Bradley et fil., 1987).

(uvula)

is

electrically

stimulated

The uvula receives auditory, somato-sensory

and proprioceptive inputs, the authors speculate that the cerebellum
may be

involved in a

changes.

startle response resulting in cardiovascular

Our results suggest that RRF terminals are present in the

cerebellum and release of plasma RRF is increased during stress.

It

can be speculated that in addition to sending a projection to the
pituitary or median eminence, that there is a collateral RRF projection
to the cerebellum.

This pathway may be activated during either a

startle or stress response which might have some influence on the
cerebellar neurons that regulate cardiovascular function in addition to
releasing RRF into the circulation.

2. Role of RRF in stress
The role that RRF plays in stress-induced renin secretion needs to
be further defined.
secretion

is

not

injections

of the

It appears that the effect of stress on renin
regulated

by

a

serotonergic

serotonin-selective neurotoxin,

mechanism,

since

5,7-DHT into

the

dorsal raphe nucleus did not affect the stress-induced increase in PRA
nor did pretreatment with the S-HT2 antagonist LY53857 (Lorens et al.,
1986).

Stress is a stimulus that increases sympathetic nerve activity

resulting

in an

increase

in PRA

(Jindra i l Jll.,

hypertension (Dobrakovova et al., 1984).

1984;

1980)

and

Privitera et al. (1979) found

that administration of propranolol intracisternally to rats suppresses
renin

secretion

propranolol

and

produces

hypotension.

intravenously do not produce the

Identical

doses

same effects.

of

Renal
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denervation selectively attenuates the decrease in renin secretion but
not the hypotensive effect of propranolol.
is

the

finding

that

Contrary to these results

injections of the catecholamine neurotoxin 6-

, hydroxydopamine (6-0HDA),

combined with adrenal medullectomy did not

prevent the stress-induced increase in PRA (Richardson-Morton et al.,
unpublished observations).

This study indicates that the peripheral

sympathetic nervous system is not the sole mediator of the stressinduced increase 'in PRA.

However, intraperitoneal administration of

propranolol greatly attenuates the renin response to stress (Van de Kar
et

al.,

1985).

Therefore,

this

Propranolol
study

does

peripheral beta blockade.

not

crosses

the

blood-brain

differentiate

barrier.

between central

and

Further studies by Richardson-Morton et 1l]..

(1987) have shown that injections of 6-0HDA into the PVN attenuates the
stress-induced

increase

in

PRA,

catecholaminer~ic

mechanism of action is involved.

suggesting

that

a

central

The PVN appears to

play a pivotal role in the regulation of the stress-induced increase in
PRA (Richardson-Morton et al., 1987; 1986; Gotoh et 1l].., 1987) and may
also be

invol~ed

in the regulation of the release of RRF since lesions

of this nucleus prevent the PCA-induced increase in PRA (Gotoh et al.,
1987).

Therefore

catecholaminergic

I

would

systems

speculate

converge

on

that
the

the
PVN

regulate the release of RRF from the hypothalamus.

serotonergic
to

and

differentially

It is also likely

that catecholamine receptors on cell bodies in the PVN are activated

' the release of RRF.
during stress and trigger
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J. CONCLUSION
These studies provide evidence for a blood-borne renin-releasing
factor.

RRF cell bodies are localized in the hypothalamus and RRF is

released from the hypothalamus when these neurons are depolarized.

The

present studies have shown that the release of RRF is stimulated by
activation of serotonergic receptors and stressful stimuli.
studies to identify other physiological factors,

Further

such as changes in

sodium balance or blood pressure, that may increase the release of RRF
need to be performed.
We postulate a neural circuit for the regulation of the release of
RRF.

This circuit is represented in Figure 8.

From the studies

performed by Van de Kar et al. (1982) and Karteszi et al. (1982) it has
been demonstrated that the dorsal raphe nucleus sends a serotonergic
projection -to
secretion.

the

mediobasal

hypothalamus

which

stimulates

renin

Data presented by Richardson-Morton et al. (1987) and Gotoh

et al. (1987) suggest that neurons in the PVN mediate both the stressinduced and PCA-induced increases in renin secretion.

Since the PVN

receives very little serotonergic innervation, we have considered the
possibility that the projection from the dorsal raphe may synapse on an
/

interneuron in the arcuate nucleus.

The arcuate nucleus receives

considerable serotonergic innervation from the dorsal raphe nucleus and
is known to project to neurons in the PVN.
of

neurons

circulation.

in

the

PVN

results

in

the

We propose that stimulation
release

of

RRF

into

the

RRF then circulates in the blood to the kidney and causes

the release of renin.
levels of ANG II.

An increase in PRA increases the circulating

ANG II would then feedback on the CNS system that
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Figure 9.
release.

Postulated neuronal

circuit

for

the

regulation of RRF
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regulates renin secretion by stimulating neurons in the SFO.
al.

Tanaka et

(1986) have indicated that there are projections from the SFO to

the PVN that can regulate the firing of PVN neurons.

As the work

continues in this area, it is possible that this neuronal circuit may
change with future results.

/
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